<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Rituximab for people with multiple sclerosis - Filippini, G - 2021 | Cochrane Library</title> <meta content="Rituximab for people with multiple sclerosis - Filippini, G - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013874.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Rituximab for people with multiple sclerosis - Filippini, G - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013874.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013874.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Rituximab for people with multiple sclerosis" name="citation_title"/> <meta content="Graziella Filippini" name="citation_author"/> <meta content="Carlo Besta Foundation and Neurological Institute" name="citation_author_institution"/> <meta content="filippini.graziella@gmail.com" name="citation_author_email"/> <meta content="Jera Kruja" name="citation_author"/> <meta content="UHC Mother Theresa, University of Medicine" name="citation_author_institution"/> <meta content="Cinzia Del Giovane" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD013874.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/11/08" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013874.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013874.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013874.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Fingolimod Hydrochloride; Glatiramer Acetate; *Multiple Sclerosis [drug therapy]; *Multiple Sclerosis, Chronic Progressive [drug therapy]; Rituximab [adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013874.pub2&amp;doi=10.1002/14651858.CD013874.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="z6k50IFd";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013874\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013874\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013874\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013874\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ms","fa","fr"],languageCode:"en",accessStatus:"not-found",doi:"10.1002/14651858.CD013874.pub2",title:"Rituximab for people with multiple sclerosis",firstPublishedDate:"Nov 8, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013874.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013874.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013874.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013874.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013874.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013874.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013874.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013874.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013874.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013874.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3901 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013874.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-sec-0144"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-sec-0055"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-sec-0134"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/appendices#CD013874-sec-0149"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/table_n/CD013874StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/table_n/CD013874StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Rituximab for people with multiple sclerosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/information#CD013874-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Graziella Filippini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/information#CD013874-cr-0005">Jera Kruja</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013874.pub2/information#CD013874-cr-0006">Cinzia Del Giovane</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/information/en#CD013874-sec-0164">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 08 November 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013874.pub2">https://doi.org/10.1002/14651858.CD013874.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013874-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013874-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013874-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013874-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013874-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013874-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013874-abs-0001" lang="en"> <section id="CD013874-sec-0001"> <h3 class="title" id="CD013874-sec-0001">Background</h3> <p>Multiple sclerosis (MS) is the most common neurological cause of disability in young adults. Off‐label rituximab for MS is used in most countries surveyed by the International Federation of MS, including high‐income countries where on‐label disease‐modifying treatments (DMTs) are available.  </p> </section> <section id="CD013874-sec-0002"> <h3 class="title" id="CD013874-sec-0002">Objectives</h3> <p>To assess beneficial and adverse effects of rituximab as 'first choice' and as 'switching' for adults with MS. </p> </section> <section id="CD013874-sec-0003"> <h3 class="title" id="CD013874-sec-0003">Search methods</h3> <p>We searched CENTRAL<i>, </i>MEDLINE, Embase, CINAHL, and trial registers for completed and ongoing studies on 31 January 2021. </p> </section> <section id="CD013874-sec-0004"> <h3 class="title" id="CD013874-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and controlled non‐randomised studies of interventions (NRSIs) comparing rituximab with placebo or another DMT for adults with MS. </p> </section> <section id="CD013874-sec-0005"> <h3 class="title" id="CD013874-sec-0005">Data collection and analysis</h3> <p>We followed standard Cochrane methodology. We used the Cochrane Collaboration’s tool for assessing risk of bias. We rated the certainty of evidence using GRADE for: disability worsening, relapse, serious adverse events (SAEs), health‐related quality of life (HRQoL), common infections, cancer, and mortality. We conducted separate analyses for rituximab as 'first choice' or as 'switching', relapsing or progressive MS, comparison versus placebo or another DMT, and RCTs or NRSIs. </p> </section> <section id="CD013874-sec-0006"> <h3 class="title" id="CD013874-sec-0006">Main results</h3> <p>We included 15 studies (5 RCTs, 10 NRSIs) with 16,429 participants of whom 13,143 were relapsing MS and 3286 progressive MS. The studies were one to two years long and compared rituximab as 'first choice' with placebo (1 RCT) or other DMTs (1 NRSI), rituximab as 'switching' against placebo (2 RCTs) or other DMTs (2 RCTs, 9 NRSIs). The studies were conducted worldwide; most originated from high‐income countries, six from the Swedish MS register. Pharmaceutical companies funded two studies. We identified 14 ongoing studies. </p> <p><b>Rituximab as 'first choice' for relapsing MS</b> </p> <p>Rituximab versus placebo: no studies met eligibility criteria for this comparison.</p> <p>Rituximab versus other DMTs: one NRSI compared rituximab with interferon beta or glatiramer acetate, dimethyl fumarate, natalizumab, or fingolimod in active relapsing MS at 24 months' follow‐up. Rituximab likely results in a large reduction in relapses compared with interferon beta or glatiramer acetate (hazard ratio (HR) 0.14, 95% confidence interval (CI) 0.05 to 0.39; 335 participants; moderate‐certainty evidence). Rituximab may reduce relapses compared with dimethyl fumarate (HR 0.29, 95% CI 0.08 to 1.00; 206 participants; low‐certainty evidence) and natalizumab (HR 0.24, 95% CI 0.06 to 1.00; 170 participants; low‐certainty evidence). It may make little or no difference on relapse compared with fingolimod (HR 0.26, 95% CI 0.04 to 1.69; 137 participants; very low‐certainty evidence). The study<i> </i>reported no deaths over 24 months. The study did not measure disability worsening, SAEs, HRQoL, and common infections. </p> <p><b>Rituximab as 'first choice' for progressive MS</b> </p> <p>One RCT compared rituximab with placebo in primary progressive MS at 24 months' follow‐up. Rituximab likely results in little to no difference in the number of participants who have disability worsening compared with placebo (odds ratio (OR) 0.71, 95% CI 0.45 to 1.11; 439 participants; moderate‐certainty evidence). Rituximab may result in little to no difference in recurrence of relapses (OR 0.60, 95% CI 0.18 to 1.99; 439 participants; low‐certainty evidence), SAEs (OR 1.25, 95% CI 0.71 to 2.20; 439 participants; low‐certainty evidence), common infections (OR 1.14, 95% CI 0.75 to 1.73; 439 participants; low‐certainty evidence), cancer (OR 0.50, 95% CI 0.07 to 3.59; 439 participants; low‐certainty evidence), and mortality (OR 0.25, 95% CI 0.02 to 2.77; 439 participants; low‐certainty evidence). The study did not measure HRQoL. </p> <p>Rituximab versus other DMTs: no studies met eligibility criteria for this comparison.</p> <p><b>Rituximab as 'switching' for relapsing MS </b> </p> <p>One RCT compared rituximab with placebo in relapsing MS at 12 months' follow‐up. Rituximab may decrease recurrence of relapses compared with placebo (OR 0.38, 95% CI 0.16 to 0.93; 104 participants; low‐certainty evidence). The data did not confirm or exclude a beneficial or detrimental effect of rituximab relative to placebo on SAEs (OR 0.90, 95% CI 0.28 to 2.92; 104 participants; very low‐certainty evidence), common infections (OR 0.91, 95% CI 0.37 to 2.24; 104 participants; very low‐certainty evidence), cancer (OR 1.55, 95% CI 0.06 to 39.15; 104 participants; very low‐certainty evidence), and mortality (OR 1.55, 95% CI 0.06 to 39.15; 104 participants; very low‐certainty evidence). The study did not measure disability worsening and HRQoL.  </p> <p>Five NRSIs compared rituximab with other DMTs in relapsing MS at 24 months' follow‐up. The data did not confirm or exclude a beneficial or detrimental effect of rituximab relative to interferon beta or glatiramer acetate on disability worsening (HR 0.86, 95% CI 0.52 to 1.42; 1 NRSI, 853 participants; very low‐certainty evidence). Rituximab likely results in a large reduction in relapses compared with interferon beta or glatiramer acetate (HR 0.18, 95% CI 0.07 to 0.49; 1 NRSI, 1383 participants; moderate‐certainty evidence); and fingolimod (HR 0.08, 95% CI 0.02 to 0.32; 1 NRSI, 256 participants; moderate‐certainty evidence). The data did not confirm or exclude a beneficial or detrimental effect of rituximab relative to natalizumab on relapses (HR 1.0, 95% CI 0.2 to 5.0; 1 NRSI, 153 participants; very low‐certainty evidence). Rituximab likely increases slightly common infections compared with interferon beta or glatiramer acetate (OR 1.71, 95% CI 1.11 to 2.62; 1 NRSI, 5477 participants; moderate‐certainty evidence); and compared with natalizumab (OR 1.58, 95% CI 1.08 to 2.32; 2 NRSIs, 5001 participants; moderate‐certainty evidence). Rituximab may increase slightly common infections compared with fingolimod (OR 1.26, 95% CI 0.90 to 1.77; 3 NRSIs, 5187 participants; low‐certainty evidence). It may make little or no difference compared with ocrelizumab (OR 0.02, 95% CI 0.00 to 0.40; 1 NRSI, 472 participants; very low‐certainty evidence). The data did not confirm or exclude a beneficial or detrimental effect of rituximab on mortality compared with fingolimod (OR 5.59, 95% CI 0.22 to 139.89; 1 NRSI, 136 participants; very low‐certainty evidence) and natalizumab (OR 6.66, 95% CI 0.27 to 166.58; 1 NRSI, 153 participants; very low‐certainty evidence). The included studies did not measure SAEs, HRQoL, and cancer. </p> </section> <section id="CD013874-sec-0007"> <h3 class="title" id="CD013874-sec-0007">Authors' conclusions</h3> <p>For preventing relapses in relapsing MS, rituximab as 'first choice' and as 'switching' may compare favourably with a wide range of approved DMTs. A protective effect of rituximab against disability worsening is uncertain. There is limited information to determine the effect of rituximab for progressive MS.  </p> <p>The evidence is uncertain about the effect of rituximab on SAEs. They are relatively rare in people with MS, thus difficult to study, and they were not well reported in studies. There is an increased risk of common infections with rituximab, but absolute risk is small.  </p> <p>Rituximab is widely used as off‐label treatment in people with MS; however, randomised evidence is weak. In the absence of randomised evidence, remaining uncertainties on beneficial and adverse effects of rituximab for MS might be clarified by making real‐world data available. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013874-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013874-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013874-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013874-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013874-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013874-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD013874-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013874-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013874-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013874-abs-0002" lang="en"> <h3>Rituximab for people with multiple sclerosis</h3> <p><b>Key messages</b> </p> <p>– Rituximab may offer moderate‐to‐large benefit against a range of other medicines in preventing relapses in relapsing multiple sclerosis (MS). Compared with no medicines, the desirable effects would be greater. </p> <p>– There is limited information to determine the effect of rituximab for preventing disability worsening in all forms of MS.  </p> <p>– Serious harmful effects are relatively rare in people with MS making them difficult to study, and they were also not well reported in studies. </p> <p><b>What is the issue?</b> </p> <p>Rituximab is a medicine administered by intravenous (by a vein) infusion that can suppress certain immune cells. The immune system fights infections and consists of many immune cells; it is affected in MS. </p> <p>Rituximab is currently used in many low‐ to middle‐income countries that have major barriers for accessing approved medicines for MS. However, rituximab is not always reimbursed by health systems because it is not licensed for MS by marketing authorities.  </p> <p>Rituximab is considered a feasible treatment option as it is considered a highly effective treatment (similar to other approved medicines used to treat MS) but has considerably lower cost and less frequent dosing. Treatment with rituximab requires specialist care and infusion facilities, but other approved medicines do too. </p> <p><b>What did we want to find out?</b> </p> <p>We aimed to investigate the beneficial and unwanted effects of rituximab for people with MS, when is used as a 'first choice' or as 'switching' (in other words, used when other medicines do not work well or become contraindicated). </p> <p>We wanted to find out if rituximab was better than other medicines to prevent disability worsening and recurrence of relapse, and to improve well‐being. </p> <p>We also wanted to find out if rituximab was associated with any unwanted or harmful effects, for example, serious harmful effects, common infections, cancer, and mortality (death). </p> <p><b>What did we do? </b> </p> <p>We searched for studies that investigated rituximab compared with all other approved medicines for MS. We searched the literature up to January 2021. We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and quality. </p> <p><b>What did we find? </b> </p> <p>We found 15 studies that involved about 16,000 people with MS and lasted one or two years. The biggest study was of 6421 people and the smallest study was of 27 people. The studies were conducted worldwide; most originated from high‐income countries, six from the Swedish MS register. Pharmaceutical companies funded two included studies. </p> <p><b>Main results</b> </p> <p><i>Rituximab as a first choice treatment in relapsing MS:</i> </p> <p>– likely results in a large reduction in the number of people who have relapses compared with interferon beta or glatiramer acetate (evidence from one study in 335 people); </p> <p>– may reduce the number of people who have relapses compared with dimethyl fumarate and natalizumab, but the evidence is uncertain (evidence from one study). </p> <p>There was no usable information on disability worsening, well‐being, and serious harmful effects. </p> <p><i>Rituximab as a first choice treatment in progressive MS:</i> </p> <p>– likely results in little to no difference in the number of participants who have disability worsening over 24 months compared with pretend treatment (evidence from one study of 439 people); </p> <p>– the evidence is very uncertain about the effect of rituximab on well‐being and serious harmful effects. </p> <p><i>Rituximab as 'switching' for relapsing MS:</i> </p> <p>– likely results in a large reduction in the number of people who have relapses compared with interferon beta or glatiramer acetate (evidence from one study of 1383 people), and fingolimod (evidence from one study of 256 people). The evidence is very uncertain on the comparison of rituximab with natalizumab; </p> <p>– the evidence is very uncertain on disability worsening;</p> <p>– likely increases slightly the number of people who have common infections compared with interferon beta or glatiramer acetate (evidence from one study of 5477 people), and natalizumab (evidence from two studies of 5001 people). The evidence is uncertain for the comparisons of rituximab with fingolimod and ocrelizumab. </p> <p>There was no usable information on well‐being and serious harmful effects.</p> <p><i>Rituximab as 'switching' for progressive MS</i> </p> <p>Only three small studies investigated rituximab in secondary progressive MS. The evidence is uncertain about the effect of rituximab on disability worsening, well‐being, and serious harmful effects. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>– Limited confidence about the effect of rituximab on disability worsening in all forms of MS. </p> <p>– Limited information to determine the effect of rituximab for progressive forms of MS. </p> <p>– Studies were short with a median duration of 24 months.</p> <p><b>How up to date is the evidence?</b> </p> <p>This review is up to day to 31 January 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013874-sec-0144" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013874-sec-0144"></div> <h3 class="title" id="CD013874-sec-0145">Implications for practice</h3> <section id="CD013874-sec-0145"> <p> <ul id="CD013874-list-0023"> <li> <p>A policy of provision of rituximab to people with multiple sclerosis (MS) in countries that have major barriers for accessing approved disease‐modifying treatments (DMTs) for MS likely reduces the number of people who have relapses. </p> </li> <li> <p>Rituximab may reduce relapses when early highly effective therapy or escalation treatment from other DMTs are needed. </p> </li> <li> <p>A protective effect of rituximab against disability worsening is uncertain.</p> </li> <li> <p>There is limited information to determine the effect of rituximab for progressive forms of MS. </p> </li> <li> <p>The evidence is uncertain about the effect of rituximab on serious adverse events that are relatively rare in people with MS, and are thus difficult to study. </p> </li> <li> <p>There is an increased risk of common infections with rituximab, but the absolute risk is small. </p> </li> <li> <p>There is less risk of treatment discontinuation due to adverse events with rituximab compared with other DMTs. However, the true compliance rate with rituximab and other DMTs is not known. </p> </li> </ul> </p> </section> <h3 class="title" id="CD013874-sec-0146">Implications for research</h3> <section id="CD013874-sec-0146"> <p>Rituximab is widely used as off‐label treatment in people with MS, but randomised evidence is weak, and likely it will remain so in the future as well. </p> <p> <ul id="CD013874-list-0024"> <li> <p>Better understanding is needed of comparative benefits and harms of rituximab and other highly effective DMTs over the long term. </p> </li> <li> <p>Future studies are needed to assess comparative effectiveness of acceptance and adherence to highly effective DMTs. </p> </li> <li> <p>In the absence of randomised evidence, data from registries and large observational studies should be publicly available. These may be relevant sources for providing complementary data regarding the long‐term benefits of DMTs for MS. </p> </li> <li> <p>More thorough investigations are needed to assess reasons for treatment discontinuation and comparison for adverse events applicable to each DMT. </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013874-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013874-sec-0008"></div> <div class="table" id="CD013874-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Rituximab as 'first choice' versus other disease‐modifying treatments for relapsing multiple sclerosis – results from non‐randomised studies of intervention</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> relapsing multiple sclerosis<br/><b>Settings:</b> inpatient or outpatient<br/><b>Intervention:</b> rituximab as first choice treatment<br/><b>Comparison:</b> other disease‐modifying treatments as first choice treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comparison</b> </p> <p><b>intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b>* </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with rituximab</b> </p> <p><b>(95% CI)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability worsening</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study<sup>a</sup> did not measure the outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Chance of experiencing ≥ 1 relapses:</b> visits over 24 months. Data collected from the Swedish MS registry and medical records. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Interferon beta or glatiramer acetate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>270 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b><br/>(16 to 116) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.14</b> </p> <p>(0.05 to 0.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>335<br/>(1 retrospective cohort study)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias. Rituximab likely results in a large reduction in relapses when compared with interferon beta or glatiramer acetate. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Dimethyl fumarate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b><br/>(10 to 120) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.29</b> </p> <p>(0.08 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/>(1 retrospective cohort study)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 1 level for imprecision. Rituximab may reduce relapses when compared with dimethyl fumarate. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200</b> <b>per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>52</b> <b>per 1000</b> </p> <p>(13 to 200)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.24</b> </p> <p>(0.06 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170<br/>(1 retrospective cohort study)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 1 level for imprecision. Rituximab may reduce relapses when compared with natalizumab. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>180 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50</b> <b>per 1000</b> </p> <p>(8 to 285)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.26 </b> </p> <p>(0.04 to 1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/>(1 retrospective cohort study)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 2 levels for serious imprecision. The evidence is very uncertain about the effect of rituximab on relapses when compared with fingolimod. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study<sup>a</sup> did not measure the outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study<sup>a</sup> did not measure the outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Common infections</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study<sup>a</sup> did not measure the outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cancer</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study<sup>a</sup> did not measure the outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="7" rowspan="1" valign=""> <p>No reported deaths in any comparison group over 24 months' follow‐up. Death related to adverse events defined as CTCAE grade 5. Data collected from the Swedish MS registry and medical records. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*The <b>assumed risk</b> was calculated in GRADEpro based on the number of participants with the event over the total sample size in the control group, for binary and time‐to‐event outcomes. The <b>risk</b> <b>in the rituximab group </b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> (odds ratio or HR) of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>CTCAE:</b> National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0; <b>HR:</b> hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Explanations:</b> event rates in comparator based on the number of events in the included study. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>.<br/><sup>b</sup>Bias due to confounding by indication expected in the retrospective cohort study.<br/><sup>c</sup>The optimal information size criterion was not met (very few events).<br/><sup>d</sup>Results included both no effect and appreciable benefit or harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013874-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Rituximab as 'first choice' versus placebo for progressive multiple sclerosis – results from randomised controlled trials</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> primary progressive multiple sclerosis </p> <p><b>Settings:</b> inpatient or outpatient </p> <p><b>Intervention:</b> rituximab as first choice treatment </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with rituximab</b> </p> <p><b>(95% CI)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability worsening</b> measured by EDSS over 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>361 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>286 per 1000</b><br/>(202 to 385) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.71 </b> </p> <p>(0.45 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for some imprecision. Rituximab likely resulted in little to no difference in the number of participants who had disability worsening over 24 months when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> measured by clinical assessment over 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34</b> <b>per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21</b> <b>per 1000</b> </p> <p>(6 to 65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.60</b> </p> <p>(0.18 to 1.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels for very serious imprecision. Rituximab may have resulted in little to no difference in recurrence of relapses when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> measured by clinical assessment over 28 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>136 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>164 per 1000</b> </p> <p>(101 to 257)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.25</b> </p> <p>(0.71 to 2.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439<br/>(1 RCTs)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels for very serious imprecision. Rituximab may slightly increase the number of participants who have serious adverse events compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study<sup>a</sup> did not measure the outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Common infections</b> measured by clinical assessment over 28 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>653 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>682 per 1000</b> </p> <p>(585 to 765)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.14 </b> </p> <p>(0.75 to 1.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439<br/>(1 RCTs)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels for very serious imprecision. Rituximab may increase common infections compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cancer</b> measured by clinical assessment over 28 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> <p>(1 to 47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.50 </b> </p> <p>(0.07 to 3.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels for very serious imprecision. Quote: "Rituximab group: 1 patient had breast cancer and 1 had adenocarcinoma. Placebo group: 1 patient had parathyroid tumour, 1 had prostate cancer". </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> measured by clinical assessment over 28 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> <p>(0 to 37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.25</b> </p> <p>(0.02 to 2.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels for very serious imprecision. Rituximab may result in little to no difference in mortality compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The <b>assumed risk</b> was calculated based on the number of participants with the event over the total sample size in the placebo group, for binary outcomes. The <b>risk</b> <b>in the rituximab group </b> (and its 95% confidence interval) is based on the assumed risk in the placebo group and the <b>relative effect</b> (OR) of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>EDSS:</b> Expanded Disability Status Scale; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a>.<br/><sup>b</sup>Results included both appreciable benefit and no effect.<br/><sup>c</sup>We did not downgrade for risk of bias, even though the included study has some concerns.<br/><sup>d</sup>Results included both no effect and appreciable benefit or harm.<br/><sup>e</sup>Results included both no harm and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013874-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Rituximab as 'switching' versus placebo for relapsing multiple sclerosis – results from randomised controlled trials</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> relapsing multiple sclerosis<br/><b>Settings:</b> inpatient or outpatient<br/><b>Intervention:</b> rituximab as 'switching' treatment<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> <p><b> </b> </p> <p><b> </b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk with rituximab</b> </p> <p><b>(95% CI)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability worsening</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study<sup>a</sup> did not measure the outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> measured by clinical assessment over 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b><br/>(96 to 383) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.38 </b> </p> <p>(0.16 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 1 level for serious imprecision. Rituximab may result in a large reduction in recurrence of relapse over 12 months' follow‐up when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> measured by clinical assessment over 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b><br/>(45 to 327) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.90</b> </p> <p>(0.28 to 2.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on serious adverse events, when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study<sup>a</sup> did not measure the outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Common infections</b> measured by clinical assessment over 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>695 per 1000</b><br/>(481 to 848) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.91</b> </p> <p>(0.37 to 2.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 </p> <p>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on infections, when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cancer</b> measured by clinical assessment over 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.55</b> </p> <p>(0.06 to 39.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on the number of participants who have cancer, when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> measured by clinical assessment over 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.55</b> </p> <p>(0.06 to 39.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on mortality compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The <b>assumed risk</b> was calculated based on the number of participants with the event over the total sample size in the placebo group for binary outcomes. The <b>risk</b> <b>in the rituximab group </b> (and its 95% CI) is based on the assumed risk in the placebo group and the <b>relative effect</b> (OR) of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>.<br/><sup>b</sup>High risk of bias for unblinding of personnel and incomplete outcome data. Unclear risk of bias for allocation concealment and blinding of participants.<br/><sup>c</sup>The optimal information size criterion was not met (few events).<br/><sup>d</sup>The optimal information size criterion was not met (very few events). Results included both no harm and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013874-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Rituximab as 'switching' versus other disease‐modifying treatments for relapsing multiple sclerosis – results from non‐randomised studies of intervention</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> relapsing multiple sclerosis<br/><b>Settings:</b> inpatient or outpatient<br/><b>Intervention:</b> rituximab as 'switching' treatment<br/><b>Comparison:</b> other disease‐modifying treatments as 'switching' </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comparison</b> </p> <p><b>intervention</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b>* </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk with rituximab</b> </p> <p><b>(95% CI)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Disability worsening</b> measured by EDSS over 24 months: data collected from the Swedish MS registry and medical records </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Interferons or glatiramer acetate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>90 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b><br/>(48 to 125) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.86</b> </p> <p>(0.52 to 1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>853<br/>(1 retrospective cohort study)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels for very serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on disability worsening when compared with interferon beta or glatiramer acetate  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Relapse</b> measured by clinical assessment over 24 months: data collected from the Swedish MS registry and medical records </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Interferons or glatiramer acetate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>270 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b><br/>(22 to 143) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.18 </b> </p> <p>(0.07 to 0.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1383<br/>(1 retrospective cohort study)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level due to serious risk of bias. Rituximab likely results in a large reduction in recurrence of relapses when compared with interferons or glatiramer. The NNTB is 11 (95% CI 10 to 18). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b><br/>(4 to 60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.08 </b> </p> <p>(0.02 to 0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>256<br/>(1 retrospective cohort study)<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level due to serious risk of bias. Rituximab likely results in a large reduction in recurrence of relapses when compared with fingolimod. The NNTB is 6 (95% CI 6 to 9). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b><br/>(12 to 266) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.00 </b> </p> <p>(0.20 to 5.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153<br/>(1 retrospective cohort study)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on recurrence of relapses when compared with natalizumab. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the studies measured the outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies measured the outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Long‐term adverse events: common infections</b> over 24 months: data collected from MS registries and medical records. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Interferon beta or glatiramer acetate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b><br/>(40 to 89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.71</b> </p> <p>(1.11 to 2.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5477<br/>(1 retrospective cohort study‐ the national Swedish MS Register linked to national healthcare and census registries)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias in measurement of the outcome. Rituximab likely increases infections when compared with interferons or glatiramer acetate. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b><br/>(51 to 95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.26</b> </p> <p>(0.90 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5187</p> <p>(3 retrospective multicentre cohort studies)<sup>e,f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>i,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 1 level for imprecision. Heterogeneity: P = 0.24, I² = 30%. Rituximab may increase slightly common infections when compared with fingolimod. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b><br/>(51 to 95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.58</b> </p> <p>(1.08 to 2.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5001</p> <p>(2 retrospective multicentre cohort studies)<sup>f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias. Heterogeneity: P = 0.39, I² = 0%. Rituximab likely increases the number of participants who have common infections when compared with natalizumab. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ocrelizumab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/>(0 to 26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.02</b> </p> <p>(0.00 to 0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>472</p> <p>(1 retrospective multicentre cohort study). The Swedish MS register and medical records at the Rocky Mountain MS Clinic, Utah, US<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>j,l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels for very serious risk of bias and 1 level for imprecision. The evidence is very uncertain about the effect of rituximab on the number of participants who have common infections when compared with ocrelizumab. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cancer</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies measured the outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Mortality over 24 months:</b> defined as CTCAE grade 5. Data collected from the Swedish MS registry and medical records. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 5.59</b> </p> <p>(0.22 to 139.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136<br/>(1 retrospective multicentre cohort study)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>d,i,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias, 1 level for indirectness, and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on mortality compared with fingolimod. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 6.66</b> </p> <p>(0.27 to 166.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153<br/>(1 retrospective multicentre cohort study)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>d,i,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias, 1 level for indirectness, and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on mortality compared with natalizumab. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*The <b>assumed risk</b> was calculated in GRADEpro based on the number of participants with the event over the total sample size in the control group, for binary and time‐to‐event outcomes. The <b>risk</b> <b>in the rituximab group </b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> (OR or HR) of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>CTCAE:</b> National Cancer Institute. Common Terminology Criteria for Adverse Events version 4.0; <b>HR:</b> hazard ratio; <b>NNTB: </b> number needed to treat for an additional beneficial effect; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Explanations</b> </p> <p>Event rates in comparator based on the number of events in the included studies.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>.<br/><sup>b</sup>Bias due to missing data since time to disability worsening was limited to participants with a minimum of three EDSS scores reported, i.e. 321/461 (70%) participants in the rituximab group and 532/922 (58%) participants in the interferon or glatiramer acetate group.<br/><sup>c</sup>The optimal information size criterion was not met (few events). Results included both no effect and appreciable benefit or harm.<br/><sup>d</sup>Bias due to residual confounding is expected in a retrospective cohort study.<br/><sup>e</sup><a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>.<br/><sup>f</sup><a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>.<br/><sup>g</sup><a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>.<br/><sup>h</sup>Quote: "Data are not available on the validity of the registries to measure infections and on different reporting of infections between interventions" (<a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>).<br/><sup>i</sup>The optimal information size criterion was not met (very few events). Results included both no harm and appreciable harm.<br/><sup>j</sup>All retrospective cohort studies at serious risk of bias.<br/><sup>k</sup><a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>.<br/><sup>l</sup>The optimal information size criterion was not met (few events).<br/><sup>m</sup>Indirectness of outcome, one suicide in the rituximab group. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013874-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013874-sec-0009"></div> <section id="CD013874-sec-0010"> <h3 class="title" id="CD013874-sec-0010">Description of the condition</h3> <p>Multiple sclerosis (MS) is a chronic immune‐mediated disease of the central nervous system. The global prevalence of MS is estimated at 36 per 100,000 people, which means there are 2.8 million adults living with MS worldwide. MS is present in all regions of the world, but prevalence is noticeably higher in Europe and the Americas. There are at least twice as many females (69%) with MS as there are males (31%). MS can occur at any age, but the mean age at which MS is diagnosed is from 30 to 33 years. MS is the most common neurological cause of disability for young adults (<a href="./references#CD013874-bbs2-0152" title="The Multiple Sclerosis International Federation (MSIF). Atlas of MS, 3rd Edition. www.atlasofms.org September 2020.">MSIF 2020</a>). </p> <p>MS is pathologically characterised by inflammation, demyelination, and axonal and neuronal loss. Clinically, it is characterised by recurrent relapses and disability worsening. The clinical course is classified as relapsing MS, secondary progressive MS, and primary progressive MS (<a href="./references#CD013874-bbs2-0141" title="LublinFD , ReingoldSC , National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology1996;46:907-11.">Lublin 1996</a>). These forms of MS were used to design trials of interventions over two decades. An updated classification of MS forms was produced in 2013 (<a href="./references#CD013874-bbs2-0142" title="LublinFD , ReingoldSC , CohenJA , CutterGR , SørensenPS , ThompsonAJ . Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology2014;83(3):278-86.">Lublin 2014</a>). The concept of disease activity was added, based on the presence of clinical relapse or new magnetic resonance imaging (MRI) lesions in the brain. The new classification included: 1. active or inactive relapsing MS, with or without worsening; and 2. active or inactive primary or secondary progressive disease, with or without progression (<a href="./references#CD013874-bbs2-0142" title="LublinFD , ReingoldSC , CohenJA , CutterGR , SørensenPS , ThompsonAJ . Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology2014;83(3):278-86.">Lublin 2014</a>). Worldwide, 85% of people with MS are initially diagnosed with relapsing MS and 12% with progressive MS. The remaining 3% are given an unknown disease type on diagnosis (<a href="./references#CD013874-bbs2-0152" title="The Multiple Sclerosis International Federation (MSIF). Atlas of MS, 3rd Edition. www.atlasofms.org September 2020.">MSIF 2020</a>). </p> </section> <section id="CD013874-sec-0011"> <h3 class="title" id="CD013874-sec-0011">Description of the intervention</h3> <p>Rituximab is a monoclonal antibody approved for the treatment of adults with B‐cell non‐Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyarteritis, and pemphigus vulgaris (<a href="./references#CD013874-bbs2-0115" title="US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. www.accessdata.fda.gov/drugsatfda_docs/label/2020/103705s5460lbl.pdf (accessed 28 March 2020).">FDA 2020a</a>). Neurologists have used rituximab off‐label to treat neuromyelitis optica (<a href="./references#CD013874-bbs2-0105" title="DamatoV , EvoliA , IorioR . Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurology2016;73(11):1342-8.">Damato 2016</a>), myasthenia gravis (<a href="./references#CD013874-bbs2-0097" title="BanerjeeS , AdcockL . Rituximab for the Treatment of Myasthenia Gravis: a Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2018.">Banerjee 2018</a>), autoimmune encephalitis (<a href="./references#CD013874-bbs2-0153" title="NepalG , ShingYK , YadavJK , RehrigJH , OjhaR , HuangDY ,  et al. Efficacy and safety of rituximab in autoimmune encephalitis: a meta-analysis. Acta Neurologica Scandinavica2020;142(5):449-59.">Nepal 2020</a>), autoimmune neuropathies and myopathies (<a href="./references#CD013874-bbs2-0112" title="FasanoS , GordonP , HajjiR , LoyoE , IsenbergDA . Rituximab in the treatment of inflammatory myopathies: a review. Rheumatology (Oxford)2017;56(1):26-36.">Fasano 2017</a>), and MS (<a href="./references#CD013874-bbs2-0110" title="European Commission. Study on off-label use of medicinal products in the European Union. ec.europa.eu/health/sites/health/files/files/documents/2017_02_28_final_study_report_on_off-label_use_.pdf2017.">European Commission 2017</a>; <a href="./references#CD013874-bbs2-0168" title="SarsourK , Beckley-KarteyS , MelegaS , OdueyungboA , KirchnerP , KhalifeN , et al. Rituximab utilization for approved and off-label nononcology indications and patients' experiences with the Patient Alert Card. Pharmacology Research &amp; Perspectives2020;8(1):e00555.">Sarsour 2020</a>). This drug is marketed by Genentech‐Biogen in the US under the brand name Rituxan, and by Roche in Europe under the brand name MabThera. </p> <p>Rituximab is administered by intravenous infusion at single doses of 500 mg or 1000 mg, two weeks apart. The maintenance dose is 500 mg or 1000 mg every six to 12 months. The alternative induction dose, or in cases of disease breakthrough, is 375 mg/m<sup>2</sup> every week for four weeks. However, a treatment protocol has not yet been established; induction and maintenance doses may change based on the type of MS, MRI lesion load, clinical response, and CD19‐positive or CD20‐positive cell counts. The summary of product characteristics states that rituximab should be administered under the close supervision of an experienced physician. Serum rituximab's half‐life is reported to be 76.3 hours (<a href="./references#CD013874-bbs2-0143" title="MaloneyDG , Grillo-LopezAJ , BodkinDJ , WhiteCA , LilesTM , RoystonI , et al. IDECC2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. Journal of Clinical Oncology1997;15(10):3266-74.">Maloney 1997</a>). </p> <p>The most frequently observed short‐term adverse events in people receiving rituximab are infusion‐related reactions (<a href="./references#CD013874-bbs2-0115" title="US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. www.accessdata.fda.gov/drugsatfda_docs/label/2020/103705s5460lbl.pdf (accessed 28 March 2020).">FDA 2020a</a>). The majority of these reactions occur during the first infusion or within 24 hours of the infusion. The final report of the Rheumatoid Arthritis Global Clinical Trial Program, based on over 11 years' follow‐up, reported that rituximab remained well tolerated over time and for multiple courses (<a href="./references#CD013874-bbs2-0181" title="vanVollenhovenRF , FleischmannRM , FurstDE , LaceyS , LehanePB . Long-term safety of rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 years. Journal of Rheumatology2015;42(10):1761-6.">van Vollenhoven 2015</a>). Under long‐term therapy with rituximab or other B‐cell‐depleting drugs, and with alternative immunomodulatory agents for MS, immunoglobulin deficiency syndromes can occur that may be associated with severe infections (<a href="./references#CD013874-bbs2-0126" title="HallbergS , BoremalmM , EvertssonB , LillvallE , JohanssonF , LyckeJ , et al. Risk of hypogammaglobulinemia in long-term treatment with rituximab in multiple sclerosis. ECTRIMS online library. 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2019 Sept 11-13; Stockholm (Sweden)2019. [Abstract 64]">Hallberg 2019</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>; <a href="./references#CD013874-bbs2-0179" title="TsaoL ,  Otani IM, BoveR . Hypogammaglobulinemia in multiple sclerosis patients receiving disease-modifying immunomodulatory agents. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB16.">Tsao 2019</a>; <a href="./references#CD013874-bbs2-0181" title="vanVollenhovenRF , FleischmannRM , FurstDE , LaceyS , LehanePB . Long-term safety of rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 years. Journal of Rheumatology2015;42(10):1761-6.">van Vollenhoven 2015</a>). Hepatitis B virus (HBV) reactivation following chemotherapy that includes rituximab has been reported in people who have either had hepatitis B or are a carrier of HBV (<a href="./references#CD013874-bbs2-0111" title="EvensAM , JovanovicBD , SuYC , RaischDW , GangerD , BelknapSM , et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Annals of Oncology2011;22(5):1170-80.">Evens 2011</a>; <a href="./references#CD013874-bbs2-0159" title="PourcherV . What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature. Revue Neurologique (Paris)2020;176(4):235-43.">Pourcher 2020</a>). Progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection caused by a virus, can occur in rituximab‐treated people with haematological malignancies or other autoimmune diseases. Most people with haematological malignancies diagnosed with PML received rituximab in combination with chemotherapy or as part of a haematopoietic stem cell transplant (<a href="./references#CD013874-bbs2-0115" title="US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. www.accessdata.fda.gov/drugsatfda_docs/label/2020/103705s5460lbl.pdf (accessed 28 March 2020).">FDA 2020a</a>). People with autoimmune diseases diagnosed with PML had prior or concurrent immunosuppressive therapy (<a href="./references#CD013874-bbs2-0101" title="BergerJR , MalikV , LaceyS , BrunettaP , LehanePB . Progressive multifocal leucoencephalopathy in rituximab-treated rheumatic diseases: a rare event. Journal of Neurovirology2018;24(3):323-31.">Berger 2018</a>; <a href="./references#CD013874-bbs2-0115" title="US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. www.accessdata.fda.gov/drugsatfda_docs/label/2020/103705s5460lbl.pdf (accessed 28 March 2020).">FDA 2020a</a>). Most cases of PML were diagnosed within 12 months of their last infusion of rituximab (<a href="./references#CD013874-bbs2-0115" title="US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. www.accessdata.fda.gov/drugsatfda_docs/label/2020/103705s5460lbl.pdf (accessed 28 March 2020).">FDA 2020a</a>). Rituximab is listed as having "no or very low risk for PML" by <a href="./references#CD013874-bbs2-0186" title="YukitakeM . Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: a comprehensive review. Clinical and Experimental Neuroimmunology2018;9(Suppl 1):37-47.">Yukitake 2018</a>. Cardiac and vascular events (hypotension, hypertension, arrhythmias, and angina) have been reported with rituximab (<a href="./references#CD013874-bbs2-0115" title="US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. www.accessdata.fda.gov/drugsatfda_docs/label/2020/103705s5460lbl.pdf (accessed 28 March 2020).">FDA 2020a</a>). Two registry studies in Sweden showed no evidence of an increased risk of cancer with rituximab use in 3585 people with rheumatic disease (<a href="./references#CD013874-bbs2-0183" title="WadstromH , FrisellT , AsklingJ . Malignant neoplasms in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors, tocilizumab, abatacept, or rituximab in clinical practice: a nationwide cohort study from Sweden. JAMA Internal Medicine2017;177(11):1605-12.">Wadstrom 2017</a>), and in 4187 people with MS (<a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>). However, the results of one observational study showed an association between malignant melanoma and breast cancer with rituximab use (<a href="./references#CD013874-bbs2-0030" title="CalditoNG , ShiraniA , SalterA , StuveO . Adverse event profile differences between rituximab and ocrelizumab: findings from the FDA Adverse Event Reporting Database. Multiple Sclerosis2021;27(7):1066-76. ">Caldito 2021</a>).  </p> <p>Several disease‐modifying treatments (DMTs) have been discovered and approved for people with relapsing MS. Infused approved DMTs include: alemtuzumab, mitoxantrone, natalizumab, and ocrelizumab. Injectable approved DMTs include: interferon betas, glatiramer acetate, peginterferon beta‐1a, and ofatumumab. Oral approved DMTs include: cladribine, dimethyl fumarate, diroximel fumarate, fingolimod, monomethyl fumarate, ozanimod, siponimod, and teriflunomide. Recently the US Food and Drug Administration (FDA) approved siponimod (<a href="./references#CD013874-bbs2-0113" title="US Food and Drug Administration. New Drug Application (NDA): 209884. www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process (accessed 15 September 2020).">FDA 2019a</a>), ozanimod (<a href="./references#CD013874-bbs2-0116" title="US Food and Drug Administration. New Drug Application (NDA): 209899. www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=209899 (accessed 13 September 2020).">FDA 2020b</a>), and cladribine (<a href="./references#CD013874-bbs2-0114" title="FDA. New Drug Application (NDA): 022561. www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=022561 (accessed 15 September 2020).">FDA 2019b</a>) for active secondary progressive MS. </p> <p>Several national and international guidelines on the use of DMTs for MS are available (<a href="#CD013874-tbl-0005">Table 1</a>). Common to all guidelines is a moderate or low level of evidence available to assign strength to treatment recommendations, because there are few randomised studies that directly compared different DMTs as 'first choice' treatment or as 'switching'. Recommendations on the use of rituximab vary among guidelines, reflecting – among other things – the differences in regulatory agencies' recommendations and different regional or local health policies. For example, the use of rituximab has increased rapidly within Sweden for treating relapsing MS, since, under existing Swedish free right to prescription provisions, the treating hospital assumes responsibility and liabilities associated with off‐label use of rituximab (<a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>). The data from the national Swedish MS Registry showed an increasing prescription rate of rituximab in relation to other DMTs during the years 2011 to 2016. In June 2017, the proportion of people with MS starting rituximab as 'first choice' treatment was more than 50% (<a href="./references#CD013874-bbs2-0102" title="BerntssonSG , KristofferssonA , BoströmI , FeresiadouA , BurmanJ , LandtblomAM . Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden – outlier or predecessor?Acta Neurologica Scandinavica2018;138:327-31.">Berntsson 2018</a>). Rituximab is recommended by the Middle East and North Africa Committee (MENACTRIMS) Consensus as an off‐label treatment for highly active MS and as an escalation therapy for all levels of MS activity in special populations, such as refugees, or in countries where other appropriate options are not available (<a href="./references#CD013874-bbs2-0185" title="YamoutB , SahraianM , BohlegaS , Al-JumahM , GoueiderR , DahdalehM , et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Multiple Sclerosis and Related Disorders2020;37:101459.">Yamout 2020</a>). The European guideline does not include recommendations on the use of rituximab, as regulations on this treatment vary broadly between different European countries (<a href="./references#CD013874-bbs2-0151" title="MontalbanX , GoldR , ThompsonAJ , Otero-RomeroS , AmatoMP , ChandraratnaD , et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal2018;24(2):96-120.">Montalban 2018</a>).  </p> <div class="table" id="CD013874-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Treatment guidelines for multiple sclerosis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>European ECTRIMS/EAN Guideline</b> </p> <p><b>(</b><a href="./references#CD013874-bbs2-0151" title="MontalbanX , GoldR , ThompsonAJ , Otero-RomeroS , AmatoMP , ChandraratnaD , et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal2018;24(2):96-120."><b>Montalban 2018</b> </a><b>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>American Academy of Neurology practice guideline</b> (<a href="./references#CD013874-bbs2-0161" title="Rae-GrantA , DayGS , MarrieRA , RabinsteinA , CreeBA , GronsethGS , et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology2018;90(17):777-88.">Rae‐Grant 2018</a>) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Brazilian Consensus</b> (<a href="./references#CD013874-bbs2-0144" title="MarquesVD , PassosGR , MendesMF , CallegaroD , Lana-PeixotoMA , Comini-FrotaER , et al. Brazilian consensus for the treatment of multiple sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis. Arquivos de Neuro-psiquiatria2018;76(8):539-54.">Marques 2018</a>) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>The Middle East and North Africa Committee Consensus</b> (<a href="./references#CD013874-bbs2-0185" title="YamoutB , SahraianM , BohlegaS , Al-JumahM , GoueiderR , DahdalehM , et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Multiple Sclerosis and Related Disorders2020;37:101459.">Yamout 2020</a>) </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Question 1</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with CIS, what is the benefit of starting treatment with a DMT compared to no treatment? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with CIS, are DMTs superior to placebo in decreasing the risk of conversion to MS? </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with CIS, are DMTs efficacious in preventing conversion to MS?</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Should people with CIS be treated with DMTs?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recommendation</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Offer interferon or glatiramer acetate to people with CIS and an abnormal MRI with lesions suggestive of MS who do not fulfil criteria for MS. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Clinicians may recommend at least annual MRI for the first 5 years and follow‐up rather than initiating DMT in people with CIS who have not had relapses in the preceding 2 years, and do not have active new MRI lesions on recent imaging. </p> <p>2. After discussing the risks and benefits, clinicians should prescribe DMT to people with CIS and ≥ 2 brain lesions characteristic of MS who decide they want this therapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It seems reasonable to start DMTs only in people with high‐risk CIS<sup>a</sup> as well as to choose safer drugs. Efficacy in CIS has been demonstrated with the interferon betas, cladribine, glatiramer </p> <p>acetate, and teriflunomide. Since no direct comparison between these is available, any of these drugs are deemed appropriate for the treatment of high‐risk CIS<sup>a</sup>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the overall clinical and radiological picture is suggestive of MS, people with CIS and high MRI lesion load (&gt; 9 T2 lesions), or with severe relapses with incomplete recovery, or both, should be treated. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Strong</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Level C: "may"</p> <p>2. Level B: "should"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Question 2</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with RRMS, what is the benefit of treating with a DMT compared to no treatment or another DMT? </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with RRMS, are DMTs superior to placebo or other DMTs in preventing relapse at 2 years, reducing MRI new disease activity, and preventing disease progression? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with relapsing MS, are DMTs efficacious in reducing relapses, MRI disease activity, and disability? </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Should people with RRMS be treated with DMTs?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recommendation</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Offer early treatment with DMTs to people with active RRMS<sup>b</sup>. </p> <p>2. For active RRMS, choosing between the wide range of available DMTs, from the modestly effective to the highly efficacious, depends on individual characteristics and comorbidities, disease severity or activity, drug safety profile, and accessibility of the drug, in discussion with the person with active RRMS. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinicians should:</p> <p>1. offer DMTs to people with RRMS with recent clinical relapses or MRI activity;</p> <p>2. prescribe alemtuzumab, fingolimod, or natalizumab for people with highly active MS<sup>b</sup>. </p> <p>Clinicians may:</p> <p>3. recommend azathioprine or cladribine for people with RRMS who do not have access to approved DMTs. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. It would seem reasonable to start</p> <p>treatment with interferons, glatiramer acetate, pegylated interferon beta, dimethyl fumarate, or teriflunomide, (good safety profile and more easily available, including in the Brazilian public health system). </p> <p>2. Consider alemtuzumab, cladribine, fingolimod, natalizumab, and ocrelizumab for people with highly active relapsing MS<sup>c</sup>. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. In treatment‐naive people, interferons, glatiramer acetate, teriflunomide, and dimethyl fumarate can be initiated. </p> <p>2. In people with highly active disease<sup>d</sup> fingolimod, siponimod, natalizumab, ocrelizumab, or cladribine may be initiated. </p> <p>3. In people with rapidly evolving aggressive disease<sup>e</sup> natalizumab, ocrelizumab, or alemtuzumab are recommended after careful risk stratification. </p> <p>4. Rituximab can be used off‐label for highly active disease and rapidly evolving aggressive disease in special populations such as refugees, or in countries where other appropriate </p> <p>options are not available.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of evidence</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Strong</p> <p>2. Consensus statement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. and 2. Level B: "should"</p> <p>3. Level C: "may"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Question 3</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with active SPMS, what is the benefit of treating with a DMT compared to no treatment or another DMT? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with SPMS, are DMTs efficacious?</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with non‐active SPMS, are DMTs efficacious?</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Should people with SPMS be treated with DMTs?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recommendation</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consider treatment with interferons, mitoxantrone, ocrelizumab, or cladribine for people with active SPMS. </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Clinicians should prescribe alemtuzumab, fingolimod, or natalizumab for people with highly active MS<sup>b</sup>. </p> <p>2. Clinicians may advise discontinuation of DMT in people with SPMS who do not have ongoing relapses or MRI activity and have not been ambulatory (EDSS ≥ 7) for ≥ 2 years. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Not prescribing a DMT is an acceptable choice in people with SPMS who no longer present relapses. </p> <p>2. In cases of rapidly progressive disease, cyclophosphamide, mitoxantrone, and autologous haematopoietic stem cell transplantation may be used as off‐label treatments. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Consider treatment with ocrelizumab or siponimod in people with active SPMS, aged ≤ 60 years and EDSS ≤ 6.5 (i.e. not needing a wheelchair). </p> <p>2. In people with rapidly progressive SPMS not responding to ocrelizumab or siponimod or who have no access to these medications, cyclophosphamide, methotrexate, or mycophenolate may be warranted. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weak</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Level B: "should"</p> <p>2. Level C: "may"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Question 4</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with PPMS, what is the benefit of treating with a DMT compared to no treatment?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with PPMS, are DMTs superior to placebo or other DMTs as measured by relapse rate or disease progression? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with PPMS, are DMTs efficacious in delaying the progression of disability?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Should people with PPMS be treated with DMTs?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recommendation</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consider treatment with ocrelizumab for people with PPMS.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinicians should offer ocrelizumab to people with PPMS.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ocrelizumab should be the treatment of choice for people with PPMS, after consideration</p> <p>of the expected benefits and potential risks on a case‐by‐case basis.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consider treatment with ocrelizumab for people with PPMS, aged ≤ 55 years, EDSS ≤ 6.5 (i.e. not needing a wheelchair), and disease duration ≤ 10–15 years. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weak</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Level B: "should"</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Question 5</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. In people with RRMS treated with interferon or glatiramer acetate and evidence of disease activity at 6 or 12 months, what is the benefit of switching to more efficacious drugs? </p> <p>2. In people with relapsing MS who stop taking a highly efficacious drug, what is the benefit of further treatment? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with RRMS who experience disease activity while on a DMT, is changing to a different DMT superior to continuing the present DMT in terms of relapse and MRI disease activity? </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>When to consider DMT switching in people with RRMS?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>When to consider DMT switching in people with RRMS?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recommendation</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Offer a more efficacious drug to people treated with interferon or glatiramer acetate who show evidence of disease activity. </p> <p>2. Consider starting another highly efficacious drug, taking into account disease activity, half‐life and biological activity of the previous drug, and the potential for rebound (particularly with natalizumab). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Clinicians should discuss switching from 1 DMT to another in people with MS treated long enough for the treatment to take full effect when they experience ≥ 1 relapse, ≥ 2 new MRI lesions, or increased disability, over a 1‐year period of using a DMT. </p> <p>2. Clinicians should evaluate the degree of disease activity, adherence, AE profiles, and mechanism of action of DMTs when switching DMTs in people with MS with breakthrough disease activity during DMT use. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. If the management of highly active MS<sup>c</sup> with potent DMTs has achieved a satisfactory response and stability for several years, it would be </p> <p>acceptable (though not mandatory) to consider switching to a lower potency DMT.</p> <p>2. If a person with relapsing MS fails to achieve satisfactory responses, presents intolerance or safety concerns with interferons, dimethyl fumarate, glatiramer acetate, pegylated interferon, teriflunomide, a switch to alemtuzumab, cladribine, fingolimod, natalizumab, ocrelizumab should be considered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. In people with moderately active disease and suboptimal response<sup>f</sup> to interferons, dimethyl fumarate, glatiramer acetate, teriflunomide, treatment escalation to fingolimod, siponimod, natalizumab, ocrelizumab, or cladribine should be considered. </p> <p>2. Rituximab can be used off‐label as an escalation therapy for all levels of MS activity, in special populations such as refugees, or in countries </p> <p>where other appropriate options are not available.</p> <p>3. In people with evidence of suboptimal response to any of the second‐line medications, off‐label cyclophosphamide, autologous haematopoietic stem cell transplantation, or mitoxantrone should be considered. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Strong</p> <p>2. Consensus statement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. and 2. Level B: "should"</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Question 6</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with RRMS who experience AEs while on a DMT, is switching necessary?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recommendation</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinicians should:</p> <p>1. discuss a change to non‐injectable or less frequently injectable DMTs in people with MS who report intolerable discomfort with the injections or in those who report injection fatigue on injectable DMTs; </p> <p>2. discuss a medication switch with people with MS for whom AEs negatively influence adherence; </p> <p>3. discuss switching DMT or reducing dosage or frequency when there are serious infections or persistent laboratory abnormalities; </p> <p>4. discuss switching to a DMT with a lower risk of progressive multifocal leucoencephalopathy with people with MS taking natalizumab who are or become antibody–positive to John Cunningham (JCV) virus, while on therapy; </p> <p>5. discuss switching to an alternate DMT for people with MS who develop a malignancy while using azathioprine, methotrexate, mycophenolate, cyclophosphamide, fingolimod, teriflunomide, alemtuzumab, or dimethyl fumarate; </p> <p>6. switch DMTs in people with MS who have persistent natalizumab antibodies.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1., 2., 3., 4., 5., and 6. Level B: "should"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>High‐risk CIS defined by one or more typical MRI T2 lesion(s), provided both the clinical presentation and MRI lesion(s) are suggestive of central nervous system demyelination and not attributable to other diseases.<br/><sup>b</sup>Active RRMS or highly active MS defined by clinical relapses or MRI activity (active lesions – contrast‐enhancing lesions; new or unequivocally enlarging T2 lesions assessed at least annually), or both.<br/><sup>c</sup>Highly active MS defined as: 1. at least two disabling relapses with incomplete resolution and at least one contrast‐enhancing lesion or significant increase in T2 lesion load in the previous year in treatment‐naive people; or 2. breakthrough disease activity in the previous year, under an adequate course of at least one DMT (in the absence of intolerance or non‐adherence), presenting with at least one relapse in the previous year while on therapy and at least nine MRI T2 lesions or at least one contrast‐enhancing lesion.<br/><sup>d</sup>Highly active disease defined as: 1. at least two relapses in the previous year; 2. relapse severity; 3. incomplete recovery; 4. at least 10 MRI T2 lesions; 5. multiple contrast enhancing lesions.<br/><sup>e</sup>Rapidly evolving aggressive disease defined as the presence of at least two disabling relapses with incomplete recovery in the previous year and at least 10 MRI T2 lesions.<br/><sup>f</sup>Suboptimal response to chronic DMTs should be considered after one year of treatment in people with at least one relapse or disability progression or both, or at least two active MRI lesions (gadolinium or new T2‐weighted, or both) after one year of adequate treatment and using as baseline an MRI performed six months after treatment initiation. </p> <p>AE: adverse events; CIS: clinically isolated syndrome; DMT: disease‐modifying treatment; ECTRIMS/EAN: European Committee of Treatment of Research in Multiple Sclerosis and European Academy of Neurology; EDSS: Expanded Disability Status Scale; MRI: magnetic resonance imaging; MS: multiple sclerosis; PPMS: primary progressive multiple sclerosis; RRMS: relapsing‐remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis. </p> </div> </div> </section> <section id="CD013874-sec-0012"> <h3 class="title" id="CD013874-sec-0012">How the intervention might work</h3> <p>The inflammation in the central nervous system in MS stems from complex interactions between T cells and antigen‐presenting cells, such as B cells and myeloid cells (macrophages, dendritic cells, and microglia) (<a href="./references#CD013874-bbs2-0104" title="ComiG , Bar-OrA , LassmannH , UccelliA , HartungHP , MontalbanX , et al. Expert Panel of the 27th Annual Meeting of the European Charcot Foundation. Role of B Cells in Multiple Sclerosis and Related Disorders. Annals of Neurology2021;89(1):13-23.">Comi 2021</a>; <a href="./references#CD013874-bbs2-0187" title="ZhongM , van derWaltA , CampagnaMP , StankovichJ , ButzkuevenH , JokubaitisV . The pharmacogenetics of rituximab: potential implications for anti-CD20 therapies in multiple sclerosis. Neurotherapeutics2020;17(4):1768-84. [DOI: 10.1007/s13311-020-00950-2]">Zhong 2020</a>). The pro‐inflammatory role of B cells in MS involves antigen presentation to activate pathogenic T cells and macrophages, production of pro‐inflammatory cytokines, and formation and maintenance of ectopic lymphoid organs in the central nervous system (<a href="./references#CD013874-bbs2-0125" title="GreenfieldAL , HauserSL . B cell therapy for multiple sclerosis: entering an era. Annals of Neurology2018;83(1):13-26.">Greenfield 2018</a>; <a href="./references#CD013874-bbs2-0127" title="HauserSL . The Charcot Lecture: beating MS: a story of B cells, with twists and turns. Multiple Sclerosis2015;21:8-21.">Hauser 2015</a>; <a href="./references#CD013874-bbs2-0165" title="SabatinoJJ , Pröbstel A-K, ZamvilSS . B cells in autoimmune and neurodegenerative central nervous system diseases. Nature Reviews. Neuroscience2019;20(12):728-45.">Sabatino 2019</a>). B cells are highly selective for antigens bound to their cell receptor (BCR) (<a href="./references#CD013874-bbs2-0125" title="GreenfieldAL , HauserSL . B cell therapy for multiple sclerosis: entering an era. Annals of Neurology2018;83(1):13-26.">Greenfield 2018</a>). The antigen–BCR complex is internalised and processed, its constituent peptides are then complexed with the major histocompatibility complex (MHC) class II molecules, and the antigen–MHC complex is transported to the cell surface where it can activate T cells (Th1 and Th17) by involvement of the T cell receptor and costimulatory molecules (<a href="./references#CD013874-bbs2-0099" title="BatistaFD , HarwoodNE . The who, how and where of antigen presentation to B cells. Nature Reviews. Immunology2009;9(1):15-27.">Batista 2009</a>). In MS, priming of T cells is caused by autoreactive B cells that demonstrate higher levels of antigen‐presenting activity compared to B cells of healthy controls or individuals with other neuroinflammatory diseases (<a href="./references#CD013874-bbs2-0135" title="JelcicI , Al NimerF , WangJ , LentschV , PlanasR , JelcicI , et al. Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis. Cell2018;175(1):85-100.e23.">Jelcic 2018</a>; <a href="./references#CD013874-bbs2-0146" title="MathiasA , PerriardG , CanalesM , SonesonC , DelorenziM , SchluepM , et al. Increased ex vivo antigen presentation profile of B cells in multiple sclerosis. Multiple Sclerosis2017;23(6):802-9.">Mathias 2017</a>). The binding of autoantigen to BCR also causes aberrant B cells to produce pro‐inflammatory and regulatory cytokines. B cells of people with MS cultured in vitro have been found to secrete higher levels of pro‐inflammatory cytokines and lower levels of regulatory cytokines (<a href="./references#CD013874-bbs2-0098" title="Bar-OrA , FawazL , FanB , DarlingtonPJ , RiegerA , GhorayebC , et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?Annals of Neurology2010;67(4):452-61.">Bar‐Or 2010</a>; <a href="./references#CD013874-bbs2-0108" title="DuddyM , NiinoM , AdatiaF , HebertS , FreedmanM , AtkinsH , et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. Journal of Immunology2007;178(10):6092-9.">Duddy 2007</a>). In the milieu of pro‐inflammatory cytokines, chemokines, and lymphotoxin signalling, B cells support the development of ectopic B‐cell follicles that have been detected in the meninges of people with secondary progressive MS (<a href="./references#CD013874-bbs2-0171" title="SerafiniB , RosicarelliB , MagliozziR , StiglianoE , AloisiF . Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathology2004;14(2):164-74.">Serafini 2004</a>). </p> <p>Rituximab binds selectively to the CD20 antigen expressed on the surface of pre‐B cells, mature and memory B cells, and some plasmablasts, but not B‐cell progenitors (pro‐B cells) and differentiated plasma cells (i.e. B cells that do not express CD20) (<a href="./references#CD013874-bbs2-0125" title="GreenfieldAL , HauserSL . B cell therapy for multiple sclerosis: entering an era. Annals of Neurology2018;83(1):13-26.">Greenfield 2018</a>; <a href="./references#CD013874-bbs2-0174" title="St ClairEW . Good and bad memories following rituximab therapy. Arthritis and Rheumatism2010;62(1):1-5.">St Clair 2010</a>). Therefore, administration of rituximab causes selective loss of circulating and tissue‐based B cells that are responsible for antigen presentation and cytokine production, without affecting B‐cell reconstitution or pre‐existing humoral immunity. Mechanisms of B‐cell lysis include primarily complement‐dependent cytotoxicity (CDC) but also antibody‐dependent cellular cytotoxicity (ADCC) (<a href="./references#CD013874-bbs2-0125" title="GreenfieldAL , HauserSL . B cell therapy for multiple sclerosis: entering an era. Annals of Neurology2018;83(1):13-26.">Greenfield 2018</a>). Other modes of action of rituximab have been proposed (e.g. depletion of CD20 cells or Epstein‐Barr herpesvirus (EBV) reservoir depletion) (<a href="./references#CD013874-bbs2-0134" title="IneichenBV , MoridiT , GranbergT , PiehlF . Rituximab treatment for multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England)2020;26(2):137-52.">Ineichen 2020</a>). </p> <p>Rituximab was detectable in the serum of people three to six months after completion of treatment (<a href="./references#CD013874-bbs2-0115" title="US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. www.accessdata.fda.gov/drugsatfda_docs/label/2020/103705s5460lbl.pdf (accessed 28 March 2020).">FDA 2020a</a>). Following intravenous administration of rituximab, B lymphocytes typically remain depleted in peripheral blood for six to nine months (<a href="./references#CD013874-bbs2-0125" title="GreenfieldAL , HauserSL . B cell therapy for multiple sclerosis: entering an era. Annals of Neurology2018;83(1):13-26.">Greenfield 2018</a>; <a href="./references#CD013874-bbs2-0164" title="RollP , PalanichamyA , KneitzC , DornerT , TonyHP . Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis and Rheumatism2006;54(8):2377-86.">Roll 2006</a>). In non‐blood tissues, including the central nervous system, the extent and duration of depletion is not fully known but is likely to be partial, to depend on the dose, and to be modulated by individual factors such as genetic background (<a href="./references#CD013874-bbs2-0125" title="GreenfieldAL , HauserSL . B cell therapy for multiple sclerosis: entering an era. Annals of Neurology2018;83(1):13-26.">Greenfield 2018</a>). </p> </section> <section id="CD013874-sec-0013"> <h3 class="title" id="CD013874-sec-0013">Why it is important to do this review</h3> <p>The off‐label use of rituximab to treat MS has been reported in most countries (70 of the 102 countries reported in the Multiple Sclerosis International Federation's (MSIF) Atlas of MS) (<a href="./references#CD013874-bbs2-0139" title="Laurson-DoubeJ , RijkeN , HelmeA , BanekeP , BanwellB , ViswanathanS , et al. Ethical use of off-label disease-modifying therapies for multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England)2021;27(9):1403-10.">Laurson‐Doube 2021</a>). Several published observational data have strengthened the evidence for effectiveness and safety of rituximab in MS, and reported a discontinuation rate that was lower than that of other DMTs (<a href="./references#CD013874-bbs2-0124" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7.">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0166" title="SalzerJ , SvenningssonR , AlpingP , NovakovaL , BjörckA , FinkK , et al. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology2016;87(20):2074-81.">Salzer 2016</a>). The identification of beneficial and adverse effects of rituximab for both relapsing MS and progressive forms of MS, including switching drug regimens, increases the importance of this review mainly for low‐ and medium‐income countries. </p> <p>Given that the period of patent protection has expired, it is extremely unlikely that a registration trial of rituximab for MS will ever been undertaken. Therefore, evidence on beneficial and adverse effects of rituximab for MS will not be provided by randomised trials. Considering that rituximab is widely used as off‐label treatment in people with MS, we have a duty to people with MS, practitioners, and policymakers to provide these groups with a summary of available evidence that includes controlled non‐randomised studies (<a href="./references#CD013874-bbs2-0162" title="ReevesBC , DeeksJJ , HigginsJP , SheaB , TugwellP , WellsGA . Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Reeves 2019</a>). </p> <p>Ocrelizumab and ofatumumab, which are anti‐CD20 monoclonal antibodies similar to rituximab, have been approved as treatments for relapsing and active progressive forms of MS, but these medicines are not available in low‐income countries due to prohibitive costs. Rituximab is a relatively inexpensive treatment, cheaper than any other approved DMTs for MS, and it is a feasible option in resource‐limited settings (<a href="./references#CD013874-bbs2-0145" title="MathewT , JohnSK , KamathV , MurgodU , ThomasK , BaptistAA , et al. Efficacy and safety of rituximab in multiple sclerosis: experience from a developing country. Multiple Sclerosis and Related Disorders2020;43:102210.">Mathew 2020</a>). With increasing incidence and prevalence of MS globally, especially in low‐ and middle‐income countries, it is essential to ensure that people with MS have timely access to safe and effective treatments (<a href="./references#CD013874-bbs2-0137" title="Lancet Neurology. Essential medicines for patients with multiple sclerosis. Lancet Neurology2019;18(12):1067.">Lancet Neurology 2019</a>). </p> <p>We considered that a new review was more appropriate, rather than updating the previous Cochrane Review (<a href="./references#CD013874-bbs2-0189" title="HeD , GuoR , ZhangF , ZhangC , DongS , ZhouH . Rituximab for relapsing‐remitting multiple sclerosis. Cochrane Database of Systematic Reviews2013, Issue 12. Art. No.: CD009130. Art. No: CD009130. [DOI: 10.1002/14651858.CD009130.pub3]">He 2013</a>), because changes to the review methods were substantive. We decided to add non‐randomised studies to the review that was previously restricted to randomised controlled trials (RCTs), to widen the evidence base, making use of the Risk Of Bias in Non‐randomised Studies – of Interventions tool (ROBINS‐I) in critical evaluation of the validity of non‐randomised studies. We now added progressive forms of MS to the review that was previously restricted to relapsing MS. New DMTs have been approved since the early 2010s to treat relapsing and progressive MS, therefore, we added new comparisons including all DMTs that were used at 31 January 2021. We included important new outcomes (e.g. mortality, common infections, cancer) that were not addressed in the original review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013874-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013874-sec-0014"></div> <p>To assess beneficial and adverse effects of rituximab as 'first choice' and as 'switching' for adults with MS. </p> <p>Specific comparisons included:</p> <p> <ul id="CD013874-list-0001"> <li> <p>rituximab as 'first choice' treatment compared with placebo or other DMTs for relapsing forms of MS; </p> </li> <li> <p>rituximab as 'first choice' treatment compared with placebo or other DMTs for progressive forms of MS; </p> </li> <li> <p>rituximab as 'switching' from another DMT compared with placebo or other DMTs for relapsing forms of MS; </p> </li> <li> <p>rituximab as 'switching' from another DMT compared with placebo or other DMTs for progressive forms of MS. </p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013874-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013874-sec-0015"></div> <section id="CD013874-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013874-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included parallel RCTs and controlled non‐randomised studies of interventions (NRSIs) of between‐group design (i.e. open‐label extension (OLE) studies, controlled clinical trials, controlled cohort studies, regression discontinuity designs, case‐control studies, and registries). We had two main justifications for including NRSIs in the review. First, to provide evidence of the effects of rituximab for which only few RCTs were available. Second, to address long‐term outcomes and different populations that are typical of real‐world practice. We excluded studies of within‐group design (e.g. before‐after (pre–post) studies with no control group, interrupted time series, and case reports). </p> <p>We excluded studies that did not record any relevant outcomes.</p> <p>We applied no limitations with respect to the length of follow‐up or methods of analysis. We included full‐text publications, results published in non‐commercial trial registries (e.g. ClinicalTrials.gov record), and abstracts if sufficient information was available on study design, characteristics of participants, interventions, and outcomes. </p> </section> <section id="CD013874-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included adults (aged 18 years or older), of either sex, who were treatment‐naive or non‐responsive to their current DMT. We accepted any definition of non‐response that the included studies used because the criteria for treatment failure, either using clinical or imaging criteria, were still not agreed upon and different criteria were used in clinical routine practice. Diagnostic criteria for MS were the Poser criteria (<a href="./references#CD013874-bbs2-0158" title="PoserCM , PatyDW , ScheinbergL , McDonaldWI , DavisFA , EbersGC , et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology1983;13(3):227-31.">Poser 1983</a>), and the McDonald criteria and its revisions (<a href="./references#CD013874-bbs2-0147" title="McDonaldWI , CompstonA , EdanG , GoodkinD , HartungHP , LublinFD , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology2001;50(1):121-7.">McDonald 2001</a>; <a href="./references#CD013874-bbs2-0156" title='PolmanCH , ReingoldSC , EdanG , FilippiM , HartungHP , KapposL , et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology2005;58(6):840-6.'>Polman 2005</a>; <a href="./references#CD013874-bbs2-0157" title="PolmanCH , ReingoldSC , BanwellB , ClanetM , CohenJA , FilippiM , et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology2011;69(2):292-302.">Polman 2011</a>; <a href="./references#CD013874-bbs2-0176" title="ThompsonAJ , BanwellBL , BarkhofF , CarrollWM , CoetzeeT , ComiG , et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology2018;17(2):162-73.">Thompson 2018</a>). We included all forms of MS (i.e. relapsing MS, secondary progressive MS, and primary progressive MS), regardless of disease duration and disability degree according to the Expanded Disability Status Scale (EDSS) (<a href="./references#CD013874-bbs2-0136" title="KurtzkeJF . Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology1983;33:1444-52.">Kurtzke 1983</a>). </p> </section> <section id="CD013874-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Rituximab as 'first choice' and as 'switching' treatment, as monotherapy or in combination treatments, irrespective of doses, timing, and frequency of treatment. We included combination treatments only if they were used in all the comparison groups.  </p> <p>We included studies comparing rituximab with placebo or with approved DMTs, interferons, peg interferon, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide, dimethyl fumarate, cladribine, alemtuzumab, daclizumab, or ocrelizumab. We included studies that assessed switching to rituximab from another DMT compared to placebo or any other DMT, independently of the reason for switching, method, or time when the switch was made. </p> </section> <section id="CD013874-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We included short‐term (12 to 24 months) and long‐term (&gt; 24 months) outcomes reported in the included studies. </p> <section id="CD013874-sec-0021"> <h5 class="title">Primary outcomes</h5> <section id="CD013874-sec-0022"> <h6 class="title">Critical outcomes</h6> <p> <ul id="CD013874-list-0002"> <li> <p>Disability worsening: number of participants with sustained disability worsening based on clinical follow‐up visits. Worsening was defined as at least a 1‐point increase on the EDSS (<a href="./references#CD013874-bbs2-0136" title="KurtzkeJF . Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology1983;33:1444-52.">Kurtzke 1983</a>), or a 0.5‐point increase if the baseline EDSS score was more than 5.5, confirmed during two consecutive clinical examinations separated by an interval of at least six months free of attacks and carried out by the same physician. EDSS is an ordinal scale, where a score of 0 is no disability, 3 indicates mild disability, 6 walking stick requirement, 7 wheelchair use, and 10 is death from MS. An advantage of the EDSS over other disability measures is its international acceptance (e.g. by the European Medicines Agency (EMA)) as a primary endpoint in clinical trials (<a href="./references#CD013874-bbs2-0109" title="European Medicines Agency (EMA). Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. EMA/CHMP/771815/2011, Rev. 2. www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-multiple-sclerosis_en-0.pdf2015.">EMA 2015</a>), and its broad use in trials that enables cross‐study comparisons (<a href="./references#CD013874-bbs2-0149" title="Meyer-MoockS , FengYS , MaeurerM , DippelFW , KohlmannT . Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurology2014;14:58.">Meyer‐Moock 2014</a>). We also assessed time‐to‐disability worsening. </p> </li> <li> <p>Recurrence of relapse: number of participants with clinical relapse, based on clinical follow‐up visits. 'Relapse' was defined as the appearance of one or more new symptoms due to MS, or the deterioration of pre‐existing symptoms, persisting more than 24 hours in the absence of fever, and preceded by a period of stability of at least one month (<a href="./references#CD013874-bbs2-0147" title="McDonaldWI , CompstonA , EdanG , GoodkinD , HartungHP , LublinFD , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology2001;50(1):121-7.">McDonald 2001</a>). We also assessed time‐to‐relapse. </p> </li> <li> <p>Serious adverse events (SAEs): number of participants with SAEs, as defined by the authors of the study. If an insufficient number of studies reported the total number of SAEs and person‐years, we used the number of participants with at least one SAE as defined in the study. </p> </li> </ul> </p> </section> </section> <section id="CD013874-sec-0023"> <h5 class="title">Secondary outcomes</h5> <section id="CD013874-sec-0024"> <h6 class="title">Important prioritised outcomes</h6> <p>The following four outcomes, together with the critical outcomes, were prioritised to form the basis of the GRADE assessment and were summarised in the review's abstract and in the summary of findings tables. </p> <p> <ul id="CD013874-list-0003"> <li> <p>Quality of life: number of participants reporting quality of life impairment, assessed according to validated measures (e.g. the Multiple Sclerosis Quality of Life‐54 tool (MSQOL‐54), which is a multidimensional health‐related quality of life measure (<a href="./references#CD013874-bbs2-0182" title="VickreyBG , HaysRD , HarooniR , MyersLW , EllisonGW . A health-related quality of life measure for multiple sclerosis. Quality of Life Research1995;4(3):187-206.">Vickrey 1995</a>)). MSQOL‐54 includes the generic 36‐item Short‐Form quality of life instrument, supplemented with 18 MS‐specific items that were based on expert opinion and literature review. There is no single overall score for MSQOL‐54. Two summary scores, physical health and mental health, can be derived from a weighted combination of scale scores (scale scores range from 0 to 100 and a higher scale score indicates improved quality of life). </p> </li> <li> <p>Number of participants with common infections.</p> </li> <li> <p>Number of participants with cancer.</p> </li> <li> <p>Mortality.</p> </li> </ul> </p> </section> <section id="CD013874-sec-0025"> <h6 class="title">Additional important outcomes </h6> <p> <ul id="CD013874-list-0004"> <li> <p>Annualised relapse rate (ARR): mean number of new relapses per participant, adjusted for the duration of follow‐up to annualise it. ARR is a frequently reported clinical outcome in trials on relapsing MS. </p> </li> <li> <p>Cognitive decline: number of participants with cognitive worsening, assessed according to validated neurocognitive batteries for MS (e.g. the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) (<a href="./references#CD013874-bbs2-0100" title="BenedictRH , AmatoMP , DeLucaJ , GeurtsJJ . Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurology2020;19(10):860-71.">Benedict 2020</a>; <a href="./references#CD013874-bbs2-0138" title="LangdonDW , AmatoMP , BoringaJ , BrochetB , FoleyF , FredriksonS , et al. Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Multiple Sclerosis2012;18:891-8.">Langdon 2012</a>). </p> </li> <li> <p>Number of participants with new or enlarging T2‐weighted MRI lesions*. A T2‐weighted MRI sequence provides information about the total number of lesions. T2 lesions appear as bright spots on the scan and could correlate to a panel of different MS pathological hallmarks. However, new T2 lesions are used as a measure of disease activity. </p> </li> <li> <p>Number of participants with new gadolinium‐enhancing positive T1‐weighted MRI lesions*. T1‐weighted MRI lesions, mostly black holes, are believed to represent permanent tissue damage. Gadolinium‐enhancing T1 lesions are a surrogate for blood–brain barrier breakdown. </p> </li> <li> <p>Number of participants who discontinued treatment due to adverse events. We also assessed time‐to‐discontinuation. </p> </li> <li> <p>Number of participants with grade 3 and grade 4 adverse events (<a href="./references#CD013874-bbs2-0180" title="US Department of Health and Human Services. Criteria for Adverse Events (CTCAE) v5.0. ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf2017.">US Department of Health and Human Services 2017</a>). </p> </li> <li> <p>Number of participants with long‐term adverse events: opportunistic infections, hypogammaglobulinaemia, cardiovascular events (hypotension, hypertension, arrhythmias, and angina), and HBV reactivation. </p> </li> <li> <p>Number of participants with short‐term adverse events: infusion‐related reactions.</p> </li> </ul> </p> <p>*We judged MRI lesions as surrogate outcomes, but included them in the review in the presumption that changes in the surrogate reflect changes in relapse and disability that are important to patients. </p> </section> </section> </section> </section> <section id="CD013874-sec-0026"> <h3 class="title">Search methods for identification of studies</h3> <p>We applied no time, language, or publication status restrictions to the search for primary studies. </p> <section id="CD013874-sec-0027"> <h4 class="title">Electronic searches</h4> <p>We designed search strategies for electronic databases according to methods suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013874-bbs2-0140" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , MetzendorfMI , et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Lefebvre 2019</a>). The Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group's Information Specialist designed and executed the search strategies. We searched the following databases and trials registries for primary studies, updated on 31 January 2021. The search strategies are documented in <a href="./appendices#CD013874-sec-0150">Appendix 1</a>. For studies that are listed in trials registries and not yet published in full elsewhere, we included them as ongoing studies for the current review, and will add or update data in updates of the review once they are available as full‐text reports. </p> <section id="CD013874-sec-0028"> <h5 class="title">Databases of medical literature</h5> <p> <ul id="CD013874-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library) (2021, Issue 1). </p> </li> <li> <p>MEDLINE (PubMed) (1966 to 31 January 2021).</p> </li> <li> <p>Embase (Embase.com) (1974 to 31 January 2021).</p> </li> <li> <p>CINAHL (via EBSCO) (1981 to 31 January 2021).</p> </li> </ul> </p> </section> <section id="CD013874-sec-0029"> <h5 class="title">Trials registries and registry platforms to identify ongoing studies and results of completed studies </h5> <p> <ul id="CD013874-list-0006"> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="https://trialsearch.who.int/Default.aspx" target="_blank">trialsearch.who.int)</a>. </p> </li> <li> <p>US National Institutes of Health clinical trial register <a href="http://(www.clinicaltrials.gov/" target="_blank">(www.clinicaltrials.gov</a>). </p> </li> <li> <p>European Union Clinical Trials Register (<a href="http://www.clinicaltrialsregister.eu" target="_blank">www.clinicaltrialsregister.eu</a>). </p> </li> </ul> </p> </section> </section> <section id="CD013874-sec-0030"> <h4 class="title">Searching other resources</h4> <p>We reviewed the reference lists of relevant articles, review articles, and textbooks. We contacted study investigators to request missing data. </p> </section> </section> <section id="CD013874-sec-0031"> <h3 class="title" id="CD013874-sec-0031">Data collection and analysis</h3> <section id="CD013874-sec-0032"> <h4 class="title">Selection of studies</h4> <p>We used the search strategy described in the <a href="#CD013874-sec-0026">Search methods for identification of studies</a> section to obtain titles and abstracts of studies. Two review authors (GF and JK) independently screened the titles and abstracts and discarded studies that were not applicable; however, they initially retained studies and reviews that might have included relevant data or information on eligible studies. Two review authors (GF and JK) independently assessed the retrieved abstracts and, when necessary, the full‐text articles to determine which studies satisfied the inclusion criteria. The two review authors compared multiple reports of the same study and used the most comprehensive report. They linked multiple publications as companion reports, but excluded true duplicates. GF and JK resolved discrepancies in judgement by discussion, and reported excluded studies and their reasons for exclusion in the <a href="./references#CD013874-sec-0171" title="">Characteristics of excluded studies</a> table. We reported included studies in the <a href="./references#CD013874-sec-0170" title="">Characteristics of included studies</a> table. We created a PRISMA flow chart reporting the selection process (<a href="./references#CD013874-bbs2-0150" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097.">Moher 2009</a>). </p> </section> <section id="CD013874-sec-0033"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (GF and JK) independently extracted data using a predefined data extraction form in an Excel spreadsheet. They resolved any disagreements by discussion. We requested additional data through correspondence with four study authors (<a href="./references#CD013874-bbs2-0117" title="FilippiniG . Outcomes for relapsing and progressive multiple sclerosis [personal communication]. Email to: O Stuve 2 March 2021.">Filippini 2021a</a>; <a href="./references#CD013874-bbs2-0118" title="FilippiniG . Outcomes for relapsing and progressive multiple sclerosis [personal communication]. Email to: E Alvarez 2 March 2021.">Filippini 2021b</a>; <a href="./references#CD013874-bbs2-0119" title="FilippiniG . Outcome for relapsing and progressive multiple sclerosis [personal communication]. Email to: P Alping 2 March 2021.">Filippini 2021c</a>; <a href="./references#CD013874-bbs2-0120" title="FilippiniG . Total number of patients treated with fingolimod and those treated with glatiramer. Email to: A Langer-Gould 2 April 2021.">Filippini 2021d</a>). Authors of two included studies provided us with additional outcome data. </p> <section id="CD013874-sec-0034"> <h5 class="title">Outcome data</h5> <p>We extracted the following data from each included study:</p> <p> <ul id="CD013874-list-0007"> <li> <p>number of participants who had disability worsening based on clinical follow‐up visits;</p> </li> <li> <p>number of participants who had clinical relapses based on clinical follow‐up visits;</p> </li> <li> <p>number who withdrew due to any adverse event;</p> </li> <li> <p>measures and results of critical and important outcomes that were reported in the included studies (e.g. hazard ratio (HR) for time‐to‐event outcomes). </p> </li> </ul> </p> <p>We extracted the authors' definition and measure used in the study to assess each reported outcome. For continuous outcomes, we extracted mean and standard deviation of the comparison groups, where possible. We extracted arm‐level data when possible, otherwise we extracted effect sizes. For NRSIs, we extracted unadjusted and adjusted effect sizes. We extracted data at the authors' defined time points. </p> </section> <section id="CD013874-sec-0035"> <h5 class="title">Other data</h5> <p>From each included study, we extracted data on the following:</p> <p> <ul id="CD013874-list-0008"> <li> <p>study: first author or acronym, number of centres and location, study setting, year of publication, years that the study was conducted (recruitment and follow‐up), publication status (full‐text publication, abstract publication, unpublished data); </p> </li> <li> <p>study design (RCT or NRSI), inclusion and exclusion criteria, number of randomised participants, withdrawals, early termination of trial; </p> </li> <li> <p>participants: age, sex, diagnostic criteria, type and duration of MS, important baseline data (EDSS score, percentage of participants with previous use of DMTs, MRI lesions); </p> </li> <li> <p>interventions: first choice or switching intervention, comparison, concomitant medications, duration of follow‐up; </p> </li> <li> <p>conflict of interests of study authors;</p> </li> <li> <p>funding of the study.</p> </li> </ul> </p> <p>One review author (GF) transferred data into Review Manager Web software (<a href="./references#CD013874-bbs2-0163" title="The Cochrane CollaborationReview Manager Web (RevMan Web). Version 2.2.1. The Cochrane Collaboration, 2021. Available from revman.cochrane.org.">Review Manager Web</a>). </p> </section> </section> <section id="CD013874-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For the scope of this review, we assessed the effect of assignment to the intervention (intention‐to‐treat effect) for disability worsening, relapses, treatment discontinuation due to adverse events, and T1 and T2 MRI lesions. We also assessed the effect of adhering to the intervention (per‐protocol effect) for all the other outcomes (numbers of participants with SAEs and further adverse events).  </p> <section id="CD013874-sec-0037"> <h5 class="title">Randomised controlled trials</h5> <p>Two reviews authors (JK and GF) independently assessed the risk of bias for each study using the Cochrane Collaboration’s tool for assessing risk of bias that include: random sequence generation, allocation concealment, blinding of participants, blinding of outcome assessor, incomplete outcome data, selective outcome reporting, and other bias, as recommended in the <i>Cochrane Handbook for Systematic Reviews of</i> <i>Interventions</i> (<a href="./references#CD013874-bbs2-0129" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). We judged the risk of bias of each study and classified it as low, high, or unclear risk of bias. We judged incomplete outcome data at low risk of bias when numbers and causes of dropouts were balanced between arms (i.e. in the absence of a significant difference) and appeared to be unrelated to the outcome. We resolved any disagreements between the review authors by discussion. </p> </section> <section id="CD013874-sec-0038"> <h5 class="title">Controlled non‐randomised studies of interventions</h5> <p>Two reviews authors (JK, GF) independently assessed the risk of bias using the ROBINS‐I (version August 2016) (<a href="./references#CD013874-bbs2-0175" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , ViswanathanM , et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ2016;355:i4919.">Sterne 2016</a>). Based on the inclusion and exclusion criteria for this review, we defined our generic target trial as rituximab versus placebo or versus other DMTs for the treatment of people with MS. Therefore, we used the ROBINS‐I analogue of starting experimental intervention versus starting control intervention to evaluate risk of bias. </p> <p>The ROBINS‐I tool includes the following bias domains: confounding, selection of participants into the study, classification of interventions, deviations from intended interventions, missing data, measurement of outcomes, and selection of reported result.  </p> <p>We applied the ROBINS‐I tool to groups of outcomes according to 'effect of assignment' (including disability worsening, recurrence of relapse, treatment discontinuation due to adverse events, new or enlarging T2‐weighted MRI lesions; new gadolinium‐enhancing positive T1‐weighted MRI lesions) and 'effect of adherence' (including all other outcomes). We assigned an overall risk of bias to each group based on the worst assessment across all bias domains using the recommended levels (low, moderate, serious, or critical risk of bias, or no information) (<a href="./references#CD013874-bbs2-0175" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , ViswanathanM , et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ2016;355:i4919.">Sterne 2016</a>). We resolved any disagreements between the review authors by discussion. </p> <p>Baseline confounding by indication is likely to be the most frequent confounder in NRSIs that meet the inclusion criteria. For example, participants with high pretreatment MS activity are likely to be treated with a highly efficacious drug (e.g. fingolimod, natalizumab), whereas participants with low pretreatment MS activity are likely to be treated with a less powerful drug (e.g. interferon beta or glatiramer acetate). A cohort study comparing two or more DMTs for MS should control for baseline age, sex, MS duration, relapse within the previous year, EDSS score, MRI activity, and proportion of participants previously treated with DMTs. All these variables are prognostic for the outcomes included in the review and are also likely to influence choice of treatment. In some NRSIs, particularly those based on registries (i.e. routinely collected data), participants might have been observed for different follow‐up periods due to differences in drug licensing and availability across different geographical and historical cohorts (<a href="./references#CD013874-bbs2-0178" title="TrojanoM , TintoreM , MontalbanX , HillertJ , KalincikT , IaffaldanoP , et al. Treatment decisions in multiple sclerosis – insights from real-world observational studies. Nature Reviews. Neurology2017;13:105-18.">Trojano 2017</a>). This different follow‐up period could confound the results, particularly regarding long‐term outcomes. For each NRSI, we recorded whether the study controlled for these important confounding domains and used an analysis method to reduce confounding. </p> </section> <section id="CD013874-sec-0039"> <h5 class="title">Adverse events</h5> <p>We extracted data on the prespecified adverse events and the total number of withdrawals due to adverse events. </p> </section> <section id="CD013874-sec-0040"> <h5 class="title">Assessment of bias in conducting the systematic review</h5> <p>We conducted the review according to the published protocol (<a href="./references#CD013874-bbs2-0188" title="Filippini G, Kruja J, He D, Del Giovane C. Rituximab for people with multiple sclerosis. Cochrane Database of Systematic Reviews2021, Issue 2. Art. No: CD013874. [DOI: 10.1002/14651858.CD013874]">Filippini 2021</a>), and reported any deviations from it in the <a href="#CD013874-sec-0168">Differences between protocol and review</a> section. </p> </section> </section> <section id="CD013874-sec-0041"> <h4 class="title">Measures of treatment effect</h4> <section id="CD013874-sec-0042"> <h5 class="title">Randomised controlled trials</h5> <p>We extracted and report HRs with 95% confidence intervals (CIs) for time‐to‐event outcomes (time to disability worsening, time to relapse, and time to treatment discontinuation). For continuous outcomes (ARR, cognitive decline, and quality of life), we calculated the mean difference (MD) if studies used the same metric, or the standardised mean difference (SMD) if studies used different metrics, with 95% CIs. For dichotomous outcomes, we reported the odds ratio (OR) with 95% CI. </p> </section> <section id="CD013874-sec-0043"> <h5 class="title">Controlled non‐randomised studies of interventions</h5> <p>For dichotomous outcomes, we reported OR with 95% CIs. For continuous outcomes (ARR, cognitive decline, and quality of life), we calculated the MD if studies used the same metric, or the SMD if studies used different metrics, with 95% CI. For time‐to‐event outcomes (time to disability worsening, time to relapse, and time to treatment discontinuation), we reported HRs with 95% CI.  </p> </section> </section> <section id="CD013874-sec-0044"> <h4 class="title">Unit of analysis issues</h4> <p>Cluster‐randomised trials and cross‐over trials are not relevant to DMTs for MS.</p> <section id="CD013874-sec-0045"> <h5 class="title">Studies with multiple treatment groups</h5> <p>For multiple arm trials, the intervention groups of relevance were all those that could be included in a pairwise comparison of intervention groups which, if investigated alone, would have met the criteria for including studies in the review. For example, if we identified a study comparing rituximab versus glatiramer acetate versus rituximab plus glatiramer acetate, we used one comparison (rituximab versus glatiramer acetate), since it addressed the review's objective. Thus, data from the rituximab plus glatiramer treatment group were not relevant to the review. However, if the study compared rituximab versus glatiramer versus fingolimod, the two pairwise comparisons of rituximab versus glatiramer and rituximab versus fingolimod, were relevant to the review. In this case, we treated multiple arm studies as multiple independent two‐arm studies. </p> <p>We listed all treatment arms in the <a href="./references#CD013874-sec-0170" title="">Characteristics of included studies</a> table, even if they are not used in the review. </p> <p>For multiple arm trials involving the same agent at different doses compared to a control treatment, we had planned to convert the treatment arms into a single arm by merging the different doses. We did not include studies involving the same agent at different doses without a comparison group. </p> </section> </section> <section id="CD013874-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We used data that reflected the intention‐to‐treat analysis (the effect of assignment) for each included outcome except for adverse events, for which we assessed the risk of bias in relation to the effect of adherence (per protocol effect). We attempted to retrieve missing data from study authors. In order to assess the effect of missing outcome data where not reported or provided, we assumed that treated and control group participants who were missing both had an unfavourable outcome. If standard deviations were missing for continuous outcomes, we calculated them according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013874-bbs2-0130" title="HigginsJP , LiT , DeeksJJ . Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Higgins 2019</a>). </p> </section> <section id="CD013874-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We quantified statistical heterogeneity using the I<sup>2</sup> statistic (<a href="./references#CD013874-bbs2-0128" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>). We interpreted it using the following guide: I<sup>2</sup> statistic &gt; 30% signifies moderate heterogeneity, I<sup>2</sup> &gt; 75% signifies considerable heterogeneity (<a href="./references#CD013874-bbs2-0106" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>). </p> </section> <section id="CD013874-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <section id="CD013874-sec-0049"> <h5 class="title">Reporting bias</h5> <p>As specified in the <a href="#CD013874-sec-0017">Types of studies</a> section, we included results that were published in non‐commercial trial registries. This was to ensure that we captured completed studies that had not been published elsewhere, in order to minimise publication bias. We included studies irrespective of their publication status, as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013874-bbs2-0148" title="McKenzieJE , BrennanSE , RyanRE , ThomsonHJ , JohnstonRV , ThomasJ . Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">McKenzie 2019</a>). We had planned to evaluate potential publication bias using a funnel plot; however, there were fewer than 10 studies were available for meta‐analysis (<a href="./references#CD013874-bbs2-0155" title="PageMJ , HigginsJP , SterneJA . Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from training.cochrane.org/handbook/archive/v6.">Page 2019</a>). </p> </section> <section id="CD013874-sec-0050"> <h5 class="title">Selective non‐reporting bias</h5> <p>We expected that most of the included NRSIs did not have an available protocol, and that even protocols for RCTs might lack a detailed analysis plan. Therefore, we decided that if a study appeared to be carried out appropriately, we checked for consistencies between the outcome measurements and analyses described in the methods and those reported in the results of the included studies. </p> </section> </section> <section id="CD013874-sec-0051"> <h4 class="title">Data synthesis</h4> <p>We conducted an initial qualitative comparison of all the included studies to examine whether pooling of results was reasonable. This considered differences in study populations, inclusion and exclusion criteria, interventions, and outcome assessment. If the clinical and methodological characteristics of individual studies were sufficiently homogeneous, we pooled the data in meta‐analyses. </p> <p>We conducted separate analyses for RCTs and NRSIs, relapsing and progressive forms of MS, for rituximab as 'first choice' treatment (treatment naive) and rituximab as 'switching' from another DMT. When articles reported on a cohort (same database, e.g. the Swedish MS register) that overlapped with a cohort in another paper, we did not pool the comparators since participants in the rituximab group were the same across comparisons. </p> <p>For RCTs, when meta‐analysis was feasible, we used the random‐effects model for pooling the data. For binary outcomes, we based the estimation of the between‐study variance using the Mantel‐Haenszel method. We used the inverse variance method for continuous outcomes, outcomes where HRs were available, or outcomes where only one study was included (fixed‐effect model). </p> <p>If a meta‐analysis was feasible for controlled NRSIs, we analysed outcomes with adjusted effect estimates if these were adjusted for the same factors using the inverse‐variance method, as recommended in Chapter 24 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013874-bbs2-0162" title="ReevesBC , DeeksJJ , HigginsJP , SheaB , TugwellP , WellsGA . Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.">Reeves 2019</a>). We used Review Manager Web software for analyses (<a href="./references#CD013874-bbs2-0163" title="The Cochrane CollaborationReview Manager Web (RevMan Web). Version 2.2.1. The Cochrane Collaboration, 2021. Available from revman.cochrane.org.">Review Manager Web</a>). </p> <p>We excluded from all meta‐analyses results from NRSI judged to be at 'critical' risk of bias using ROBINS‐I. </p> </section> <section id="CD013874-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had planned subgroup analyses for active or inactive MS. These analyses were not performed because only two RCTs and three NRSIs provided the information. We did subgroup analyses for treatment comparisons: placebo or each individual DMT. </p> </section> <section id="CD013874-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>We had planned a sensitivity analysis to remove from analyses those data at critical or high risk of bias. This was not performed because we judged four of five included RCTs at high risk of bias. </p> </section> <section id="CD013874-sec-0054"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the main results of the review in summary of findings tables, according to recommendations described in Chapter 14 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013874-bbs2-0170" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.">Schünemann 2020</a>). For the included NRSIs, we followed GRADE guidance 18 (<a href="./references#CD013874-bbs2-0169" title="SchünemannHJ , CuelloC , AklEA , MustafaRA , MeerpohlJJ , ThayerK , et al. GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence. Journal of Clinical Epidemiology2019;111:105-14.">Schünemann 2019</a>). For time‐to‐event outcomes, we calculated absolute effects at specific time points, as recommended in GRADE guidance 27 (<a href="./references#CD013874-bbs2-0173" title="SkoetzN , GoldkuhleM , vanDalenEC , AklEA , TrivellaM , MustafaRA , et al. GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and evidence profiles. Journal of Clinical Epidemiology2020;118:124-31.">Skoetz 2020</a>). We expressed the findings and certainty of the evidence as suggested in the informative statement guidance (<a href="./references#CD013874-bbs2-0167" title="SantessoN , GlentonC , DahmP , GarnerP , AklA , AlperB , et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology2020;119:126-35.">Santesso 2020</a>).  </p> <p>In the protocol, we had planned to present four summary of findings tables and additional tables for comparison versus placebo. In the review phase, due to the large number of treatment comparisons, we decided to restrict the results showed in the summary of findings to the effect estimates of rituximab as 'first choice' treatment and as 'switching' versus other DMTs for relapsing MS, critical and prioritised important outcomes (<a href="./full#CD013874-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013874-tbl-0004">summary of findings Table 4</a>). We decided to keep all possible treatment comparisons for which evidence were available because we believe that this information is important for clinicians and patients who use different treatments in the clinical practice. We reported completed tables, including results from RCTs, NRSIs, and for progressive MS, in <a href="#CD013874-tbl-0006">Table 2</a>. </p> <div class="table" id="CD013874-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Rituximab as 'switching' for multiple sclerosis – results from RCTs and non‐randomised studies of intervention</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> relapsing or progressive forms of multiple sclerosis<br/><b>Settings:</b> inpatient or outpatient<br/><b>Intervention:</b> rituximab as 'switching' from another DMT<br/><b>Comparison:</b> placebo or other DMTs as 'switching' treatment </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comparison</b> </p> <p><b>intervention</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b>* </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with rituximab</b> </p> <p><b>(95% CI)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chance of sustained disability worsening</b> over 24–36 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Interferons or glatiramer acetate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>90 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b><br/>(48 to 125) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.86</b> </p> <p>(0.52 to 1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>853<br/>(1 retrospective cohort study)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on disability worsening at 24 months' follow‐up, when compared with interferon beta or glatiramer acetate. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Other DMTs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>SPMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>360 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>196 per 1000</b><br/>(110 to 340) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.49</b> </p> <p>(0.26 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88<br/>(1 retrospective cohort study)<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on disability worsening at 36 months' follow‐up, when compared with other DMTs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Chance of experiencing ≥ 1 relapses</b> over 12–24 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b><br/>(96 to 383) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.38 </b> </p> <p>(0.16 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>f,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is low, downgraded 1 level for serious risk of bias and 1 level for serious imprecision. Rituximab may result in a large reduction in recurrence of relapse over 12 months' follow‐up when compared with placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Interferons or glatiramer acetate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b><i>RRMS</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>270 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b><br/>(22 to 143) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.18 </b> </p> <p>(0.07 to 0.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1383<br/>(1 retrospective cohort study)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is moderate, downgraded 1 level due to serious risk of bias. Rituximab likely results in a very large reduction in recurrence of relapses over 24 months' follow‐up, when compared with interferons or glatiramer. The NNTB is 11 (95% CI 10 to 18). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b><i>RRMS</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b><br/>(4 to 60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.08 </b> </p> <p>(0.02 to 0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>256<br/>(1 retrospective cohort study)<sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is moderate, downgraded 1 level due to serious risk of bias. Rituximab likely results in a large reduction in recurrence of relapses over 24 months' follow‐up, when compared with fingolimod. The NNTB is 6 (95% CI 6 to 9). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b><i>RRMS</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b><br/>(12 to 266) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.0 </b> </p> <p>(0.2 to 5.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153<br/>(1 retrospective cohort study)<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on recurrence of relapses over 24 months' follow‐up, when compared with natalizumab.  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b><i>MS of all types</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/>(13 to 79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.35</b> </p> <p>(0.14 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453<br/>(1 retrospective cohort study)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>f,l,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias, 1 level for indirectness, and 1 level for serious imprecision. The evidence is very uncertain about the effect of rituximab on recurrence of relapses over 24 months' follow‐up, when compared with fingolimod. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dimethyl fumarate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b><i>MS of all types</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/>(15 to 75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.23</b> </p> <p>(0.10 to 0.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>524<br/>(1 retrospective cohort study)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>f,l,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias, 1 level for indirectness, and 1 level for serious imprecision. The evidence is very uncertain about the effect of rituximab on recurrence of relapses over 24 months' follow‐up, when compared with dimethyl fumarate. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b><i>MS of all types</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/>(14 to 78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.54</b> </p> <p>(0.22 to 1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>633<br/>(1 retrospective cohort study)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>f,l,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias, 1 level for indirectness, and 1 level for serious imprecision. The evidence is very uncertain about the effect of rituximab on recurrence of relapses over 24 months' follow‐up, when compared with natalizumab. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>SAEs</b> over 12–24 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b><br/>(45 to 327) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.90</b> </p> <p>(0.28 to 2.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>h,n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on SAEs, when compared with placebo. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b><i>SPMS</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>444 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>224 per 1000</b><br/>(46 to 615) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.36</b> </p> <p>(0.06 to 2.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/>(1 RCT)<sup>o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>n,p</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on SAEs, when compared with placebo. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Other DMTs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS </i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> </b>No data were available </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Glatiramer acetate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>SPMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84<br/>(1 RCT)<sup>q</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cheshmavar 2021 reported 0 SAEs over 12 months' follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Chance of impaired quality of life:</b> none of the studies reported the outcome. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Common infections</b> over 12–24 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>695 per 1000</b><br/>(481 to 848) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.91</b> </p> <p>(0.37 to 2.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 </p> <p>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>h,n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on infections, when compared with placebo. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>SPMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>444 per 1000</b><br/>(138 to 809) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.40</b> </p> <p>(0.08 to 2.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/>(1 RCT)<sup>o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>n,p</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on infections, when compared with placebo. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Interferon beta or glatiramer acetate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b><br/>(40 to 89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.71</b> </p> <p>(1.11 to 2.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5477<br/>(The national Swedish MS Register linked to national healthcare and census registries)<sup>r</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>s</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is moderate, downgraded 1 level for serious risk of bias in measurement of the outcome. Rituximab likely increases infections when compared with interferons or glatiramer acetate. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b><br/>(51 to 95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.26</b> </p> <p>(0.90 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5187</p> <p>(3 retrospective cohort studies)<sup>i,j,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>n,t</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is low, downgraded 1 level for serious risk of bias and 1 level for imprecision. Heterogeneity: P = 0.24, I² = 30%. Rituximab may increase slightly infections when compared with fingolimod. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b><br/>(51 to 95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.58</b> </p> <p>(1.08 to 2.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5001</p> <p>(2 non‐randomised studies: the national Swedish MS Register linked to national healthcare and census registries, and 2 retrospective cohort studies)<sup>j,r</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>t</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is moderate, downgraded 1 level for serious risk of bias. Heterogeneity: P = 0.39, I² = 0%. Rituximab likely increases the number of participants who have common infections when compared with natalizumab. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Ocrelizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/>(0 to 26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.02</b> </p> <p>(0.00 to 0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>472</p> <p>(1 retrospective cohort study)<sup>u</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>f,l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias and 1 level for imprecision. The evidence is very uncertain about the effect of rituximab on the number of participants who have infections when compared with ocrelizumab. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Glatiramer acetate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>SPMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b><br/>(7 to 429) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 3.00</b> </p> <p>(0.30 to 30.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> <p>(1 RCT)<sup>q</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>c,v</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on common infections, when compared with glatiramer acetate. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cyclophosphamide</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>SPMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>433 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>230 per 1000</b><br/>(97 to 459) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.39</b> </p> <p>(0.14 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> <p>(1 RCT)<sup>w</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>c,x</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias and 1 level for some imprecision. The evidence is very uncertain about the effect of rituximab on the number of participants who have infections, when compared with cyclophosphamide. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>MS of all types</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b><br/>(9 to 80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.06</b> </p> <p>(0.34 to 3.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453<br/>(1 retrospective cohort study)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>l,m,n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias, 1 level for indirectness, and 1 level for serious imprecision. The evidence is very uncertain about the effect of rituximab on infections when compared with fingolimod. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dimethyl fumarate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>MS of all types</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>(7 to 96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.39</b> </p> <p>(0.63 to 9.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453<br/>(1 retrospective cohort study)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>l.m.n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias, 1 level for indirectness, and 1 level for some imprecision. The evidence is very uncertain about the effect of rituximab on infections when compared with dimethyl fumarate. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>MS of all types</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b><br/>(7 to 107) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 4.22</b> </p> <p>(1.00 to 17.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453<br/>(1 retrospective cohort study)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>f,l,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias, 1 level for indirectness, and 1 level for some imprecision. The evidence is very uncertain about the effect of rituximab on infections when compared with natalizumab </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Cancer</b> over 24–36 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.55</b> </p> <p>(0.06 to 39.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>h,n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on the number of participants who have cancer, when compared with placebo. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>SPMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>111 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b><br/>(4 to 516) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.47</b> </p> <p>(0.03 to 8.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/>(1 RCT)<sup>o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>n,p</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on the number of participants who have cancer, when compared with placebo. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>MS of all types</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b><br/>(6 to 18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.60</b> </p> <p>(0.35 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5807<br/> (The Swedish MS Register linked to the Swedish Cancer Register and the national patient Register)<sup>y</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>f,z</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is low downgraded 1 level for serious risk of bias and 1 level for some imprecision. Rituximab may reduce the number of participants who have cancer over 36 months, when compared with fingolimod. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>MS of all types</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b><br/>(4 to 13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.74</b> </p> <p>(0.42 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5857<br/> (The Swedish MS Register linked to the Swedish Cancer Register and the national patient Register)<sup>y</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>f,z</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is low, downgraded 1 level for serious risk of bias and 1 level for some imprecision. Rituximab may reduce the number of participants who have cancer over 36 months, when compared with natalizumab. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Mortality</b> over 24 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.55</b> </p> <p>(0.06 to 39.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>h,n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on mortality compared with placebo. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 5.59</b> </p> <p>(0.22 to 139.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136<br/>(1 retrospective cohort study)<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>e,n,aa</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias, 1 level for indirectness, and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on mortality compared with fingolimod. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 6.66</b> </p> <p>(0.27 to 166.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153<br/>(1 retrospective cohort study)<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>e,n,aa</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias, 1 level for indirectness, and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on mortality compared with natalizumab. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median risk of comparator across studies) is provided in footnotes. The <b>risk</b> <b>in the rituximab group </b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>DMT:</b> disease‐modifying treatment; <b>HR:</b> hazard ratio; <b>MS:</b> multiple sclerosis; <b>NNTB: </b> number needed to treat for an additional beneficial effect; <b>OR:</b> odds ratio;<b> RCT:</b> randomised controlled trial; <b>RRMS:</b> relapsing‐remitting multiple sclerosis; <b>SAE:</b> serious adverse event; <b>SPMS:</b> secondary progressive multiple sclerosis. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Explanations</b> </p> <p>Event rates in comparator based on the number of events in the included studies.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>.<br/><sup>b</sup>Bias due to missing data since time to disability worsening was limited to people with a minimum of three Expanded Disability Status Scale scores reported, i.e. 321/461 (70%) participants in the rituximab group and 532/922 (58%) participants in the interferon or glatiramer acetate group.<br/><sup>c</sup>The optimal information size criterion was not met (few events). Results included both no effect and appreciable benefit or harm.<br/><sup>d</sup><a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>.<br/><sup>e</sup>Bias due to residual confounding is expected in a retrospective cohort study.<br/><sup>f</sup>The optimal information size criterion was not met (few events).<br/><sup>g</sup><a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>.<br/><sup>h</sup>High risk of bias for unblinding of personnel and incomplete outcome data. Unclear risk of bias for allocation concealment and blinding of participants.<br/><sup>i</sup><a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>.<br/><sup>j</sup><a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>.<br/><sup>k</sup><a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>.<br/><sup>l</sup>Very serious risk of bias. All known important confounding domains not appropriately measured and controlled for.<br/><sup>m</sup>Indirectness of population.<br/><sup>n</sup>The optimal information size criterion was not met (very few events). Results included both no harm and appreciable harm.<br/><sup>o</sup><a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a>.<br/><sup>p</sup>High risk of bias for inadequate allocation concealment, incomplete outcome data, and other bias. Unclear risk of bias for blinding of participants and outcome assessment.<br/><sup>q</sup><a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a>.<br/><sup>r</sup><a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>.<br/><sup>s</sup>Quote: "Data are not available on the validity of the registries to measure infections and on different reporting of infections between interventions"(<a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>).<br/><sup>t</sup>All the retrospective cohort studies were at serious risk of bias.<br/><sup>u</sup><a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>.<br/><sup>v</sup>High risk of bias for inadequate allocation concealment and lack of blinding of participants and personnel.<br/><sup>w</sup><a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a>.<br/><sup>x</sup>High risk of bias for inadequate allocation concealment, lack of blinding of participants, personnel and outcome assessment, and incomplete outcome data.<br/><sup>y</sup><a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>.<br/><sup>z</sup>The register linkage allowed adjustment for many important confounders; however, residual confounding might still be an issue.<br/><sup>aa</sup>Indirectness of outcome, one suicide in the rituximab group. </p> </div> </div> <p>We reported the following outcomes in the summary of findings tables:</p> <p> <ul id="CD013874-list-0009"> <li> <p>number of participants with disability worsening;</p> </li> <li> <p>number of participants with recurrence of relapses;</p> </li> <li> <p>number of participants with SAEs;</p> </li> <li> <p>number of participant reporting impairment in quality of life;</p> </li> <li> <p>number of participants with common infections;</p> </li> <li> <p>number of participants with cancer;</p> </li> <li> <p>number of deaths.</p> </li> </ul> </p> <p>In the summary of findings tables, we prioritised long‐term outcomes if they were available, otherwise we included short‐term outcomes. We assessed the certainty of evidence for each outcome considering the risk of bias, indirectness, inconsistency, imprecision of effect estimates, and risk of publication bias. Using GRADEpro GDT software (<a href="./references#CD013874-bbs2-0123" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 12 October 2020. Available at gradepro.org.">GRADEpro GDT</a>), we assigned one of four levels of certainty of evidence: high, moderate, low, or very low. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013874-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013874-sec-0055"></div> <section id="CD013874-sec-0056"> <h3 class="title">Description of studies</h3> <p>For a full description of studies, see the <a href="./references#CD013874-sec-0170" title="">Characteristics of included studies</a>; <a href="./references#CD013874-sec-0171" title="">Characteristics of excluded studies</a>; <a href="./references#CD013874-sec-0172" title="">Characteristics of studies awaiting classification</a>; and <a href="./references#CD013874-sec-0173" title="">Characteristics of ongoing studies</a> tables. </p> <section id="CD013874-sec-0057"> <h4 class="title">Results of the search</h4> <p>We identified 3574 records (MEDLINE 1380, Embase 1655, CINAHL 413, CENTRAL 70, clinical trials registries 56). After removing duplicates, we screened 3247 records based on their titles and abstracts, and we excluded 3152 records that we considered not pertinent. We evaluated the remaining 95 records and screened the full texts, or, if these were not available, abstract publications or trials registry entries. </p> <p>We identified 32 eligible studies (50 records): 15 included studies (25 records) (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>; <a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a>; <a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>; <a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a>; <a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>; <a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>; <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>), 14 ongoing studies (22 records), and three studies awaiting classification (<a href="./references#CD013874-bbs2-0079" title="Berrios MoralesI , EleftheriouE , MarandaL , IoneteC . The safety and efficacy of rituximab use in secondary progressive multiple sclerosis (SPMS) at UMMHC: five years follow up data. Multiple Sclerosis Journal2016;22:805. MoralesIB , EleftheriouE , MarandaL , PolitiL , IoneteC . The safety and efficacy of rituximab use in secondary-progressive multiple sclerosis (SPMS) at UMMHC: five years follow up data. Neurology2017;88(Suppl 1):16. ">Berrios Morales 2016</a>; <a href="./references#CD013874-bbs2-0080" title="FrisellT , CuijpersM , PiehlF . Rate of cardiovascular disease among Swedish multiple sclerosis patients treated with rituximab, natalizumab, fingolimod, and dimethyl fumarate: a nationwide cohort study. Multiple Sclerosis Journal2019;25:314. ">Frisell 2019</a>; <a href="./references#CD013874-bbs2-0081" title="KalincikT , MalpasCB , SharminS , RoosI , PattiF , ButzkuevenH , et al. Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS. Multiple Sclerosis Journal2019;25:912-4. ">Kalincik 2019</a>). We excluded 63 studies (74 records) with reasons. See <a href="#CD013874-fig-0001">Figure 1</a> for the study flow diagram (<a href="./references#CD013874-bbs2-0150" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097.">Moher 2009</a>). </p> <div class="figure" id="CD013874-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram. Search updated to 31 January 2021. DMT: disease‐modifying treatment." data-id="CD013874-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram. Search updated to 31 January 2021. DMT: disease‐modifying treatment.</p> </div> </div> </div> </section> <section id="CD013874-sec-0058"> <h4 class="title">Included studies</h4> <p>We included 15 studies describing 16,429 participants of whom approximately 6000 received rituximab (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>; <a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a>; <a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>; <a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a>; <a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>; <a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>; <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>). These included studies were published between 2008 and 2020. Upon request, authors of one NRSI provided additional outcome data (<a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>): they provided us with the number of any invasive cancer outcome stratified by therapy and MS type. The <a href="./references#CD013874-sec-0170" title="">Characteristics of included studies</a> table provides details of included studies. </p> <section id="CD013874-sec-0059"> <h5 class="title">Design </h5> <p>We included five RCTs (<a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a>; <a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a>; <a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>; <a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a>; <a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a>), and 10 controlled NRSIs (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>; <a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>; <a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>; <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>). </p> </section> <section id="CD013874-sec-0060"> <h5 class="title">Setting</h5> <p>One RCT (<a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a>) and one controlled NRSI (<a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>) originated from the USA, two RCTs originated from the USA and Canada (<a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>; <a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a>), two RCTs originated from Iran (<a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a>; <a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a>), six NRSIs originated from Sweden (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>; <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>), one NRSI originated from Sweden and the USA (<a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>), one NRSI originated from Spain (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>), and one NRSI originated from Switzerland and the Netherlands (<a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>). </p> </section> <section id="CD013874-sec-0061"> <h5 class="title">Participants</h5> <p>One RCT (<a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>) and seven NRSIs (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>;<b> </b><a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>; <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>) included participants with relapsing MS. Three of these studies included participants meeting the definition of active relapsing MS (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>). Four RCTs (<a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a>; <a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a>; <a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a>; <a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a>) and one NRSI (<a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>) evaluated participants with progressive MS. Two of these studies included participants meeting the definition of active progressive MS (<a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a>; <a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a>). Two NRSIs included participants as grouped relapsing and progressive MS (<a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>). </p> </section> <section id="CD013874-sec-0062"> <h5 class="title">Interventions</h5> <p>One RCT evaluated rituximab as a 'first choice' treatment compared with placebo (<a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a>) and one NRSI evaluated rituximab as a 'first choice' compared with other DMTs (<a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>). Two RCTs evaluated rituximab compared with placebo in participants who had previously been treated with other DMTs (<a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>; <a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a>). Two RCTs (<a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a>; <a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a>) and nine NRSIs (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>; <a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>; <a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>; <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>) evaluated rituximab compared with other DMTs in participants who had previously been treated with other DMTs. The majority of the included studies administered similar doses of rituximab. </p> </section> <section id="CD013874-sec-0063"> <h5 class="title">Outcomes</h5> <p>For a detailed description of outcome measures reported in each included study, see <a href="./references#CD013874-sec-0170" title="">Characteristics of included studies</a> table. </p> <p>Three RCTs provided critical and important beneficial outcomes (<a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a>; <a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>; <a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a>). We could not include outcome data from two RCTs. One did not report any of our prioritised outcomes (<a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a>). The other study was terminated early because an interim analysis on cerebrospinal fluid showed a lower‐than‐expected depletion of intrathecal B cells and 27 included participants were not followed up to measure outcomes (<a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a>). Seven controlled NRSIs provided outcome data (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>; <a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>; <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>). Three NRSIs did not measure beneficial outcomes (<a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>). We did not include outcomes from one NRSI that included 55 participants, 27 of whom received rituximab because of the critical risk of bias assessed with ROBINS‐I (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>).  </p> <p>We evaluated harm outcomes from all included RCTs. Eight included NRSIs reported harm outcomes (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>; <a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>). One study compared the risk of cancer in a large population of people with MS treated with different DMTs (<a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>), and one examined the risk of serious infections associated with DMTs in one large population of people with MS (<a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>). One study did not measure harm outcomes (<a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>), and one study reported the number of participants with adverse events in the rituximab group only (<a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>). </p> </section> <section id="CD013874-sec-0064"> <h5 class="title">Outcome timing</h5> <p>Median outcome timing was 24 months (12 months from five studies, 18 months from one study, 24 months from eight studies, and 36 months from two studies). </p> </section> <section id="CD013874-sec-0065"> <h5 class="title">Randomised controlled trials</h5> <p><a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a> randomised 84 participants with active secondary progressive MS into two groups. The rituximab group received three courses of intravenous infusion of rituximab 1000 mg every six months, and the control group received glatiramer acetate 40 mg three times per week through subcutaneous injection. Timing of outcome assessments was 12 months. </p> <p><a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a> randomised 80 participants with active secondary progressive MS into two groups. The rituximab group received intravenous infusion of rituximab 1000 mg repeated after two weeks, and then every six months with the same dosage if there was an increase in CD19 and CD20 levels, and the control group received intravenous pulse of cyclophosphamide<b> </b>1000 mg every month until two years. Timing of outcome assessments was 24 months. </p> <p><a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a> randomised 104 participants with relapsing MS into two groups. The rituximab group received a single course of intravenous infusion of rituximab 1000 mg on days one and 15, and the control group received a single course of intravenous infusion of placebo 1000 mg on days one and 15. Timing of outcome assessments were 24 and 48 weeks. </p> <p><a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a> randomised 439 participants with primary progressive MS into two groups. The rituximab group received four courses of two intravenous infusion of rituximab 1000 mg each, two weeks apart, and the control group received four courses of two intravenous infusion of placebo 1000 mg each, two weeks apart. Sixty‐five percent of participants had no prior treatment with DMTs. Timing of beneficial outcome assessments was 96 weeks. Adverse events were monitored until 122 weeks.  </p> <p><a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a> randomised 27 participants with secondary progressive MS into two groups. The rituximab group received intrathecal injection of rituximab 25 mg (1:1 dilution in normal saline) followed by intravenous infusion of rituximab 200 mg at day 0 and 15, and 25 mg of intrathecal rituximab at months 1.5 and 12. The control group received intrathecal and intravenous placebo at month zero, followed by additional intravenous placebo at month 0.5 and another dose of intrathecal placebo at months 1.5 and 12. Timing of outcome assessments was 24 months. </p> </section> <section id="CD013874-sec-0066"> <h5 class="title">Controlled non‐randomised studies of interventions</h5> <p><a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a> (the Grup d'Investigació i Tractament de l'Esclerosi Múltiple (GITEM) register) conducted a multicentre cohort study that retrospectively compared 28 participants with active relapsing MS, who switched from fingolimod to alemtuzumab, administered daily intravenously on five consecutive days at month zero, and on three consecutive days at month 12, with 27 participants with active relapsing MS, who switched from fingolimod to intravenous infusion of rituximab 1000 mg on day one and day 15. For maintenance, an isolated dose of rituximab 1000 mg was administrated when the percentage of total CD19 cells was 2% or more. Timing of outcome assessments was 12 months. </p> <p><a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a> conducted a multicentre cohort study, based on the Swedish MS register, that retrospectively compared 114 participants with relapsing MS who switched from natalizumab, due to John Cunningham (JC) virus antibody positivity, to rituximab or fingolimod. Participants who received intravenous infusions of rituximab 500 mg or 1000 mg every six months were compared to participants who received oral administration of fingolimod 0.5 mg once daily. Authors adjusted for confounding factors, including sex, age, time receiving natalizumab, washout time, baseline EDSS, follow‐up time, and study centre. Timing of outcome assessments was 18 months. </p> <p><a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a> conducted a nationwide register‐based cohort study, linking data from the Swedish MS register to the Swedish Cancer register and other national healthcare and census registers. Primary outcome was time to first invasive cancer. The study included 4187 first‐ever initiations of rituximab, 1620 of fingolimod, and 1670 of natalizumab in 6136 people with MS matched for age, sex, and location to 37,801 people from a general population without MS. </p> <p><a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a> conducted a multicentre cohort study, based on the Swedish MS register, that retrospectively compared 241 participants with active relapsing MS who switched from interferon beta or glatiramer acetate, due to treatment failure, to rituximab or natalizumab or fingolimod. Participants who received intravenous infusions of rituximab 500 mg or 1000 mg every six months were compared to participants who received intravenous infusions of natalizumab 300 mg every four weeks and to participants who received oral administration of fingolimod 0.5 mg once daily. Authors adjusted for confounding factors, including sex, age at inclusion, duration of MS since debut, time receiving last DMT before switch, time from disease activity to switch, EDSS at baseline, and centre. Timing of outcome assessments was 24 months. </p> <p><a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a> conducted a multicentre cohort study, based on the Swedish MS register and the Rocky Mountain MS Clinic database, that retrospectively compared 472 people with relapsing MS. Participants who received a single intravenous infusion of rituximab 500 mg or 1000 mg followed by a single infusion of 500 mg every five to seven months were compared to participants who received two intravenous infusions of ocrelizumab 300 mg two weeks apart followed by a single infusion of 600 mg every five to seven months. Timing of outcome assessments was 12 months. </p> <p><a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a> conducted a propensity score‐matched cohort study, based on the Swedish MS register, that retrospectively compared 488 participants with active relapsing MS who received a 'first choice' treatment of rituximab, interferon beta or glatiramer acetate, dimethyl fumarate, fingolimod, or natalizumab. The rituximab group received intravenous infusions of 500 or 1000 mg every six months. The interferon beta or glatiramer acetate group received subcutaneous injection of interferon beta 1b 0.25 mg every other day, intramuscular injection of interferon beta 1a 0.03 mg once per week, subcutaneous injection of interferon beta 1a 0.022 mg or 0.044 mg once per week, or subcutaneous injection of glatiramer acetate 20 mg daily. The dimethyl fumarate group received oral administration of dimethyl fumarate 120 mg once daily for seven days tapered upwards to 240 mg twice a day. The fingolimod group received oral administration of fingolimod 0.5 mg once daily. The natalizumab group received intravenous infusions of natalizumab 300 mg every 4 weeks. Matching criteria included age, sex, baseline EDSS score, MS duration after debut and diagnosis, relapse in the year before treatment initiation, region, and follow‐up time. Timing of outcome assessments was 24 months. </p> <p><a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a> conducted a nationwide register‐based cohort study linking the Swedish MS register to national healthcare and census registries using the national personal identity number. Primary outcome was serious infections that were defined as all infections resulting in hospitalisations. The study included 6421 participants with relapsing MS who initiated treatment with rituximab (3260 participants), interferon beta or glatiramer acetate (2217 participants), fingolimod (1535 participants), and natalizumab (1588 participants). HRs were adjusted for age, sex, educational level, country of birth, sick leave, disability pension, hospitalisations in the previous five years, history of infections, cancer, antidepressant use, antipsychotic use, major adverse cardiovascular events, arrhythmia, year of treatment start, region of treating clinic, relapses last year, MS duration, EDSS, MS Impact Scale‐29, EuroQol 5‐Dimension scale, and Symbol Digit Modalities test. </p> <p><a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a> conducted a multicentre case‐control study that retrospectively compared 44 participants with secondary progressive MS who were treated with rituximab at two MS centres in Basel and Lugano, Switzerland, to 44 participants with secondary progressive MS, who were never treated with rituximab and were recruited from two cohorts, one at the MS centre in Basel and one at the MS centre in Amsterdam, the Netherlands. Timing of outcome assessments was 36 months. Doses of rituximab were not reported and the control group had never been treated with rituximab. </p> <p><a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a> conducted a propensity score‐matched cohort nationwide study based on the Swedish MS register between April 2005 and November 2015. Authors retrospectively compared 461 participants with relapsing MS, who switched from previous DMTs to rituximab, with 922 participants with relapsing MS who switched from previous DMTs to interferon‐beta or glatiramer acetate. The rituximab group received intravenous infusions of 500 mg or 1000 mg every six months. The interferon beta or glatiramer acetate group received subcutaneous injection of interferon beta 1b 0.25 mg every other day, intramuscular injection of interferon beta 1a 0.03 mg once per week, subcutaneous injection of interferon beta 1a 0.022 mg or 0.044 mg once per week, or subcutaneous injection of glatiramer acetate 20 mg daily. Matching criteria included sex, age, EDSS and disease duration at baseline, number of prebaseline DMT starts, proportion of disease duration on treatment, the number of DMT starts as a proportion of disease duration, relapse activity in the 12‐ and 24‐months prebaseline, the index year of the DMT start, and the number of assessments per year of follow‐up. Timing of outcome assessments was 24 months. </p> <p><a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a> conducted a single‐centre cohort study that retrospectively compared 1246 participants with all types of MS who received rituximab, fingolimod, dimethyl fumarate, or natalizumab. The rituximab group (182 participants) received an induction dose of intravenous infusions of 1000 mg at day one and day 14, and 500 mg every six months. Doses and frequency of fingolimod (271 participants), dimethyl fumarate (342 participants), natalizumab (451 participants) were not reported. The study controlled for confounding through statistical analyses for the primary outcome, a composite measure consisting of clinical relapse, gadolinium‐positive lesions, or new T2 lesions on follow‐up MRI. However, authors reported only unadjusted data for relapse and MRI lesions that were our predefined outcomes of interest. Timing of outcome assessments was 24 months. </p> </section> </section> <section id="CD013874-sec-0067"> <h4 class="title">Excluded studies</h4> <p>We excluded 63 studies that did not match our inclusion criteria. The <a href="./references#CD013874-sec-0171" title="">Characteristics of excluded studies</a> table provides details on these studies. </p> <p> <ul id="CD013874-list-0010"> <li> <p>Fifty‐one studies were of ineligible design: 39 were before‐after (pre–post) studies, cross‐sectional studies, or case series with no control group (<a href="./references#CD013874-bbs2-0016" title="AirasL , NylundM , MannonenI , MatilainenM , SucksdorffM , RissanenE . Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland. Multiple Sclerosis and Related Disorders2020;40:101980. ">Airas 2020</a>; <a href="./references#CD013874-bbs2-0017" title="AlcaláC , GascónF , Pérez-MirallesF , Islam-JakobssonP , SalzerJ , BjörckA , et al. Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study. Journal of Neurology2018;265:1690-7. Perez MirallesFC , Alcala VicenteC , Gascon GimenezF , Escutia RoigM , Bernad FelicesA , Casanova EstruchB . Real-life experience with rituximab for the treatment of multiple sclerosis: report from two MS referral centres. Multiple Sclerosis Journal2017;23(3):343. ">Alcalá 2018</a>; <a href="./references#CD013874-bbs2-0018" title="AlldredgeB , JordanA , ImitolaJ , RackeMK . Safety and efficacy of rituximab: experience of a single multiple sclerosis center. Clinical Neuropharmacology2018;41(2):56-9. ">Alldredge 2018</a>; <a href="./references#CD013874-bbs2-0019" title="AlvarezE , PiccioL , MikesellRJ , TrinkausK , ParksBJ , NaismithRT , et al. Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures. Multiple Sclerosis Journal – Experimental, Translational and Clinical2015;1:2055217315623800. AlvarezE , SeibertJ , VollmerB , BlackburnJ , StrobelM , FreemanJ , et al. Assessing the efficacy, tolerability, and safety of rituximab for the treatment of multiple sclerosis: experience in 313 patients at a large academic center. Multiple Sclerosis Journal2015;23(11):544. ">Alvarez 2015</a>; <a href="./references#CD013874-bbs2-0021" title="Bar-OrA , CalabresiPA , ArnoldD , MarkowitzC , ShaferS , KasperLH , et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Annals of Neurology2008;63(6):803. ">Bar‐Or 2008</a>; <a href="./references#CD013874-bbs2-0023" title="BellinviaA , PrestipinoE , PortaccioE , RazzoliniL , FondericoM , FratangeloR , et al. Experience with rituximab therapy in a real-life sample of multiple sclerosis patients. Neurological Sciences2020;41(10):2939-45. [DOI: 10.1007/s10072-020-04434-1]">Bellinvia 2020</a>; <a href="./references#CD013874-bbs2-0024" title="BergmanJ , BurmanJ , GilthorpeJD , ZetterbergH , JiltsovaE , BergenheimT , et al. Intrathecal treatment trial of rituximab in progressive MS: an open-label phase 1b study. Neurology2018;91(20):e1893-e1901. ">Bergman 2018</a>; <a href="./references#CD013874-bbs2-0026" title="BhargavaP , WickenC , SmithMD , StrowdRE , CorteseI , ReichDS , et al. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement. Multiple Sclerosis and Related Disorders2019;30:136-40. ">Bhargava 2019</a>; <a href="./references#CD013874-bbs2-0027" title="BoremalmM , SundströmP , SalzerJ . Discontinuation and dose reduction of rituximab in patients with relapsing remitting multiple sclerosis. Multiple Sclerosis Journal2020;26(Suppl 3):528-9. BoremalmM , SundströmP , SalzerJ . Discontinuation and dose reduction of rituximab in relapsing-remitting multiple sclerosis. Journal of Neurology2021;268(6):2161-8. [DOI: 10.1007/s00415-021-10399-8]">Boremalm 2021</a>; <a href="./references#CD013874-bbs2-0032" title="CrossAH , KleinRS , PiccioL . Rituximab combination therapy in relapsing multiple sclerosis. Therapeutic Advances in Neurological Disorders2012;5(6):311-9. ">Cross 2012</a>; <a href="./references#CD013874-bbs2-0033" title="D'AmicoE , ZanghìA , ChisariCG , FermoSL , ToscanoS , ArenaS , et al. Effectiveness and safety of rituximab in demyelinating diseases spectrum: an Italian experience. Multiple Sclerosis and Related Disorders2019;27:324-6. ">D'Amico 2019</a>; <a href="./references#CD013874-bbs2-0034" title="DasG , DamotteV , GelfandJM , BevanC , CreeBA , DoL , et al. Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD. Neurology, Neuroimmunology &amp; Neuroinflammation2018;5(3):e453. ">Das 2018</a>; <a href="./references#CD013874-bbs2-0035" title="deFlonP , GunnarssonM , LaurellK , SöderströmL , BirganderR , LindqvistT , et al. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology2016;87(2):141-7. deFlonP , LaurellK , SöderströmL , GunnarssonM , SvenningssonA . Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS. Multiple Sclerosis Journal2017;23(9):1249-57. deFlonP . Treatment with the monoclonal antibody rituximab in multiple sclerosis [Dissertation for PhD]. Umeå (Sweden): The Dean of the Medical Faculty, 2018. EUCTR2010-023021-38-SE. Switch To RItuXimab in MS. A phase 2 open label study of Rituximab in MS patients previously treated with self-injectables using a target based therapy approach – STRIX-MS. www.clinicaltrialsregister.eu (first received 26 November 2010). ">de Flon 2016</a>; <a href="./references#CD013874-bbs2-0036" title="DisantoG , RipellinoP , RiccitelliGC , SaccoR , ScottiB , FuciliA , et al. De-escalating rituximab dose results in stability of clinical, radiological, and serum neurofilament levels in multiple sclerosis. Multiple Sclerosis2021;27(8):1230-9. [DOI: 10.1177/1352458520952036]">Disanto 2021</a>; <a href="./references#CD013874-bbs2-0037" title="DunnN , JutoA , RynerM , ManouchehriniaA , PiccoliL , FinkK , et al. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Multiple Sclerosis Journal2018;24(9):1224-33. ">Dunn 2018</a>; <a href="./references#CD013874-bbs2-0038" title="DurozardP , MaaroufA , BoutiereC , RuetA , BrochetB , VukusicS , et al. Efficacy of rituximab in refractory RRMS. Multiple Sclerosis Journal2019;25(6):828-36. ">Durozard 2019</a>; <a href="./references#CD013874-bbs2-0039" title="EllrichmannG , BolzJ , PeschkeM , DuschaA , HellwigK , Lee De-H, et al. Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. Journal of Neurology2019;266(1):57-67. ">Ellrichmann 2019</a>; <a href="./references#CD013874-bbs2-0040" title="EUCTR2013-002378-26. Switch To RItuXimab in MS extension. An extension study of STRIX-MS – a phase 2 open label study of Rituximab in MS patients previously treated with self-injectables using a target based therapy approach. www.clinicaltrialsregister.eu/ctr-search/trial/2013-002378-26/results (first received 7 October 2018). ">EUCTR2013‐002378‐26</a>; <a href="./references#CD013874-bbs2-0044" title="HellgrenJ , RisedalA , KällénK . Rituximab in multiple sclerosis at general hospital level. Acta Neurologica Scandinavica2020;141(6):491-9. ">Hellgren 2020</a>; <a href="./references#CD013874-bbs2-0047" title="KuempfelT , ThielS , MeinlI , BayasA , CipleaA , HoffmannF , et al. Anti CD20 therapies and pregnancy in neuroimmunological disorders – a case series from Germany. Neurology2019;92:Suppl 15. ">Kuempfel 2019</a>; <a href="./references#CD013874-bbs2-0051" title="LeonidouE , PantzarisM , KleopaKA , LoizidouMA , KyriakidesT , ChristouYP . A retrospective observational study of rituximab treatment in multiple sclerosis patients in Cyprus. Postgraduate Medicine2019;131(7):486-9. ">Leonidou 2019</a>; <a href="./references#CD013874-bbs2-0052" title="MaaroufA , RicoA , BoutiereC , PerrigueyM , DemortiereS , PelletierJ , et al. Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?Neurology Neuroimmunology &amp; Neuroinflammation2020;7(5):e825. ">Maarouf 2020</a>; <a href="./references#CD013874-bbs2-0053" title="Lo ReM , CapobiancoM , RagoneseP , RealmutoS , MalucchiS , BerchiallaP , et al. Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers. Neurology and Therapy2015;4(2):147-57. MalucchiS , CapobiancoM , Di SapioA , Lo ReM , SperliF , MalentacchiM , et al. Rituximab as an effective treatment option after natalizumab withdrawal. Multiple Sclerosis Journal2016;22(Suppl 3):653-4. ">Malucchi 2016</a>; <a href="./references#CD013874-bbs2-0054" title="MathewT , BaptistAA , KamathV , MurgodU , TherambilM , ShajiA , et al. Rituximab in multiple sclerosis: real world experience from three tertiary care MS centers from southern India. Multiple Sclerosis Journal2019;25:751. MathewT , JohnSK , KamathV , MurgodU , ThomasK , Angela BaptistaA , et al. Efficacy and safety of rituximab in multiple sclerosis: experience from a developing country. Multiple Sclerosis and Related Disorders2020;43:102210. ">Mathew 2020</a>; <a href="./references#CD013874-bbs2-0055" title="MazdehM , KhamsehM , TaheriM , Ghafouri-FardS . Effect of rituximab on Expanded Disability Status Scale and relapse rate in multiple sclerosis patients. Journal of Molecular Neuroscience2020;70(8):1165-8. ">Mazdeh 2020</a>; <a href="./references#CD013874-bbs2-0056" title="MidagliaL , Alvarez BravoG , Robles CedeñoR , ZabalzaA , QuibusL , Carbonell-MirabentP , et al. Rituximab treatment for MS: an observational multicentric dose comparison. Strategies for disease modification. Multiple Sclerosis Journal2020;26(Suppl 3):14-5. ">Midaglia 2020</a>; <a href="./references#CD013874-bbs2-0057" title="CrossAH , KleinRS , PiccioL . Rituximab combination therapy in relapsing multiple sclerosis. Therapeutic Advances in Neurological Disorders2012;5(6):311-9. NaismithRT , PiccioL , LyonsJA , LauberJ , TutlamNT , ParksBJ , et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology2010;74(23):1860-7. PiccioL , NaismithRT , TrinkausK , KleinRS , ParksBJ , LyonsJA , et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Archives of Neurology2010;67(6):707-14. ">Naismith 2010</a>; <a href="./references#CD013874-bbs2-0058" title="Naser MoghadasiA , DarkiA , MasoumiP , HashemiSN , GhadiriF . Evaluating the efficacy and safety of ZytuxTM (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: an observational study. Multiple Sclerosis and Related Disorders2019;36:101419. ">Naser Moghadasi 2019</a>; <a href="./references#CD013874-bbs2-0061" title="NielsenAS , MiravalleA , Langer-GouldA , CooperJ , EdwardsKR , KinkelRP . Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis. Multiple Sclerosis Journal2012;18(3):377-8. ">Nielsen 2012</a>; <a href="./references#CD013874-bbs2-0064" title="SahraianMA , AzimiA , NavardiS , AlaS , Naser MoghadasiA . Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Multiple Sclerosis and Related Disorders2020;46:102472. ">Sahraian 2020</a>; <a href="./references#CD013874-bbs2-0065" title="SalzerJ , SvenningssonR , AlpingP , NovakovaL , BjörckA , FinkK , et al. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology2016;87(20):2074-81. ">Salzer 2016</a>; <a href="./references#CD013874-bbs2-0066" title="SchwakeC , GoldR . Severe pneumonia with formation of a pulmonary cavity associated with long-term rituximab therapy in multiple sclerosis. Neurological Research and Practice2020;2:30. [DOI: 10.1186/s42466-020-00074-0]">Schwake 2020</a>; <a href="./references#CD013874-bbs2-0068" title="ShimaA , HamaguchiT , TadaY , YamadaM . Treatment with rituximab in the acute phase of relapsing remitting multiple sclerosis. Internal Medicine (Tokyo, Japan)2020;59(1):121-4. ">Shima 2020</a>; <a href="./references#CD013874-bbs2-0070" title="ToppingJ , DobsonR , LapinS , MaslyanskiyA , KropshoferH , LeppertD , et al. The effects of intrathecal rituximab on biomarkers in multiple sclerosis. Multiple Sclerosis &amp; Related Disorders2016;6:49-53. ">Topping 2016</a>; <a href="./references#CD013874-bbs2-0072" title="TsaoL , OtaniIM , BoveL . Hypogammaglobulinemia in multiple sclerosis patients receiving disease-modifying immunomodulatory agents. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB16. ">Tsao 2019</a>; <a href="./references#CD013874-bbs2-0075" title="WolfAB , RyersonLZ , PandeyK , McGettiganBM , VollmerT , CorboyJR , et al. Rituximab-induced serum sickness in multiple sclerosis patients. Multiple Sclerosis and Related Disorders2019;36:101402. ">Wolf 2019</a>; <a href="./references#CD013874-bbs2-0076" title="YamoutBI , El-AyoubiNK , NicolasJ , El KouziY , KhourySJ , ZeineddineMM . Safety and efficacy of rituximab in multiple sclerosis: a retrospective observational study. Journal of Immunology Research2018;2018:9084759. ">Yamout 2018</a>; <a href="./references#CD013874-bbs2-0077" title="ZeccaC , BovisF , NoviG , CapobiancoM , LanzilloR , FrauJ , et al. Treatment of multiple sclerosis with rituximab: a multicentric Italian-Swiss experience. Multiple Sclerosis Journal2020;26(12):1519-31. ">Zecca 2020</a>; <a href="./references#CD013874-bbs2-0078" title="Zhovtis RyersonL . Serious adverse events related to Rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder patients. Multiple Sclerosis Journal2018;24(2):935-6. ">Zhovtis Ryerson 2018</a>); 11 were retrospective cohort studies with no control group (<a href="./references#CD013874-bbs2-0020" title="BarmettlerS , OngMS , FarmerJR , ChoiH , WalterJ . Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Network Open2018;1(7):e184169. ">Barmettler 2018</a>; <a href="./references#CD013874-bbs2-0022" title="BarraME , SoniD , VoKH , ChitnisT , StankiewiczJM . Experience with long-term rituximab use in a multiple sclerosis clinic. Multiple Sclerosis Journal Experimental, Translational and Clinical2016;2:2055217316672100. ">Barra 2016</a>; <a href="./references#CD013874-bbs2-0025" title="BerntssonSG , KristofferssonA , BoströmI , FeresiadouA , BurmanJ , LandtblomAM . Rapidly increasing off- label use of rituximab in multiple sclerosis in Sweden – outlier or predecessor?Acta Neurologica Scandinavica2018;138:327-31. ">Berntsson 2018</a>; <a href="./references#CD013874-bbs2-0028" title="BoströmI , BurmanJ , LandtblomAM . Adverse events of rituximab in a Swedish MS population sample. Multiple Sclerosis Journal2016;22:871. ">Boström 2016</a>; <a href="./references#CD013874-bbs2-0029" title="BrownBA , TorabiM . Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre. Drug Safety2011;34(2):117-23. ">Brown 2011</a>; <a href="./references#CD013874-bbs2-0031" title="CipleaAI , Langer-GouldA , deVriesA , SchaapT , ThielS , RingelsteinM , et al. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurology, Neuroimmunology &amp; Neuroinflammation2020;7(4):e723. ">Ciplea 2020</a>; <a href="./references#CD013874-bbs2-0046" title="JutoA , FinkK , Al NimerF , PiehlF . Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity. Multiple Sclerosis and Related Disorders2020;37:101468. ">Juto 2020</a>; <a href="./references#CD013874-bbs2-0062" title="PerssonR , LeeS , Ulcickas YoodM , Wagner Usn McCM , MintonN , NiemcrykS , et al. Infections in patients diagnosed with multiple sclerosis: a multi-database study. Multiple Sclerosis and Related Disorders2020;41:101982. ">Persson 2020</a>; <a href="./references#CD013874-bbs2-0069" title="SmithJB , HellwigK , FinkK , LyellDJ , PiehlF , Langer-GouldA . Rituximab, MS, and pregnancy. Neurology Neuroimmunology &amp; Neuroinflammation2020;7(4):e734. ">Smith 2020</a>; <a href="./references#CD013874-bbs2-0071" title="TorgautenHM , MyhrKM , WergelandS , BøL , AarsethJH , Torkildsen Ø. Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – a cohort study. Multiple Sclerosis Journal – Experimental, Translational and Clinical2021;7(1):2055217320973049. [DOI: 10.1177/2055217320973049]">Torgauten 2021</a>; <a href="./references#CD013874-bbs2-0073" title="AlvarezE , NairK , SheltonI , SelvaS , VogeN , ZanganehN , et al. Evaluating the tolerability and safety of switching from rituximab to ocrelizumab: infusion related reactions in relapsing forms of multiple sclerosis. Neurology2019;92 (15 Suppl):P4.2-015. VollmerBL , WallachAI , CorboyJR , DubovskayaK , AlvarezE , KisterI . Serious safety events in rituximab-treated multiple sclerosis and related disorders. Annals of Clinical and Translational Neurology2020;7(9):1477-87. [DOI: 10.1002/acn3.51136]">Vollmer 2020b</a>); and one study investigated the adverse events of rituximab reported to the FDA Adverse Event Reporting Database (<a href="./references#CD013874-bbs2-0030" title="CalditoNG , ShiraniA , SalterA , StuveO . Adverse event profile differences between rituximab and ocrelizumab: findings from the FDA Adverse Event Reporting Database. Multiple Sclerosis2021;27(7):1066-76. ">Caldito 2021</a>). </p> </li> <li> <p>Nine studies were of ineligible intervention: five studies did not compare rituximab with other DMTs (<a href="./references#CD013874-bbs2-0042" title="HallbergS , BoremalmM , EvertssonB , LillvallE , JohanssonF , LyckeJ , et al. Risk of hypogammaglobulinemia in long-term treatment with rituximab in multiple sclerosis. Multiple Sclerosis Journal2019;25(Suppl 2):20. ">Hallberg 2019</a>; <a href="./references#CD013874-bbs2-0043" title="HeA , MerkelB , BrownJW , Zhovits RyersonL , KisterI , MalpasCB , et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurology2020;19(4):307-16. ">He 2020</a>; <a href="./references#CD013874-bbs2-0048" title="Langer-GouldA , PiehlF , SmithJ , FrisellT . Mortality rates in large US and Swedish rituximab-treated multiple sclerosis cohorts. Multiple Sclerosis Journal2018;24:231830. ">Langer‐Gould 2018</a>; <a href="./references#CD013874-bbs2-0050" title="Langer-GouldA , SmithJB , AlbersKB , XiangAH , WuJ , KerezsiEH , et al. Pregnancy-related relapses and breastfeeding in a contemporary multiple sclerosis cohort. Neurology2020;94(18):e1939-e1949. ">Langer‐Gould 2020</a>; <a href="./references#CD013874-bbs2-0074" title="WijnandsJM , ZhuF , KingwellE , FiskJD , EvansC , MarrieRA , et al. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. Journal of Neurology, Neurosurgery and Psychiatry2018;89(10):1050-6. ">Wijnands 2018</a>); one study investigated rituximab as an induction treatment followed by glatiramer acetate in all participants (<a href="./references#CD013874-bbs2-0045" title="HonceJM , NairKV , SillauS , ValdezB , MiravalleA , AlvarezE , et al. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology2019;92(7):e723-e732. NCT01569451. Comparison of rituximab induction therapy followed by glatiramer acetate (GATEWAYII). clinicaltrials.gov/show/NCT01569451 (first received 3 April 2012). ">Honce 2019</a>); one study investigated switching from rituximab to ocrelizumab (<a href="./references#CD013874-bbs2-0059" title="AlvarezE , NairK , SheltonI , ZanganehN , SillauS , CorboyJ , et al. Tolerability and safety of switching from rituximab to ocrelizumab: evaluating factors associated with infusion related reactions. Multiple Sclerosis Journal2019;25(S2):775. NCT02980042. Tolerability and safety of switching from rituximab to ocrelizumab in patients with relapsing forms of multiple sclerosis. clinicaltrials.gov/show/NCT03979456 (first received 14 January 2020). ">NCT02980042</a>); one study evaluated different doses of rituximab with no control group (<a href="./references#CD013874-bbs2-0060" title="NCT03979456. RItuximab long-term DOSE trial in Multiple Sclerosis – RIDOSE-MS. clinicaltrials.gov/show/NCT03979456 (first received 7 June 2019). ">NCT03979456</a>); and one study investigated women who suspended rituximab and natalizumab before conception (<a href="./references#CD013874-bbs2-0063" title="RazazN , PiehlF , FrisellT , Langer-GouldAM , McKayKA , FinkK . Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurology (R) Neuroimmunology &amp; Neuroinflammation2020;7(6):e903. ">Razaz 2020</a>). </p> </li> <li> <p>Two studies reported outcomes that were not relevant. One reported only the JC antibody titres (<a href="./references#CD013874-bbs2-0041" title="GottesmanMH , FarleyS , Friedman-UrevichS , YeJ , GruenebergD , MartoneL . JC titers in multiple sclerosis (MS) patients treated with rituximab, fingolimod and dimethyl fumarate at an American MS center. Multiple Sclerosis Journal2017;23:96-7. ">Gottesman 2017</a>), and the other study reported only "evidence of disease activity (EDA)" (<a href="./references#CD013874-bbs2-0067" title="ScottiB , DisantoG , SaccoR , GuigliM , ZeccaC , GobbiC . Effectiveness and safety of rituximab in multiple sclerosis: an observational study from Southern Switzerland. Plos One2018;13(5):e0197415. ">Scotti 2018</a>). </p> </li> <li> <p>One study was in abstract form only (<a href="./references#CD013874-bbs2-0049" title="Langer-GouldA , AlpingP , SmithJ , LiB , PiehlF , FrisellT . Rituximab does not increase the risk of malignancy or breast cancer in two large US and Swedish rituximab-treated multiple sclerosis cohorts. Multiple Sclerosis Journal2019;25(S2):570. ">Langer‐Gould 2019</a>). We wrote to the authors asking for additional data, but received no reply (<a href="./references#CD013874-bbs2-0120" title="FilippiniG . Total number of patients treated with fingolimod and those treated with glatiramer. Email to: A Langer-Gould 2 April 2021.">Filippini 2021d</a>). This was a retrospective multicentre cohort study conducted in the USA (Kaiser Permanent Southern California, KPSC) and Sweden. The KPSC cohort included 1175 people with MS treated with rituximab compared with glatiramer acetate. The Swedish cohort included 3165 people with MS treated with rituximab compared with fingolimod. </p> </li> </ul> </p> </section> <section id="CD013874-sec-0068"> <h4 class="title">Studies awaiting assessment</h4> <p>We kept three eligible studies under 'awaiting classification' because their data were only available in abstract form (<a href="./references#CD013874-bbs2-0079" title="Berrios MoralesI , EleftheriouE , MarandaL , IoneteC . The safety and efficacy of rituximab use in secondary progressive multiple sclerosis (SPMS) at UMMHC: five years follow up data. Multiple Sclerosis Journal2016;22:805. MoralesIB , EleftheriouE , MarandaL , PolitiL , IoneteC . The safety and efficacy of rituximab use in secondary-progressive multiple sclerosis (SPMS) at UMMHC: five years follow up data. Neurology2017;88(Suppl 1):16. ">Berrios Morales 2016</a>; <a href="./references#CD013874-bbs2-0080" title="FrisellT , CuijpersM , PiehlF . Rate of cardiovascular disease among Swedish multiple sclerosis patients treated with rituximab, natalizumab, fingolimod, and dimethyl fumarate: a nationwide cohort study. Multiple Sclerosis Journal2019;25:314. ">Frisell 2019</a>; <a href="./references#CD013874-bbs2-0081" title="KalincikT , MalpasCB , SharminS , RoosI , PattiF , ButzkuevenH , et al. Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS. Multiple Sclerosis Journal2019;25:912-4. ">Kalincik 2019</a>). Sufficient information was not available on study design, characteristics of participants, interventions, and outcomes. We will include the studies in the update of this review. </p> </section> <section id="CD013874-sec-0069"> <h4 class="title">Ongoing studies</h4> <p>We identified 14 ongoing studies. Eleven are RCTs (<a href="./references#CD013874-bbs2-0082" title="EUCTR2017-000426-35-AT. Efficacy of rituximab at low doses in multiple sclerosis – a prospective, randomized, double-blind, active controlled, pilot trial. www.clinicaltrialsregister.eu/ctr-search/trial/2017-000426-35/AT (first received 12 March 2018). ">EUCTR2017‐000426‐35‐AT</a>; <a href="./references#CD013874-bbs2-0084" title="Danish non-inferiority study of ocrelizumab and rituximab in MS (DanNORMS): a randomized study comparing the efficacy of ocrelizumab and rituximab in active multiple sclerosis. www.clinicaltrialsregister.eu/ctr-search/trial/2020-002981-15/DK (first received 13 July 2020. NCT04688788. Non-inferiority study of ocrelizumab and rituximab in active multiple sclerosis (DanNORMS). clinicaltrials.gov/ct2/show/NCT04688788 (first received 30 December 2020). ">EUCTR2020‐002981‐15‐DK</a>; <a href="./references#CD013874-bbs2-0085" title="IRCT20130812014333N125. Comparison of effectiveness and complication of rituximab and fingolimod in improvement disability motion. en.irct.ir/trial/38158 (first received 7 June 2019). ">IRCT20130812014333N125</a>; <a href="./references#CD013874-bbs2-0086" title="EUCTR2014-005493-11. Intrathecal rituximab in progressive multiple sclerosis (EFFRITE). www.clinicaltrialsregister.eu/ctr-search/trial/2014-005493-11/FR (first received 15 March 2018). NCT02545959. Intrathecal rituximab in progressive multiple sclerosis (EFFRITE). clinicaltrials.gov/show/NCT02545959 (first received 10 September 2015). ">NCT02545959</a>; <a href="./references#CD013874-bbs2-0087" title="EUCTR2015-004116-38. RItuximab versus FUmarate in Newly Diagnosed Multiple Sclerosis – RIFUND-MS. www.clinicaltrialsregister.eu/ctr-search/trial/2015-004116-38/SE (first received 20 October 2015). EUCTR2018-000721-31. RItuximab Long-Term DOSE Trial in Multiple Sclerosis – RIDOSE-MS. www.clinicaltrialsregister.eu/ctr-search/trial/2018-000721-31/SE (first received 24 April 2018). NCT02746744. RItuximab versus FUmarate in Newly Diagnosed Multiple Sclerosis (RIFUND-MS). clinicaltrials.gov/show/NCT02746744 (first received 21 April 2016). NCT03979456. RItuximab Long-Term DOSE Trial in Multiple Sclerosis – RIDOSE-MS. clinicaltrials.gov/ct2/show/NCT03979456 (first received 7 June 2019). ">NCT02746744</a>; <a href="./references#CD013874-bbs2-0089" title="NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">NCT03315923</a>; <a href="./references#CD013874-bbs2-0090" title="NCT03500328. Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS). clinicaltrials.gov/show/NCT03500328 (first received 18 April 2018). ">NCT03500328</a>; <a href="./references#CD013874-bbs2-0091" title="NCT03535298. Determining the Effectiveness of earLy Intensive Versus Escalation approaches for RRMS (DELIVER-MS). clinicaltrials.gov/show/NCT03535298 (first received 24 May 2018). ">NCT03535298</a>; <a href="./references#CD013874-bbs2-0092" title="NCT04047628. Best available therapy versus autologous hematopoetic stem cell transplant for multiple sclerosis (BEAT-MS). clinicaltrials.gov/show/NCT04047628 (first received 7 August 2019). ">NCT04047628</a>; <a href="./references#CD013874-bbs2-0093" title="EUCTR2019-001505-24. Norwegian study of Oral cladribine versus Rituximab in Multiple Sclerosis (NOR-MS). A prospective randomized open-label blinded endpoint (PROBE) multicenter non-inferiority study. www.clinicaltrialsregister.eu/ctr-search/trial/2019-001505-24/NO (first received 28 May 2019. NCT04121403. Norwegian study of oral cladribine and rituximab in multiple sclerosis (NOR-MS). clinicaltrials.gov/show/NCT04121403 (first received 9 October 2019). Nygaard G, LorentzenA , Hognestad T, SimonsenC , Kampman M, Flemmen H, et al. A prospective randomized open-label blinded endpoint multicenter non-inferiority study of oral cladribine and rituximab in multiple sclerosis (NOR-MS). Multiple Sclerosis Journal2020;26(Suppl 3):207-8. ">NCT04121403</a>; <a href="./references#CD013874-bbs2-0095" title="NCT04578639. Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS). clinicaltrials.gov/ct2/show/NCT04578639 (first received 8 October 2020). ">NCT04578639</a>). One study is expected to be completed in August 2021, and plans to evaluate 200 participants (<a href="./references#CD013874-bbs2-0087" title="EUCTR2015-004116-38. RItuximab versus FUmarate in Newly Diagnosed Multiple Sclerosis – RIFUND-MS. www.clinicaltrialsregister.eu/ctr-search/trial/2015-004116-38/SE (first received 20 October 2015). EUCTR2018-000721-31. RItuximab Long-Term DOSE Trial in Multiple Sclerosis – RIDOSE-MS. www.clinicaltrialsregister.eu/ctr-search/trial/2018-000721-31/SE (first received 24 April 2018). NCT02746744. RItuximab versus FUmarate in Newly Diagnosed Multiple Sclerosis (RIFUND-MS). clinicaltrials.gov/show/NCT02746744 (first received 21 April 2016). NCT03979456. RItuximab Long-Term DOSE Trial in Multiple Sclerosis – RIDOSE-MS. clinicaltrials.gov/ct2/show/NCT03979456 (first received 7 June 2019). ">NCT02746744</a>). Three large RCTs are planned for completion in 2023: <a href="./references#CD013874-bbs2-0090" title="NCT03500328. Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS). clinicaltrials.gov/show/NCT03500328 (first received 18 April 2018). ">NCT03500328</a> with 900 participants; <a href="./references#CD013874-bbs2-0091" title="NCT03535298. Determining the Effectiveness of earLy Intensive Versus Escalation approaches for RRMS (DELIVER-MS). clinicaltrials.gov/show/NCT03535298 (first received 24 May 2018). ">NCT03535298</a> with 800 participants; and <a href="./references#CD013874-bbs2-0093" title="EUCTR2019-001505-24. Norwegian study of Oral cladribine versus Rituximab in Multiple Sclerosis (NOR-MS). A prospective randomized open-label blinded endpoint (PROBE) multicenter non-inferiority study. www.clinicaltrialsregister.eu/ctr-search/trial/2019-001505-24/NO (first received 28 May 2019. NCT04121403. Norwegian study of oral cladribine and rituximab in multiple sclerosis (NOR-MS). clinicaltrials.gov/show/NCT04121403 (first received 9 October 2019). Nygaard G, LorentzenA , Hognestad T, SimonsenC , Kampman M, Flemmen H, et al. A prospective randomized open-label blinded endpoint multicenter non-inferiority study of oral cladribine and rituximab in multiple sclerosis (NOR-MS). Multiple Sclerosis Journal2020;26(Suppl 3):207-8. ">NCT04121403</a> with 264 participants. One RCT is planned for completion in 2025 (<a href="./references#CD013874-bbs2-0095" title="NCT04578639. Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS). clinicaltrials.gov/ct2/show/NCT04578639 (first received 8 October 2020). ">NCT04578639</a>), and two RCTs in 2028 (<a href="./references#CD013874-bbs2-0084" title="Danish non-inferiority study of ocrelizumab and rituximab in MS (DanNORMS): a randomized study comparing the efficacy of ocrelizumab and rituximab in active multiple sclerosis. www.clinicaltrialsregister.eu/ctr-search/trial/2020-002981-15/DK (first received 13 July 2020. NCT04688788. Non-inferiority study of ocrelizumab and rituximab in active multiple sclerosis (DanNORMS). clinicaltrials.gov/ct2/show/NCT04688788 (first received 30 December 2020). ">EUCTR2020‐002981‐15‐DK</a>; <a href="./references#CD013874-bbs2-0092" title="NCT04047628. Best available therapy versus autologous hematopoetic stem cell transplant for multiple sclerosis (BEAT-MS). clinicaltrials.gov/show/NCT04047628 (first received 7 August 2019). ">NCT04047628</a>). Another three RCTs are reported as completed in the study registries, but results are not published yet (<a href="./references#CD013874-bbs2-0085" title="IRCT20130812014333N125. Comparison of effectiveness and complication of rituximab and fingolimod in improvement disability motion. en.irct.ir/trial/38158 (first received 7 June 2019). ">IRCT20130812014333N125</a>; <a href="./references#CD013874-bbs2-0086" title="EUCTR2014-005493-11. Intrathecal rituximab in progressive multiple sclerosis (EFFRITE). www.clinicaltrialsregister.eu/ctr-search/trial/2014-005493-11/FR (first received 15 March 2018). NCT02545959. Intrathecal rituximab in progressive multiple sclerosis (EFFRITE). clinicaltrials.gov/show/NCT02545959 (first received 10 September 2015). ">NCT02545959</a>; <a href="./references#CD013874-bbs2-0089" title="NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">NCT03315923</a>). The prospective completion date was not available for one RCT (<a href="./references#CD013874-bbs2-0082" title="EUCTR2017-000426-35-AT. Efficacy of rituximab at low doses in multiple sclerosis – a prospective, randomized, double-blind, active controlled, pilot trial. www.clinicaltrialsregister.eu/ctr-search/trial/2017-000426-35/AT (first received 12 March 2018). ">EUCTR2017‐000426‐35‐AT</a>). Two ongoing NRSIs are planned for completion in 2022: <a href="./references#CD013874-bbs2-0088" title="EUCTR2016-003587-39. COMBAT-MS (COMparison Between All immunoTherapies for Multiple Sclerosis). www.clinicaltrialsregister.eu/ctr-search/trial/2016-003587-39/SE (first received 23 March 2017). NCT03193866. COMparison Between All immunoTherapies for Multiple Sclerosis (COMBAT-MS). clinicaltrials.gov/show/NCT03193866 (first received 21 June 2017). ">NCT03193866</a> with 3526 participants from the Swedish registry, and <a href="./references#CD013874-bbs2-0094" title="NCT04283747. Rituximab-induced hypogammaglobulinemia in multiple sclerosis. clinicaltrials.gov/show/NCT04283747 (first received 25 February 2020). ">NCT04283747</a> with 170 participants. One NRSI did not report the prospective completion date. The <a href="./references#CD013874-sec-0173" title="">Characteristics of ongoing studies</a> table provides details on these studies. </p> </section> </section> <section id="CD013874-sec-0070"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD013874-sec-0071"> <h4 class="title">Risk of bias in randomised controlled trials</h4> <p>We assessed risk of bias of the included RCTs using the Cochrane Collaboration’s tool for assessing risk of bias (<a href="./references#CD013874-bbs2-0129" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). We rated the overall risk of bias to be unclear for <a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a> and high for the other four included RCTs (<a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a>; <a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a>; <a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>; <a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a>) (see <a href="#CD013874-fig-0002">Figure 2</a>; <a href="#CD013874-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD013874-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included randomised controlled trials." data-id="CD013874-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included randomised controlled trials. </p> </div> </div> </div> <div class="figure" id="CD013874-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included randomised controlled trial." data-id="CD013874-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included randomised controlled trial. </p> </div> </div> </div> </section> <section id="CD013874-sec-0072"> <h4 class="title">Allocation</h4> <p>We assessed this domain on a study level. All included studies were judged to be at low risk of selection bias for the domain of random sequence generation. We judged the risk of bias coming from the randomisation process to be of some concern for <a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a> and <a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a> because the authors provided no information on whether the allocation was concealed. Allocation was not concealed in the other three RCTs (<a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a>; <a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a>; <a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a>). Therefore, we judged risk of bias for this domain and these studies to be high. </p> </section> <section id="CD013874-sec-0073"> <h4 class="title">Blinding</h4> <p>Participants were aware of the assigned intervention in <a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a> and <a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a>. Therefore, we judged risk for performance bias for these studies to be high. The other three RCTs provided no information on whether placebo infusion was indistinguishable from rituximab infusion in terms of taste, appearance, and duration of infusion (<a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>; <a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a>; <a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a>). Therefore, we judged risk for performance bias and these studies to be of some concern. </p> <p>We judged risk for detection bias for all outcomes to be low for <a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a>, <a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>, and <a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a>, because assessment of outcomes was performed by an investigator who was blinded to the study group; to be of some concern for <a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a>, because the authors provided no information on whether the assessment of outcomes was blinded; and to be high for <a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a>, because the comparison treatments (rituximab and cyclophosphamide) differed in the frequencies of administration and clinical examinations, every six months for the rituximab group and monthly for the cyclophosphamide group. </p> </section> <section id="CD013874-sec-0074"> <h4 class="title">Incomplete outcome data</h4> <p>We judged risk of bias for missing outcome data to be low for all the outcomes in <a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a> and <a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a>, because outcome data were available for all participants. We judged attrition bias to be high in <a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a>, <a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>, and <a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a>, because numbers and causes of dropouts are not balanced between comparison groups (i.e. presence of a significant difference) and appeared to be related to the outcomes. </p> </section> <section id="CD013874-sec-0075"> <h4 class="title">Selective reporting</h4> <p>We judged the risk of reporting bias to be low for all the outcomes in <a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a>, <a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>, <a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a>, and <a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a>, because all these studies reported results in accordance with their published protocols (NCT03315923; NCT00097188; NCT00087529; NCT01212094). We judged reporting bias to be of some concern for <a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a>, because its study protocol was not available. </p> </section> <section id="CD013874-sec-0076"> <h4 class="title">Other potential sources of bias</h4> <p>We judged the included RCTs to be at low risk of other bias except <a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a>. We judged this study at high risk of other bias because the authors terminated the study prematurely based on an interim analysis on cerebrospinal fluid biomarkers and participants were not followed up to measure clinical outcomes. </p> </section> <section id="CD013874-sec-0077"> <h4 class="title">Risk of bias in controlled non‐randomised studies of interventions</h4> <p>We assessed the risk of bias for the NRSIs using the ROBINS‐I tool (<a href="./references#CD013874-bbs2-0175" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , ViswanathanM , et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ2016;355:i4919.">Sterne 2016</a>). We present the full judgement per study and outcomes, including the support for judgement in <a href="./appendices#CD013874-sec-0151">Appendix 2</a>; and the risk of bias summaries in <a href="#CD013874-fig-0004">Figure 4</a> and <a href="#CD013874-fig-0005">Figure 5</a>. </p> <div class="figure" id="CD013874-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="ROBINS‐I summary: review authors' judgements about each risk of bias item for each included non‐randomised study and for outcomes assessed to estimate the &quot;effect of assignment to the intervention&quot; (including disability worsening, relapses, treatment discontinuation due to adverse events, T1 and T2 magnetic resonance imaging lesions).Note: two studies did not report the outcomes and were not included in the figure (Alping 2020; Luna 2020)." data-id="CD013874-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>ROBINS‐I summary: review authors' judgements about each risk of bias item for each included non‐randomised study and for outcomes assessed to estimate the "effect of assignment to the intervention" (including disability worsening, relapses, treatment discontinuation due to adverse events, T1 and T2 magnetic resonance imaging lesions). </p> <p>Note: two studies did not report the outcomes and were not included in the figure (<a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>). </p> </div> </div> </div> <div class="figure" id="CD013874-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="ROBINS‐I summary: review authors' judgments about each risk of bias item for each included non‐randomised study and for outcomes assessed to estimate the &quot;effect of adherence to the intervention&quot; (including serious adverse events and further adverse events).Note: two studies did not report the outcomes and were not included in the figure (Naegelin 2019; Spelman 2018)." data-id="CD013874-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-FIG-05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>ROBINS‐I summary: review authors' judgments about each risk of bias item for each included non‐randomised study and for outcomes assessed to estimate the "effect of adherence to the intervention" (including serious adverse events and further adverse events). </p> <p>Note: two studies did not report the outcomes and were not included in the figure (<a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>; <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>). </p> </div> </div> </div> <section id="CD013874-sec-0078"> <h5 class="title">Overall bias</h5> <p>Overall, we rated the risk of bias for outcomes assessed to estimate the 'effect of assignment to the intervention' (including disability worsening, recurrence of relapse, treatment discontinuation due to adverse events, new or enlarging T2‐weighted MRI lesions; and new gadolinium‐enhancing positive T1‐weighted MRI lesions) to be critical in one study (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>), serious in four studies (<a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>; <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>), and moderate in three studies (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>). <a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a> assessed the risk of cancer in a large population of people with MS treated with rituximab or other DMTs and did not report those outcomes. <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a> examined the risk of serious infections associated with rituximab or other DMTs and did not report those outcomes.  </p> <p>We rated the risk of bias for outcomes assessed to estimate the 'effect of adherence to the intervention' (including SAEs and further adverse events) to be critical in one study (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>); serious in one study (<a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>); and moderate in six studies (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>). Assessment of risk of bias for SAEs and further adverse events was not applicable in two studies (<a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>; <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>). <a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a> reported common infections for the rituximab group only and did not report any other adverse events; <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a> did not report adverse events. </p> </section> <section id="CD013874-sec-0079"> <h5 class="title">Bias due to confounding</h5> <p>We judged the risk of bias to be moderate in five studies for outcomes assessed to estimate the 'effect of assignment to the intervention' because the authors adjusted for most important confounding factors. <a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a> adjusted for the continuous variables age at inclusion, time receiving previous natalizumab treatment, and washout time, and the categorical variables sex, baseline EDSS, and study centre. MRI outcome was adjusted also for follow‐up time. <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a> adjusted for the continuous variables age at inclusion, MS duration since debut, EDSS at baseline, time receiving last DMT before switch, and time from disease activity to switch, and the categorical variables sex and centre (except for discontinuation of therapy because treatment allocation correlated to centre and too few had interrupted RTX treatment). <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a> adjusted for age at inclusion, sex, baseline EDSS score, MS duration after debut and diagnosis, relapse in the year before treatment initiation, region, and follow‐up time. Propensity scores were estimated for each DMT group in comparison with rituximab. <a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a> matched their groups by propensity scores based on sex, age, EDSS score, and MS duration at baseline. <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a> matched their groups by propensity scores based on sex, age, EDSS and disease duration at baseline, number of prebaseline DMTs start, the proportion of disease duration on treatment, the number of DMT starts as a proportion of disease duration, relapse activity in the 12‐ and 24‐months prebaseline, the index year of the DMT start, and the number of assessments per year of follow‐up. We judged the risk of bias due to confounding to be serious in three studies. <a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a> did not adjust for any confounding factors; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a> did not adjust for important confounding factors, including baseline EDSS, MS duration, and study centre; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a> reported unadjusted outcomes (relapse and MRI lesions). </p> <p>We judged the risk of bias to estimate the 'effect of adherence to the intervention' to be moderate in six studies for SAEs and further adverse events (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>). We judged two studies at serious risk of bias (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>).  </p> </section> <section id="CD013874-sec-0080"> <h5 class="title">Bias in selection of participants into the study</h5> <p>We judged the risk of bias to be low for <a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>, <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>, and <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a> for outcomes assessed to estimate the 'effect of assignment to the intervention'. In these studies, participants were identified through the web‐based national Swedish MS registry and the number of participants excluded due to insufficient follow‐up or compliance was low (1.7% in <a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>, 2.8% in <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>, and 0.5% in <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>). We judged two studies at moderate risk of bias. In <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>, the selection of participants into the study may have been related to intervention and outcome, but the study authors used appropriate methods to adjust for the selection bias. In <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>, the source population was all participants with MS who initiated intervention in a single centre. We judged three studies at serious risk of bias. In <a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>, an immortal time bias occurred and the authors did not adjust for the selection bias. In <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>, the selection of participants into the study was based on characteristic of participants after the start of interventions and the authors did not adjust for the selection bias. In <a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>, selection of the participants into the study was likely related to interventions and outcome. </p> <p>We judged the risk of bias to estimate the 'effect of adherence to the intervention' to be low in four studies for SAEs and further adverse events (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>), moderate in two studies (<a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>), and serious in two studies (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>). </p> </section> <section id="CD013874-sec-0081"> <h5 class="title">Bias in classification of interventions</h5> <p>We judged the risk of bias to be moderate in seven studies for outcomes assessed to estimate the 'effect of assignment to the intervention' (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>; <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>); despite these studies collecting retrospective clinical data, the intervention and comparison groups were defined. We judged <a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a> at serious risk of bias because authors did not report dose, frequency, or intensity of the intervention in the comparison group. </p> <p>We judged the risk of bias to estimate the 'effect of adherence to the intervention' to be moderate in seven studies for SAEs and further adverse events (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>), and serious for <a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>.  </p> </section> <section id="CD013874-sec-0082"> <h5 class="title">Bias due to deviations from intended interventions</h5> <p>We judged the risk of bias for outcomes assessed to estimate the 'effect of assignment to the intervention' to be low in all included studies because deviations from intended intervention were part of usual practice. </p> <p>We judged the risk of bias to estimate the 'effect of adherence to the intervention' to be unclear in seven studies for SAEs and further adverse events (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>; <a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>). These studies did not report any information on whether there was deviation from the intended intervention. </p> </section> <section id="CD013874-sec-0083"> <h5 class="title">Bias due to missing data</h5> <p>We judged the risk of bias to be low in seven studies for outcomes assessed to estimate the 'effect of assignment to the intervention', because results were reasonably complete (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>; <a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>). We judged <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a> at serious risk of bias because the authors reported disability worsening for 70% of participants in the rituximab group and 58% of participants in the comparison group. </p> <p>We judged the risk of bias to estimate the 'effect of adherence to the intervention' to be low in seven studies for SAEs and further adverse events (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>; <a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>), and moderate for <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a> because the authors applied multiple imputation to account for missing data. </p> </section> <section id="CD013874-sec-0084"> <h5 class="title">Bias in measurement of outcomes</h5> <p>We judged the risk of bias to be moderate in seven studies for outcomes assessed to estimate the 'effect of assignment to the intervention' because outcome assessors were not blinded to the intervention and geographical imbalances in the recording of outcomes may have been, given the lack of formal study visits (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>;<b> </b><a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>; <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>). We judged <a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a> at serious risk of bias because outcome assessors were aware of the intervention assigned, and the methods of outcome assessment were not comparable across the intervention groups. </p> <p>We judged the risk of bias to estimate the 'effect of adherence to the intervention' to be low in one study for SAEs and further adverse events because outcomes were identified in the Swedish national cancer register and cancers occurring at any time after treatment were considered events (<a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>). We judged the risk of bias to be moderate in six studies for SAEs and further adverse events (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>), and serious in <a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a> because outcome assessors were aware of the intervention assigned, and the methods of outcome assessment were not comparable across the intervention groups. </p> </section> <section id="CD013874-sec-0085"> <h5 class="title">Bias in selection of the reported results</h5> <p>We judged the risk of bias to be low in seven studies for outcomes assessed to estimate the 'effect of assignment to the intervention' because the authors reported outcome measures that corresponded to all intended outcomes reported in the methods section of their articles (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>;<b> </b><a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>; <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>). We judged the risk of bias to be serious for <a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>, because outcomes were reported in different ways in the methods and results sections of the article.  </p> <p>We judged the risk of bias to estimate the 'effect of adherence to the intervention' to be low in seven studies for SAEs and further adverse events (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>;<b> </b><a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>; <a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>), and serious for <a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>.  </p> </section> </section> </section> <section id="CD013874-sec-0086"> <h3 class="title" id="CD013874-sec-0086">Effects of interventions</h3> <p>See: <a href="./full#CD013874-tbl-0001"><b>Summary of findings 1</b> Rituximab as 'first choice' versus other disease‐modifying treatments for relapsing multiple sclerosis – results from non‐randomised studies of intervention</a>; <a href="./full#CD013874-tbl-0002"><b>Summary of findings 2</b> Rituximab as 'first choice' versus placebo for progressive multiple sclerosis – results from randomised controlled trials</a>; <a href="./full#CD013874-tbl-0003"><b>Summary of findings 3</b> Rituximab as 'switching' versus placebo for relapsing multiple sclerosis – results from randomised controlled trials</a>; <a href="./full#CD013874-tbl-0004"><b>Summary of findings 4</b> Rituximab as 'switching' versus other disease‐modifying treatments for relapsing multiple sclerosis – results from non‐randomised studies of intervention</a> </p> <p>We reported here the results of critical outcomes and important outcomes that we prioritised for presentation in the <a href="./full#CD013874-tbl-0001">summary of findings Table 1</a> and the <a href="./full#CD013874-tbl-0004">summary of findings Table 4</a>. We also reported additional important outcomes. We presented the results for rituximab as 'first choice' and as 'switching', and ordered them by type of MS (relapsing or progressive), comparison (placebo or other DMT), and then by study design (RCT or NRSI). </p> <p>In <a href="#CD013874-tbl-0006">Table 2</a>, we reported the other results that we have not presented in the summary of findings tables. In <a href="#CD013874-tbl-0007">Table 3</a>, we included a simple PICOS (Population, Intervention, Comparison, Outcomes, Study) table to briefly 'map' out the current evidence identified by our review. </p> <div class="table" id="CD013874-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">PICOS table to summarise the current evidence identified in the review</span></div> <tbody> <tr> <th align="" class="headercell" colspan="4" rowspan="1" scope="col" valign="top"> <p><b>Intervention: rituximab as first‐choice </b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Population</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study design (number of included studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes (☑ evidence identified) </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Relapsing MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 0</p> <p>NRSI 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening</p> <p>Recurrence of relapse</p> <p>SAEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections</p> <p>Cancer</p> <p>Mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR</p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions</p> <p>New T1 (gadolinium) MRI lesions</p> <p>Discontinuation due to AEs</p> <p>Grade 3–4 AEs</p> <p>Long‐term AEs</p> <p>Short‐term AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Other DMTs</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Relapsing MS</p> <p><i>Also see: </i><a href="./full#CD013874-tbl-0001">summary of findings Table 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 0</p> <p>NRSI 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening</p> <p>Recurrence of relapse <b>☑</b> </p> <p>SAEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections</p> <p>Cancer</p> <p>Mortality <b>☑</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR</p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions</p> <p>New T1 (gadolinium) MRI lesions <b>☑</b> </p> <p>Discontinuation due to AEs <b>☑ </b> </p> <p>Grade 3–4 AEs <b>☑ </b> </p> <p>Long‐term AEs</p> <p>Short‐term AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Progressive MS (primary)</p> <p><i>Also see: </i><a href="./full#CD013874-tbl-0002">summary of findings Table 2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 1</p> <p>NRSI 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening <b>☑</b> </p> <p>Recurrence of relapse <b>☑</b> </p> <p>SAEs <b>☑</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections <b>☑</b> </p> <p>Cancer <b>☑</b> </p> <p>Mortality <b>☑</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR</p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions</p> <p>New T1 (gadolinium) MRI lesions</p> <p>Discontinuation due to AEs <b>☑</b> </p> <p>Grade 3–4 AEs <b>☑</b> </p> <p>Long‐term AEs</p> <p>Short‐term AEs <b>☑ (infusion‐related)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Other DMTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Progressive MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 0</p> <p>NRSI 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening</p> <p>Recurrence of relapse</p> <p>SAEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections</p> <p>Cancer</p> <p>Mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR</p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions</p> <p>New T1 MRI lesions</p> <p>Discontinuation due to AEs</p> <p>Grade 3–4 AEs</p> <p>Long‐term AEs</p> <p>Short‐term AEs</p> </td> </tr> <tr> <th align="" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>Intervention: rituximab as 'switching' </b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Population</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study design (number of included studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Relapsing MS</p> <p><i>Also see: </i><a href="./full#CD013874-tbl-0003">summary of findings Table 3</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 1</p> <p>NRSI 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening</p> <p>Recurrence of relapse <b>☑</b> </p> <p>SAEs <b>☑</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections <b>☑</b> </p> <p>Cancer <b>☑</b> </p> <p>Mortality <b>☑</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR <b>☑</b> </p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions</p> <p>New T1 (gadolinium) MRI lesions <b>☑</b> </p> <p>Discontinuation due to AEs <b>☑</b> </p> <p>Grade 3–4 AEs <b>☑</b> </p> <p>Long‐term AEs <b>☑ </b>(CV events; opportunistic infections) </p> <p>Short‐term AEs <b>☑ </b>(infusion‐related) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Other DMTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Relapsing MS</p> <p><i>Also see: </i><a href="./full#CD013874-tbl-0004">summary of findings Table 4</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 0</p> <p>NRSI 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening <b>☑ </b>(1 NRSI) </p> <p>Recurrence of relapse <b>☑ </b>(3 NRSI) </p> <p>SAEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections <b>☑ </b>(4 NRSI) </p> <p>Cancer</p> <p>Mortality <b>☑ </b>(1 NRSI) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR <b>☑ </b>(1 study) </p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions <b>☑ </b>(1 NRSI) </p> <p>New T1 (gadolinium) MRI lesions <b>☑ </b>(2 NRSI) </p> <p>Discontinuation due to AEs <b>☑ </b>(2 NRSI) </p> <p>Grade 3–4 AEs <b>☑ </b>(2 NRSI) </p> <p>Long‐term AEs <b>☑</b> (CV events (2 NRSI)) </p> <p>Short‐term AEs <b>☑ </b>(infusion‐related) (2 NRSI) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Progressive MS (secondary)</p> <p><i>Also see: </i><a href="#CD013874-tbl-0006">Table 2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 1</p> <p>NRSI 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening</p> <p>Recurrence of relapse</p> <p>SAEs <b>☑</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections</p> <p>Cancer <b>☑</b> </p> <p>Mortality </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR</p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions</p> <p>New T1 (gadolinium) MRI lesions</p> <p>Discontinuation due to AEs</p> <p>Grade 3–4 AEs</p> <p>Long‐term AEs <b>☑ </b>(CV events) </p> <p>Short‐term AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Other DMTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Progressing MS (secondary)</p> <p><i>Also see: </i><a href="#CD013874-tbl-0006">Table 2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 2</p> <p>NRSI 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening <b>☑</b> (1 NRSI) </p> <p>Recurrence of relapse</p> <p>SAEs <b>☑ </b>(1 RCT) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections <b>☑ </b>(2 RCTs) </p> <p>Cancer</p> <p>Mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR <b>☑ </b>(1 RCT) </p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions</p> <p>New T1 (gadolinium) MRI lesions <b>☑ </b>(1 RCT) </p> <p>Discontinuation due to AEs <b>☑ </b>(1 RCT) </p> <p>Grades 3–4 AEs</p> <p>Long‐term AEs <b>☑ </b>(opportunistic infections, 1 RCT) </p> <p>Short‐term AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Other DMTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Relapsing + progressing MS</p> <p><i>Also see: </i><a href="#CD013874-tbl-0006">Table 2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 0</p> <p>NRSI 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening</p> <p>Recurrence of relapse <b>☑ </b>(1 NRSI) </p> <p>SAEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections <b>☑ </b>(1 NRSI) </p> <p>Cancer <b>☑ </b>(1 NRSI) </p> <p>Mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR </p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions <b>☑ </b>(1 NRSI) </p> <p>New T1 (gadolinium) MRI lesions <b>☑ </b>(1 NRSI) </p> <p>Discontinuation due to AEs <b>☑ </b>(1 NRSI) </p> <p>Grades 3–4 AEs</p> <p>Long‐term AEs <b>☑ </b>(CV events, 1 NRSI) </p> <p>Short‐term AEs</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AE: adverse event; ARR: annualised relapse rate; CV: cardiovascular events; MRI: magnetic resonance imaging; MS: multiple sclerosis; NRSI: non‐randomised study of intervention; QoL: quality of life; RCT: randomised controlled trial; SAE: serious adverse event. </p> </div> </div> <section id="CD013874-sec-0087"> <h4 class="title">Rituximab as 'first choice' versus placebo for relapsing multiple sclerosis</h4> <p>None of the included studies assessed rituximab as 'first choice' versus placebo for relapsing MS. </p> </section> <section id="CD013874-sec-0088"> <h4 class="title">Rituximab as 'first choice' versus other disease‐modifying treatments for relapsing multiple sclerosis </h4> <p>In <a href="./full#CD013874-tbl-0001">summary of findings Table 1</a>, we provided a summary of the effect estimates of rituximab as 'first choice' treatment versus other DMTs for relapsing MS for critical and prioritised important outcomes, the certainty of NRSI evidence for each comparison, and reasons for downgrading it. </p> <section id="CD013874-sec-0089"> <h5 class="title">Randomised controlled trials</h5> <p>None of the included RCTs assessed rituximab as 'first choice' versus other DMTs for relapsing MS. </p> </section> <section id="CD013874-sec-0090"> <h5 class="title">Controlled non‐randomised studies of interventions </h5> <p>One retrospective multicentre cohort study compared 488 participants with newly diagnosed active relapsing MS who started their first treatment with rituximab (120 participants), interferon beta or glatiramer acetate (215 participants), dimethyl fumarate (86 participants), fingolimod (17 participants), or natalizumab (50 participants) (<a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>; the Swedish MS Register). </p> <section id="CD013874-sec-0091"> <h6 class="title">Critical outcomes</h6> <p><i>Disability worsening: </i>the study did not measure the outcome. </p> <p><i>Recurrence of relapses over 24 months:</i> rituximab reduced the number of participants who had relapses when compared with the following agents (<a href="./references#CD013874-fig-0006" title="">Analysis 1.1</a>): </p> <p> <ul id="CD013874-list-0011"> <li> <p>moderate‐certainty evidence for comparison with interferon beta or glatiramer acetate (HR 0.14, 95% CI 0.05 to 0.39; 1 NRSI, 335 participants); the absolute effect was 227 fewer people (95% CI 254 fewer to 154 fewer) per 1000 people having relapses with rituximab; </p> </li> <li> <p>low‐certainty evidence for comparison with dimethyl fumarate (HR 0.29, 95% CI 0.08 to 1.00; 1 NRSI, 206 participants); the absolute effect was 84 fewer people (95% CI 110 fewer to 0 fewer) per 1000 people having relapses with rituximab; </p> </li> <li> <p>low‐certainty evidence for comparison with natalizumab (HR 0.24, 95% CI 0.06 to 1.00; 1 NRSI, 170 participants); the absolute effect was 148 fewer people (95% CI 187 fewer to 0 fewer) per 1000 people having relapses with rituximab; </p> </li> <li> <p>very low‐certainty evidence for comparison with fingolimod (HR 0.26, 95% CI 0.04 to 1.69; 1 NRSI, 137 participants). </p> </li> </ul> </p> <p><i>SAEs:</i> the study did not measure the outcome. </p> </section> <section id="CD013874-sec-0092"> <h6 class="title">Important prioritised outcomes </h6> <p><i>Quality of life, common infections, cancer:</i> the study did not measure these outcomes. </p> <p><i>Mortality over 24 months:</i>  the study<i> </i>reported no deaths in any comparison group over 24 months' follow‐up. Death related to adverse events was defined as grade 5 adverse events in the Common Terminology Criteria for Adverse Events (CTCAE). </p> </section> <section id="CD013874-sec-0093"> <h6 class="title">Additional important outcomes</h6> <p><i>New gadolinium‐positive MRI lesions over 24 months:</i> rituximab probably resulted in a reduction in the number of participants who had new gadolinium‐positive MRI lesions when compared with the following agents (<a href="./references#CD013874-fig-0007" title="">Analysis 1.2</a>): </p> <p> <ul id="CD013874-list-0012"> <li> <p>moderate‐certainty evidence for comparison with interferon beta or glatiramer acetate (OR 0.10, 95% CI 0.02 to 0.43; 1 NRSI, 263 participants); the absolute effect was 150 fewer people (95% CI 166 fewer to 89 fewer) per 1000 people having new gadolinium‐positive MRI lesions with rituximab; </p> </li> <li> <p>moderate‐certainty evidence for comparison with dimethyl fumarate (OR 0.12, 95% CI 0.02 to 0.59; 1 NRSI, 177 participants); the absolute effect was 130 fewer people (95% CI 147 fewer to 56 fewer) per 1000 people having new gadolinium‐positive MRI lesions with rituximab; </p> </li> <li> <p>the evidence was very uncertain for comparison with natalizumab (OR 0.12, 95% CI 0.01 to 1.11; 1 NRSI, 147 participants) and with fingolimod (OR 0.33, 95% CI 0.01 to 10.00; 1 NRSI, 119 participants). </p> </li> </ul> </p> <p><i>Treatment discontinuation due to adverse events over 24 months:</i> the number of participants who discontinued initial treatment with rituximab was lower than that observed in participants treated with the following agents (<a href="./references#CD013874-fig-0008" title="">Analysis 1.3</a>): </p> <p> <ul id="CD013874-list-0013"> <li> <p>moderate‐certainty evidence for comparison with interferon beta or glatiramer acetate (OR 0.02, 95% CI 0.00 to 0.16; 1 NRSI, 335 participants); the absolute effect was 271 fewer people (95% CI 275 fewer to 221 fewer) per 1000 people who discontinued rituximab; </p> </li> <li> <p>moderate‐certainty evidence for comparison with dimethyl fumarate (OR 0.05, 95% CI 0.01 to 0.41; 1 NRSI, 206 participants); the absolute effect was 131 fewer people (95% CI 138 fewer to 77 fewer) per 1000 people who discontinued rituximab; </p> </li> <li> <p>low‐certainty evidence for comparison with natalizumab (OR 0.20, 95% CI 0.02 to 2.28; 1 NRSI, 170 participants) and with fingolimod (OR 0.04, 95% CI 0.00 to 0.40; 1 NRSI, 137 participants). </p> </li> </ul> </p> <p><i>Grade 3 and grade 4 adverse events over 24 months:</i> the events were few and the evidence was uncertain about the number of participants who had grade 3 and grade 4 adverse events with rituximab when compared with the following agents: </p> <p> <ul id="CD013874-list-0014"> <li> <p>very low‐certainty evidence for comparison with interferon beta or glatiramer acetate (OR 0.89, 95% CI 0.26 to 3.03; 1 NRSI, 335 participants), dimethyl fumarate (OR 2.93, 95% CI 0.32 to 26.69; 1 NRSI, 206 participants), natalizumab (OR 0.40, 95% CI 0.10 to 1.65; 1 NRSI, 170 participants), or fingolimod (OR 1.35, 0.07 to 26.21; 1 NRSI, 137 participants) (<a href="./references#CD013874-fig-0009" title="">Analysis 1.4</a>). </p> </li> </ul> </p> </section> </section> </section> <section id="CD013874-sec-0094"> <h4 class="title">Rituximab as 'first choice' versus placebo for progressive multiple sclerosis</h4> <p>In <a href="./full#CD013874-tbl-0002">summary of findings Table 2</a>, we provided a summary of the effect estimates of rituximab as 'first choice' treatment versus placebo for primary progressive MS for critical and prioritised important outcomes, the certainty of evidence, and reasons for downgrading it. </p> <section id="CD013874-sec-0095"> <h5 class="title">Randomised controlled trials</h5> <p>One RCT compared rituximab with placebo in 439 participants (65% treatment‐naive) with primary progressive MS (<a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a>). None of the included RCTs assessed rituximab as 'first choice' in secondary progressive MS. </p> <section id="CD013874-sec-0096"> <h6 class="title">Critical outcomes</h6> <p><i>Disability worsening over 24 months:</i> rituximab likely resulted in little to no difference in the number of participants who had disability worsening over 24 months compared with placebo (OR 0.71, 95% CI 0.45 to 1.11; 1 RCT, 439 participants; moderate‐certainty evidence); the absolute effect was 75 fewer people (95% CI 158 fewer to 24 more) per 1000 people having disability worsening with rituximab (<a href="./references#CD013874-fig-0010" title="">Analysis 2.1</a>). <a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a> reported that time to disability worsening was delayed in rituximab‐treated progressive MS with gadolinium‐positive MRI lesions (HR 0.41; P = 0.007), and people aged less than 51 years with gadolinium‐positive MRI lesions (HR 0.33; P = 0.009) compared with placebo.  </p> <p><i>Recurrence of relapses over 24 months:</i> rituximab may have resulted in little to no difference in recurrence of relapses when compared with placebo (OR 0.60, 95% CI 0.18 to 1.99; 1 RCT, 439 participants; low‐certainty evidence; <a href="./references#CD013874-fig-0011" title="">Analysis 2.2</a>).  </p> <p><i>SAEs over 24 months:</i> rituximab may have resulted in little to no difference in the number of participants who had SAEs (OR 1.25, 95% CI 0.71 to 2.20; 1 RCT, 439 participants; low‐certainty evidence; <a href="./references#CD013874-fig-0012" title="">Analysis 2.3</a>). </p> </section> <section id="CD013874-sec-0097"> <h6 class="title">Important prioritised outcomes </h6> <p><i>Quality of life:</i> the study did not report the outcome. </p> <p><i>Common infections over 24 months:</i> rituximab may have resulted in little to no difference in the number of participants who had common infections compared with placebo (OR 1.14, 95% CI 0.75 to 1.73; 1 RCT, 438 participants; low‐certainty evidence; <a href="./references#CD013874-fig-0013" title="">Analysis 2.4</a>). Infections reported in more than 10% of either group included upper respiratory infections, urinary tract infections, and nasopharyngitis (<a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a>). </p> <p><i>Cancer over 24 months:</i> the evidence was uncertain (OR 0.50, 95% CI 0.07 to 3.59; 1 RCT, 438 participants; low‐certainty evidence; <a href="./references#CD013874-fig-0014" title="">Analysis 2.5</a>). <a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a> reported that one participant had breast cancer and one had adenocarcinoma in the rituximab group, and one participant had parathyroid tumour and one had prostate cancer in the placebo group. </p> <p><i>Mortality over 24 months:</i> the evidence was uncertain (OR 0.25, 95% CI 0.02 to 2.77; 1 RCT, 438 participants; low‐certainty evidence; <a href="./references#CD013874-fig-0015" title="">Analysis 2.6</a>). <a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a> reported that three deaths occurred. One participant with a history of brainstem lesions and aspiration received two infusions of rituximab and withdrew early from the study after contracting pneumonia; he was subsequently hospitalised multiple times for recurrent aspiration and died approximately 10 weeks after the initial event. Two participants receiving placebo died; one had cardiopulmonary failure during the study, and the other contracted pneumonia and died after withdrawing from the trial.  </p> </section> <section id="CD013874-sec-0098"> <h6 class="title">Additional important outcomes</h6> <p><i>Treatment discontinuation due to adverse events over 24 months:</i> the number of participants who discontinued initial treatment with rituximab was higher than that observed in participants assigned to placebo, but the 95% CIs were large, so our confidence in the estimate was very limited (OR 4.64, 95% CI 0.58 to 37.00; 1 RCT, 439 participants; <a href="./references#CD013874-fig-0016" title="">Analysis 2.7</a>). </p> <p><i>Grade 3 and grade 4 adverse events over 24 months:</i> there was no effect of rituximab compared with placebo; however, the evidence was uncertain (OR 1.10, 95% CI 0.73 to 1.66; 1 RCT, 439 participants; <a href="./references#CD013874-fig-0017" title="">Analysis 2.8</a>). </p> <p><i>Infusion‐related reactions:</i> rituximab increased the number of participants who had infusion reactions within 24 hours after the first infusion (OR 6.79, 95% CI 4.31 to 10.69; 1 RCT, participants 439; <a href="./references#CD013874-fig-0018" title="">Analysis 2.9</a>), and after the second infusion (OR 1.66, 95% CI 0.98 to 2.82; 1 RCT, 439 participants; <a href="./references#CD013874-fig-0019" title="">Analysis 2.10</a>) compared with placebo. Infusion reactions decreased to rates comparable to placebo on successive courses. At week 74, reactions were lower in the rituximab group (4.9%) compared to placebo (7.2%). Infusion‐associated adverse events were primarily mild to moderate in severity. Seventeen (3.9%) participants reported grade 3 infusion‐associated events. There were no grade 4 infusion‐associated events (<a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a>). </p> </section> </section> <section id="CD013874-sec-0099"> <h5 class="title">Controlled non‐randomised studies of interventions </h5> <p>None of the included NRSIs assessed rituximab as 'first choice' versus placebo for progressive MS. </p> </section> </section> <section id="CD013874-sec-0100"> <h4 class="title">Rituximab as 'first choice' versus other DMTs for progressive multiple sclerosis</h4> <p>None of the included studies assessed rituximab as 'first choice' versus other DMTs for progressive MS. </p> </section> <section id="CD013874-sec-0101"> <h4 class="title">Rituximab as 'switching' versus placebo for relapsing multiple sclerosis</h4> <p>In <a href="./full#CD013874-tbl-0003">summary of findings Table 3</a>, we provided a summary of the effect estimates of rituximab as 'switching' versus placebo for relapsing MS for our prioritised critical and important outcomes, the certainty of evidence, and reasons for downgrading it. </p> <section id="CD013874-sec-0102"> <h5 class="title">Randomised controlled trials</h5> <p>One RCT included 104 participants with relapsing MS and compared rituximab as 'switching' with placebo (<a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>). </p> <section id="CD013874-sec-0103"> <h6 class="title">Critical outcomes</h6> <p><i>Disability worsening:</i> the study did not report the outcome.  </p> <p><i>Recurrence of relapses over 12 months:</i> rituximab may have decreased the number of participants who had relapses compared with placebo (OR 0.38, 95% CI 0.16 to 0.93; 1 RCT, 104 participants; low‐certainty evidence); the absolute effect was 198 fewer people (95% CI 304 fewer to 17 fewer) per 1000 people having relapses with rituximab (<a href="./references#CD013874-fig-0020" title="">Analysis 3.1</a>). </p> <p><i>SAEs over 12 months:</i> the evidence was very uncertain (OR 0.90, 95% CI 0.28 to 2.92; 1 RCT, 104 participants; very low‐certainty evidence; <a href="./references#CD013874-fig-0021" title="">Analysis 3.2</a>).  </p> </section> <section id="CD013874-sec-0104"> <h6 class="title">Important prioritised outcomes </h6> <p><i>Quality of life:</i> the study did not report the outcome. </p> <p><i>Common infections over 12 months:</i> the evidence was very uncertain (OR 0.91, 95% CI 0.37 to 2.24; 1 RCT, 104 participants; very low‐certainty evidence; <a href="./references#CD013874-fig-0022" title="">Analysis 3.3</a>). </p> <p><i>Cancer over 12 months:</i> the evidence was very uncertain (OR 1.55, 95% CI 0.06 to 39.15; 1 RCT, 104 participants; very low‐certainty evidence; <a href="./references#CD013874-fig-0023" title="">Analysis 3.4</a>). <a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a> reported one person with a malignant thyroid neoplasm in the rituximab group and no cancer in the placebo group. </p> <p><i>Mortality over 24 months: </i>the evidence was very uncertain (OR 1.55, 95% CI 0.06 to 39.15; 1 RCT, 104 participants; very low‐certainty evidence; <a href="./references#CD013874-fig-0024" title="">Analysis 3.5</a>). <a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a> reported one death due to homicide in the rituximab group and no deaths in the placebo group. </p> </section> <section id="CD013874-sec-0105"> <h6 class="title">Additional important outcomes</h6> <p><i>ARR, new gadolinium‐positive MRI lesions, treatment discontinuation due to adverse events, grade 3 and grade 4 adverse events, and cardiovascular events:</i> the evidence was very uncertain for the effect of rituximab on all these outcomes (<a href="./references#CD013874-fig-0025" title="">Analysis 3.6</a>; <a href="./references#CD013874-fig-0026" title="">Analysis 3.7</a>; <a href="./references#CD013874-fig-0027" title="">Analysis 3.8</a>; <a href="./references#CD013874-fig-0028" title="">Analysis 3.9</a>; <a href="./references#CD013874-fig-0029" title="">Analysis 3.10</a>).  </p> <p><i>Opportunistic infections: </i><a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a><i> </i>reported no opportunistic infections in participants treated with rituximab or placebo over 12 months. </p> <p><i>Infusion‐related reactions:</i> the number of participants who had infusion reactions within 24 hours after the first infusion of rituximab was higher than that observed in participants randomised to placebo (OR 5.40, 95% CI 2.23 to 13.09; 1 RCT, 104 participants; high‐certainty evidence); the absolute effect was 383 more people (95% CI 198 more to 497 more) per 1000 people who had infusion reactions (<a href="./references#CD013874-fig-0030" title="">Analysis 3.11</a>). Infusion‐associated adverse events were mild to moderate (grade 1 or 2) in severity. Four (7.4%) participants reported grade 3 events associated with infusion; these included headache, back pain, depression, limb pain, general pain, heat sensations, pruritus, and rash. There were no grade 4 events associated with infusion (<a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>). Within 24 hours after the second infusion, fewer participants in the rituximab group than in the placebo group had adverse events (OR 0.38, 95% CI 0.16 to 0.93; 1 RCT, 104 participants; high‐certainty evidence; <a href="./references#CD013874-fig-0031" title="">Analysis 3.12</a>). </p> </section> </section> <section id="CD013874-sec-0106"> <h5 class="title">Controlled non‐randomised studies of interventions </h5> <p>None of the included NRSIs assessed rituximab as 'switching' versus placebo for relapsing MS. </p> </section> </section> <section id="CD013874-sec-0107"> <h4 class="title">Rituximab as 'switching' versus other DMTs for relapsing multiple sclerosis</h4> <p>In <a href="./full#CD013874-tbl-0004">summary of findings Table 4</a>, we provided a summary of the effect estimates of rituximab as 'switching' versus other DMTs for relapsing MS for our prioritised critical and important outcomes, the certainty of NRSI evidence for each comparison, and reasons for downgrading it. </p> <section id="CD013874-sec-0108"> <h5 class="title">Randomised controlled trials</h5> <p>None of the included RCTs assessed rituximab as 'switching' versus other DMTs for relapsing MS. </p> </section> <section id="CD013874-sec-0109"> <h5 class="title">Controlled non‐randomised studies of interventions </h5> <p>Five retrospective multicentre cohort studies compared rituximab as 'switching' versus other DMTs in relapsing MS (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>; <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>). We did not evaluate outcome data from one controlled NRSI because of the critical risk of bias (<a href="./references#CD013874-bbs2-0001" title="AlcaláC , GascónF , Pérez-MirallesF , Domínguez JA , Gil-PerotínS , CasanovaB . Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe. Journal of Neurology2019;266(3):726-34. ">Alcalá 2019</a>). </p> <section id="CD013874-sec-0110"> <h6 class="title">Critical outcomes</h6> <p><i>Disability worsening over 24 months:</i> data for this outcome were available from one retrospective cohort nationwide study (<a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>; the Swedish MS Register). There was very low‐certainty evidence for comparison of rituximab with interferon beta or glatiramer acetate (HR 0.86, 95% CI 0.52 to 1.42; 1 NRSI, 853 participants; <a href="./references#CD013874-fig-0032" title="">Analysis 4.1</a>). </p> <p><i>Recurrence of relapses over 18 to 24 months: </i>three studies from the Swedish MS Register reported relapse outcome (time to event) in participants who switched to rituximab from another DMT (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>). Rituximab likely resulted in a large reduction in the number of participants who had relapses over 18 to 24 months when compared with the following agents (<a href="./references#CD013874-fig-0033" title="">Analysis 4.2</a>): </p> <p> <ul id="CD013874-list-0015"> <li> <p>moderate‐certainty evidence for comparison with interferons or glatiramer (HR 0.18, 95% CI 0.07 to 0.49; 1 NRSI, 1383 participants); the absolute effect was 215 fewer people (95% CI 248 fewer to 127 fewer) per 1000 people having relapses with rituximab. The number needed to treat for an additional beneficial effect (NNTB) was 11 (95% CI 10 to 18); </p> </li> <li> <p>moderate‐certainty evidence for comparison with fingolimod (HR 0.08, 95% CI 0.02 to 0.32; 1 NRSI, 256 participants); the absolute effect was 161 fewer people (95% CI 172 fewer to 116 fewer) per 1000 people having relapses with rituximab. The NNTB was 6 (95% CI 6 to 9). </p> </li> </ul> </p> <p>The evidence was very uncertain about the effect of rituximab compared with natalizumab (HR 1.00, 95% CI 0.20 to 5.00; 1 NRSI, 153 participants; very low‐certainty evidence). </p> <p><i>SAEs:</i> none of the identified studies reported the outcome. </p> </section> <section id="CD013874-sec-0111"> <h6 class="title">Important prioritised outcomes</h6> <p><i>Quality of life:</i> none of the identified studies reported the outcome. </p> <p><i>Common infections over 24 months:</i> four studies reported this outcome (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>; <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>). Rituximab increased the number of participants who had common infections when compared with the following agents (<a href="./references#CD013874-fig-0034" title="">Analysis 4.3</a>): </p> <p> <ul id="CD013874-list-0016"> <li> <p>moderate‐certainty evidence for comparison with interferon beta or glatiramer acetate (OR 1.71, 95% CI 1.11 to 2.62; 1 NRSI, 5477 participants); the absolute effect was 24 more people (95% CI 4 more to 53 more) per 1000 people having common infections with rituximab; </p> </li> <li> <p>moderate‐certainty evidence for comparison with natalizumab (OR 1.58, 95% CI 1.08 to 2.32; 2 NRSIs, 5001 participants); the absolute effect was 27 more people (95% CI 4 more to 59 more) per 1000 people having common infections with rituximab. </p> </li> </ul> </p> <p>There was low‐certainty evidence for comparison of rituximab with fingolimod (OR 1.26, 95% CI 0.90 to 1.77; 3 NRSIs, 5287 participants) and very low‐certainty evidence for comparison with ocrelizumab (OR 0.02, 95% CI 0.00 to 0.40; 1 NRSI, 472 participants). Ten/161 (6%) participants in the ocrelizumab group reported infections. There were no infections in 311 participants who received rituximab (<a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>). </p> <p><i>Cancer:</i> none of the identified studies reported the outcome. </p> <p><i>Mortality over 24 months: </i><a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a> reported one suicide due to overdosing of sedative drugs in one participant with a severe concomitant psychiatric illness in the rituximab group. There were no deaths in the fingolimod group (OR 5.59, 95% CI 0.22 to 139.89; 1 NRSI, 136 participants; very low‐certainty evidence), and no deaths in the natalizumab group (OR 6.66, 95% CI 0.27 to 166.58; 1 NRSI, 153 participants; very low‐certainty evidence), over 24 months' follow‐up (<a href="./references#CD013874-fig-0035" title="">Analysis 4.4</a>). Death related to adverse events was defined as grade 5 in the CTCAE. </p> </section> <section id="CD013874-sec-0112"> <h6 class="title">Additional important outcomes</h6> <p><i>ARR over 24 months:</i> one retrospective multicentre cohort study reported the ARR (<a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>; the Swedish MS Register). Rituximab likely reduced ARR when compared with interferons or glatiramer acetate (MD −0.02, 95% CI −0.03 to −0.01; 1 NRSI, 1383 participants; moderate‐certainty evidence; <a href="./references#CD013874-fig-0036" title="">Analysis 4.5</a>). </p> <p><i>New or enlarging T2‐weighted MRI lesions over 18 months:</i> one retrospective multicentre cohort study provided data (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; the Swedish MS Register). Rituximab may have reduced the number of participants who had new or enlarging T2 MRI lesions when compared with fingolimod (OR 0.01, 95% CI 0.00 to 0.06; 1 NRSI, 182 participants; low‐certainty evidence; <a href="./references#CD013874-fig-0037" title="">Analysis 4.6</a>). </p> <p><i>New gadolinium‐positive MRI lesions over 24 months:</i> two retrospective multicentre cohort studies provided outcome data for comparison of rituximab with fingolimod (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>). Rituximab probably reduced the number of participants who had new gadolinium‐positive MRI lesions (OR 0.09, 95% CI 0.03 to 0.30; P = 0.71, I² = 0%; 2 NRSI, 288 participants; moderate‐certainty evidence); the absolute effect was 172 fewer people (95% CI 186 fewer to 126 fewer) per 1000 people who had new gadolinium‐positive MRI lesions with rituximab (<a href="./references#CD013874-fig-0038" title="">Analysis 4.7</a>). The evidence was very uncertain about the effect of rituximab compared with natalizumab (OR 1.00, 95% CI 0.20 to 5.00; 1 NRSI, 138 participants; very low‐certainty evidence; <a href="./references#CD013874-fig-0038" title="">Analysis 4.7</a>). </p> <p><i>Treatment discontinuation due to adverse events over 24 months:</i> <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a> reported outcome data. There was very low‐certainty evidence for the comparison of rituximab with fingolimod (OR 0.13, 95% CI 0.01 to 2.37; 1 NRSI, 136 participants), and with natalizumab (OR 0.30, 95% CI 0.02 to 5.96; 1 NRSI, 153 participants). <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a> compared treatment discontinuation over the first 12 months in 311 participants treated with rituximab and 161 participants treated with ocrelizumab in one retrospective multicentre cohort study. The number of participants who discontinued treatment with rituximab was lower than that observed in participants treated with ocrelizumab (OR 0.26, 95% CI 0.11 to 0.62; 1 NRSI, 482 participants; moderate‐certainty evidence); the absolute effect was 67 fewer people (95% CI 82 fewer to 33 fewer) per 1000 people who discontinued rituximab (<a href="./references#CD013874-fig-0039" title="">Analysis 4.8</a>). </p> <p><i>Grade 3 and grade 4 adverse events over 24 months:</i> two controlled NRSIs provided data for comparison of rituximab with fingolimod (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>). <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a> also reported data for comparison with natalizumab. The evidence was very uncertain about the effect of rituximab on the number of participants who had grade 3 and grade 4 adverse events when compared with fingolimod (OR 0.34, 95% CI 0.06 to 2.09; P = 0.80, I² = 0%; 2 NRSIs, 392 participants; very low‐certainty evidence) and natalizumab (OR 0.23, 95% CI 0.01 to 4.41; 1 NRSI, 153 participants; very low‐certainty evidence) (<a href="./references#CD013874-fig-0040" title="">Analysis 4.9</a>). </p> <p><i>Cardiovascular events:</i> two NRSIs reported outcome data for the comparison of rituximab with fingolimod (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>; <a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>). The evidence was very uncertain about the effect of rituximab on the number of participants who had cardiovascular events when compared with fingolimod (OR 0.31, 95% CI 0.05 to 1.85; P = 0.65, I² = 0%; 2 NRSIs, 392 participants; very low‐certainty evidence; <a href="./references#CD013874-fig-0041" title="">Analysis 4.10</a>). There were no cardiovascular events in the comparison of rituximab with natalizumab (<a href="./references#CD013874-fig-0041" title="">Analysis 4.10</a>) (<a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>). </p> <p><i>Infusion‐related reactions:</i> there were grade 1 adverse events related to the first infusion of rituximab in 26% of participants in the rituximab group, compared with a 7% incidence of adverse events at first dosing of fingolimod (OR 4.71, 95% CI 2.19 to 10.14; 1 NRSI, 256 participants; <a href="./references#CD013874-fig-0042" title="">Analysis 4.11</a>) (<a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>). <a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a> reported infusion‐related adverse events in 0.6% of participants in the rituximab group compared with 1.2% in the ocrelizumab group. The events were few and the evidence was very low due to large imprecision (OR 0.51, 95% CI 0.07 to 3.69; 1 NRSI, 472 participants; <a href="./references#CD013874-fig-0042" title="">Analysis 4.11</a>). </p> </section> </section> </section> <section id="CD013874-sec-0113"> <h4 class="title">Rituximab as 'switching' versus placebo for secondary progressive multiple sclerosis</h4> <p> A summary of the effect estimates of rituximab as 'switching' compared with placebo for secondary progressive MS (SPMS) is shown in <a href="#CD013874-tbl-0006">Table 2</a>. </p> <section id="CD013874-sec-0114"> <h5 class="title">Randomised controlled trials</h5> <p>One small RCT included 27 participants with secondary progressive MS (<a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a>). </p> <section id="CD013874-sec-0115"> <h6 class="title">Critical outcomes</h6> <p><i>Disability worsening and relapses:</i> the study did not report the number of participants who had these outcomes. </p> <p><i>SAEs over 24 months:</i> the evidence was very uncertain about the effect of rituximab on SAEs when compared with placebo (OR 0.36, 95% CI 0.06 to 2.00; 1 RCT, 27 participants; very low‐certainty evidence; <a href="./references#CD013874-fig-0043" title="">Analysis 5.1</a>). </p> </section> <section id="CD013874-sec-0116"> <h6 class="title">Important prioritised outcomes </h6> <p><i>Quality of life:</i> the study did not report the outcome. </p> <p><i>Common infections:</i> the study did not report the outcome. </p> <p><i>Cancer over 24 months:</i> the evidence was very uncertain about the effect of rituximab on cancer when compared with placebo (OR 0.47, 95% CI 0.03 to 8.52; 1 RCT, 27 participants; very low‐certainty evidence; <a href="./references#CD013874-fig-0044" title="">Analysis 5.2</a>). <a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a> reported one participant in each group coded as "Neoplasms benign, malignant and unspecified"(ClinicalTrials.gov Identifier: NCT0121209). </p> <p><i>Mortality:</i> the study did not report the outcome. </p> </section> <section id="CD013874-sec-0117"> <h6 class="title">Additional important outcomes</h6> <p><i>Cardiovascular events over 24 months:</i> the evidence was very uncertain about the effect of rituximab on cardiovascular events when compared with placebo (OR 0.47, 95% CI 0.03 to 8.52; 1 RCT, 27 participants; very low‐certainty evidence; <a href="./references#CD013874-fig-0045" title="">Analysis 5.3</a>). </p> </section> </section> <section id="CD013874-sec-0118"> <h5 class="title">Controlled non‐randomised studies of interventions </h5> <p>None of the included NRSIs assessed rituximab as 'switching' versus placebo for progressive MS. </p> </section> </section> <section id="CD013874-sec-0119"> <h4 class="title">Rituximab as 'switching' versus other DMTs for secondary progressive multiple sclerosis</h4> <p> A summary of the effect estimates of rituximab as 'switching' compared with other DMTs for secondary progressive MS is shown in <a href="#CD013874-tbl-0006">Table 2</a>. </p> <section id="CD013874-sec-0120"> <h5 class="title">Randomised controlled trials</h5> <p>Two RCTs included participants with secondary progressive MS. <a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a> compared rituximab with glatiramer acetate in 84 participants with active secondary progressive MS, and <a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a> compared rituximab with cyclophosphamide in 80 participants with active secondary progressive MS. </p> <section id="CD013874-sec-0121"> <h6 class="title">Critical outcomes</h6> <p><i>Disability worsening and relapses:</i> the included studies did not report the number of participants who had these outcomes. </p> <p><i>SAEs:</i> there were no SAEs over 12 months' follow‐up in the comparison of rituximab with glatiramer acetate (<a href="./references#CD013874-fig-0046" title="">Analysis 6.1</a>). <a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a> did not report the outcome. </p> </section> <section id="CD013874-sec-0122"> <h6 class="title">Important prioritised outcomes </h6> <p><i>Quality of life:</i> the included studies did not report the outcome. </p> <p><i>Common infections over 12 to 24 months:</i> the evidence was very uncertain about the effect of rituximab compared with glatiramer acetate over 12 months (OR 3.00, 95% CI 0.30 to 30.08; 1 RCT, 84 participants; very low‐certainty evidence) and with cyclophosphamide over 24 months (OR 0.39, 95% CI 0.14 to 1.11; 1 RCT, 69 participants; very low‐certainty evidence) (<a href="./references#CD013874-fig-0047" title="">Analysis 6.2</a>). </p> <p><i>Cancer and mortality:</i> the included studies did not report these outcomes. </p> </section> <section id="CD013874-sec-0123"> <h6 class="title">Additional important outcomes</h6> <p><i>ARR, new gadolinium‐positive MRI lesions, and treatment discontinuation due to adverse events over 12 months:</i> the evidence was very uncertain about the effect of rituximab on all these outcomes when compared with glatiramer acetate (<a href="./references#CD013874-fig-0048" title="">Analysis 6.3</a>; <a href="./references#CD013874-fig-0049" title="">Analysis 6.4</a>; <a href="./references#CD013874-fig-0050" title="">Analysis 6.5</a>). </p> <p><i>Opportunistic infections:</i> there were no opportunistic infections in participants treated with rituximab or glatiramer acetate over 12 months (<a href="./references#CD013874-fig-0051" title="">Analysis 6.6</a>). </p> </section> </section> <section id="CD013874-sec-0124"> <h5 class="title">Controlled non‐randomised studies of interventions </h5> <p>One small case‐control study included 44 participants with secondary progressive MS who were treated with rituximab compared with 44 matched controls never treated with rituximab (<a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>).  </p> <section id="CD013874-sec-0125"> <h6 class="title">Critical outcomes</h6> <p><i>Disability worsening over 36 months:</i> we had very little confidence in the effect estimate (OR 0.49, 95% CI 0.26 to 0.93; 1 NRSI, 88 participants; very low‐certainty evidence; <a href="./references#CD013874-fig-0052" title="">Analysis 7.1</a>). </p> <p><i>Relapses and SAEs:</i> the study did not report the number of participants who had these outcomes. </p> </section> <section id="CD013874-sec-0126"> <h6 class="title">Important prioritised outcomes</h6> <p><i>Quality of life, common infections, cancer, and mortality:</i> the study did not report the outcomes. </p> </section> <section id="CD013874-sec-0127"> <h6 class="title">Additional important outcomes</h6> <p>The study did not report the outcomes.</p> </section> </section> </section> <section id="CD013874-sec-0128"> <h4 class="title">Rituximab as 'switching' versus other DMTs for grouped data as relapsing and progressive multiple sclerosis </h4> <p>A summary of the effect estimates of rituximab as 'switching' compared with other DMTs for grouped forms of MS is reported in <a href="#CD013874-tbl-0006">Table 2</a>. </p> <section id="CD013874-sec-0129"> <h5 class="title">Randomised controlled trials</h5> <p>None of the included RCTs assessed rituximab as 'switching' versus other DMTs for relapsing and progressive MS. </p> </section> <section id="CD013874-sec-0130"> <h5 class="title">Controlled non‐randomised studies of interventions</h5> <p>Two NRSIs reported grouped data as relapsing and progressive MS.<i> </i><a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a> was a retrospective cohort study conducted in a single MS centre in the USA. The study compared rituximab with fingolimod, dimethyl fumarate, and natalizumab over 24 months' follow‐up. In one nationwide register‐based cohort study, <a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a> linked data from the Swedish MS register (<a href="http://www.neuroreg.se/" target="_blank">www.neuroreg.se/</a>) to the Swedish Cancer Register and other national healthcare and census registers. In this study, first‐ever initiations of rituximab, fingolimod, and natalizumab were compared and the reported outcome was time to first invasive cancer over 36 months. </p> <section id="CD013874-sec-0131"> <h6 class="title">Critical outcomes</h6> <p><i>Disability worsening:</i> the included studies did not report the outcome. </p> <p><i>Recurrence of relapses over 24 months:</i> the evidence from one NRSI was very uncertain because we judged the effect estimates at very serious risk of bias (only unadjusted data were available) and there was indirectness related to populations (<a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>): </p> <p> <ul id="CD013874-list-0017"> <li> <p>very low‐certainty evidence for comparison of rituximab with fingolimod (OR 0.35, 95% CI 0.14 to 0.88; 1 NRSI, 453 participants), dimethyl fumarate (OR 0.23, 95% CI 0.10 to 0.55; 1 NRSI, 524 participants), and natalizumab (OR 0.54, 95% CI 0.22 to 1.32; 1 NRSI, 633 participants) (<a href="./references#CD013874-fig-0053" title="">Analysis 8.1</a>). </p> </li> </ul> </p> <p><i>SAEs:</i> the included studies did not report the outcome. </p> </section> <section id="CD013874-sec-0132"> <h6 class="title">Important prioritised outcomes </h6> <p><i>Quality of life:</i> the included studies did not report the outcome. </p> <p><i>Common infections over 24 months:</i> the evidence was very uncertain in the comparison of rituximab with the following agents: </p> <p> <ul id="CD013874-list-0018"> <li> <p>very low‐certainty evidence for comparison with fingolimod (OR 1.06, 95% CI 0.34 to 3.30; 1 NRSI, 453 participants), dimethyl fumarate (OR 2.39, 95% CI 0.63 to 9.00; 1 NRSI, 524 participants), and natalizumab (OR 4.22, 95% CI 1.00 to 17.84; 1 NRSI, 633 participants) (<a href="./references#CD013874-fig-0054" title="">Analysis 8.2</a>). </p> </li> </ul> </p> <p><i>Cancer over 36 months:</i> rituximab may have reduced the number of participants who had cancer compared with fingolimod (OR 0.60, 95% CI 0.35 to 1.03; 1 NRSI, 5807 participants; low‐certainty evidence). The evidence was very uncertain in the comparison of rituximab with natalizumab (OR 0.74, 95% CI 0.42 to 1.31; 1 NRSI, 5857 participants; very low‐certainty evidence; <a href="./references#CD013874-fig-0055" title="">Analysis 8.3</a>). <a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a> reported six breast cancers in the rituximab cohort, corresponding to an incidence rate of 8.9 per 10,000 person‐years (95% CI 3.3 to 19.4), which was similar to the rate in the general population.  </p> <p><i>Mortality:</i> the included studies did not report the outcome. </p> </section> <section id="CD013874-sec-0133"> <h6 class="title">Additional important outcomes</h6> <p><i>New or enlarging T2‐weighted MRI lesions over 24 months:</i> the evidence is very uncertain about the effect of rituximab when compared with the following DMTs: </p> <p> <ul id="CD013874-list-0019"> <li> <p>very low‐certainty evidence for comparison with fingolimod (OR 0.40, 95% CI 0.25 to 0.62; 1 NRSI, 453 participants), dimethyl fumarate (OR 0.46, 95% CI 0.30 to 0.72; 1 NRSI, 524 participants), natalizumab (OR 0.63, 95% CI 0.41 to 0.98; 1 NRSI, 633 participants) (<a href="./references#CD013874-fig-0056" title="">Analysis 8.4</a>). </p> </li> </ul> </p> <p><i>New gadolinium‐positive MRI lesions over 24 months:</i> there was very low‐certainty evidence in the comparison of rituximab with fingolimod (OR 0.04, 95% CI 0.00 to 0.27; 1 NRSI, 453 participants), dimethyl fumarate (OR 0.05, 95% CI 0.01 to 0.37; 1 NRSI, 524 participants), natalizumab (OR 0.09, 95% CI 0.01 to 0.67; 1 NRSI, 633 participants) (<a href="./references#CD013874-fig-0057" title="">Analysis 8.5</a>). </p> <p><i>Treatment discontinuation due to adverse events over 24 months:</i> there was low‐certainty evidence for comparison with fingolimod (OR 0.28, 95% CI 0.13 to 0.60; 1 NRSI, 453 participants), and dimethyl fumarate (OR 0.30, 95% CI 0.15 to 0.60; 1 NRSI, 524 participants), and very low‐certainty evidence for comparison with natalizumab (OR 1.10, 95% CI 0.48 to 2.52; 1 NRSI, 633 participants) (<a href="./references#CD013874-fig-0058" title="">Analysis 8.6</a>). </p> <p><i>Cardiovascular events over 24 months: </i>the evidence was very uncertain in the comparison with fingolimod (OR 0.16, 95% CI 0.01 to 3.04; 1 NRSI, 441 participants) and natalizumab (OR 0.82, 95% CI 0.03 to 20.29; 1 NRSI, 633 participants; <a href="./references#CD013874-fig-0059" title="">Analysis 8.7</a>). There were no cardiovascular events in the comparison with dimethyl fumarate (<a href="./references#CD013874-fig-0059" title="">Analysis 8.7</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013874-sec-0134" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013874-sec-0134"></div> <p>This review summarised the evidence on beneficial and adverse outcomes of rituximab as 'first choice' treatment or as 'switching' from another DMT for people with MS. Our priority outcomes of interest included disability worsening, recurrence of relapses, SAEs, quality of life, common infections, cancer, and mortality. We also assessed the effect of rituximab on additional important outcomes (cerebral MRI findings, treatment discontinuation, adverse events of grade 3 or grade 4 severity), which are reported in the <a href="#CD013874-sec-0086">Effects of interventions</a> section. </p> <p>The review included five RCTs (734 participants), and 10 controlled NRSIs (15,695 participants). Three RCTs compared rituximab with placebo, one with glatiramer acetate, and one with cyclophosphamide. The NRSIs compared rituximab with other active DMTs. Most studies were of short duration, with the median follow‐up being 24 months, therefore the effects of rituximab beyond two years remain uncertain.  </p> <section id="CD013874-sec-0135"> <h3 class="title" id="CD013874-sec-0135">Summary of main results</h3> <section id="CD013874-sec-0136"> <h4 class="title">Rituximab as 'first choice' treatment in relapsing multiple sclerosis</h4> <p>One controlled NRSI (488 participants) assessed rituximab versus other DMTs. The results are as follows (<a href="./full#CD013874-tbl-0001">summary of findings Table 1</a>): </p> <p> <ul id="CD013874-list-0020"> <li> <p>rituximab likely results in a large reduction in the number of participants who have relapses compared with interferon beta or glatiramer acetate, and may reduce the number of people who had relapses compared with dimethyl fumarate and natalizumab; </p> </li> <li> <p>the evidence is very uncertain about the effect of rituximab on relapses when compared with fingolimod; </p> </li> <li> <p>there were no deaths in the comparison of rituximab with the other DMTs;</p> </li> <li> <p>the study did not provide data regarding disability worsening, SAEs, quality of life, common infections, or cancer. </p> </li> </ul> </p> </section> <section id="CD013874-sec-0137"> <h4 class="title">Rituximab as 'first choice' treatment in progressive multiple sclerosis</h4> <p>One RCT (439 participants) compared rituximab with placebo in primary progressive MS. The results are as follows (<a href="#CD013874-tbl-0006">Table 2</a>): </p> <p> <ul id="CD013874-list-0021"> <li> <p>rituximab likely results in little to no difference in the number of participants who have disability worsening over 24 months; </p> </li> <li> <p>the evidence is uncertain about the effect of rituximab on the other outcomes of interest.</p> </li> </ul> </p> </section> <section id="CD013874-sec-0138"> <h4 class="title">Rituximab as 'switching' treatment in relapsing multiple sclerosis</h4> <p>Five controlled NRSIs compared rituximab as 'switching' versus other DMTs in relapsing MS. The results are as follows (<a href="./full#CD013874-tbl-0004">summary of findings Table 4</a>): </p> <p> <ul id="CD013874-list-0022"> <li> <p>the evidence is very uncertain about the effect of rituximab on disability worsening when compared with interferon beta or glatiramer acetate (1 NRSI, 853 participants); </p> </li> <li> <p>rituximab likely results in a large reduction in the number of participants who have relapses compared with interferon beta or glatiramer acetate (1 NRSI, 1383 participants), and with fingolimod (1 NRSI, 256 participants); </p> </li> <li> <p>the evidence is very uncertain about the effect of rituximab on relapses when compared with natalizumab; </p> </li> <li> <p>rituximab likely increases slightly the number of participants who have common infections compared with interferon beta or glatiramer acetate (1 NRSI, 477 participants), with natalizumab (2 NRSIs, 5001 participants). The evidence is uncertain for the comparisons with fingolimod and ocrelizumab; </p> </li> <li> <p>the evidence is very uncertain about the effect of rituximab on mortality when compared with fingolimod and natalizumab; </p> </li> <li> <p>none of the identified studies measured SAEs, quality of life, or cancer.</p> </li> </ul> </p> </section> <section id="CD013874-sec-0139"> <h4 class="title">Rituximab as switching treatment in progressive multiple sclerosis</h4> <p>Only three small studies investigated rituximab in secondary progressive MS. The evidence is uncertain about the effect of rituximab on disability worsening, SAEs, and quality of life. The studies did not provide usable information on relapses, common infections, cancer, or mortality (<a href="#CD013874-tbl-0006">Table 2</a>). </p> </section> </section> <section id="CD013874-sec-0140"> <h3 class="title" id="CD013874-sec-0140">Overall completeness and applicability of evidence</h3> <p>All eligible RCTs and controlled NRSIs (up to 31 January 2021) of rituximab for treatment of MS were included in the review. Six out of 10 included NRSIs were retrospective multicentre cohort studies based on the nationwide Swedish Multiple Sclerosis Register linked to national healthcare registers. The Swedish MS register captures data on several aspects of MS care (<a href="./references#CD013874-bbs2-0132" title="Neuroreg.Se: Swedish Multiple Sclerosis Register. neuroreg.se/ (accessed 1 July 2020).">Hillert 2020</a>), and has especially high validity for therapy data (<a href="./references#CD013874-bbs2-0096" title="AlpingP , PiehlF , Langer-GouldA , FrisellT , COMBAT-MS Study Group. Validation of the Swedish Multiple Sclerosis Register: further improving a resource for pharmacoepidemiologic evaluations. Epidemiology2019;30:230-3.">Alping 2019</a>). Participation is voluntary, but coverage has been estimated to be greater than 80% (<a href="./references#CD013874-bbs2-0131" title="HillertJ , StawiarzL . The Swedish MS Registry clinical support tool and scientific resource. Acta Neurologica Scandinavica2015;132:11-9.">Hillert 2015</a>). </p> <p>With respect to the scope of our review, data and findings relevant to rituximab when switching from another DMT were available in 13 (87%) of the 15 included studies, and rituximab as a 'first choice' treatment in two studies. Most studies included people with relapsing MS who represented 80% of those included in the review.  </p> <p>We identified 14 ongoing studies, 11 are RCTs. The publication of the results of these studies will necessitate an update of this review. </p> <p>Our review was intended to be a comprehensive review of effects of rituximab, but short duration of included studies and no or poor reporting of some outcomes were major limitations in determining the overall completeness and the balance between beneficial and adverse effects of rituximab. For example, there were no data on quality of life and cognitive decline that are important outcomes for patients and clinicians. </p> <p>We focused on treatment discontinuation due to AEs to indirectly assess acceptability of rituximab compared with other DMTs; however, the true compliance rate is not known, as it was not a topic of our investigation.  </p> <p>With respect to applicability, findings in this review originated mostly from retrospective cohort studies conducted in Sweden and only five small RCTs. This is one of controversies about treatment with rituximab in MS concerning uncertainty on benefits and harms since randomised evidence is insufficient, and other approved DMTs are available. Rituximab is an off‐label treatment for MS, and since its patent has expired, there is no interest of the pharmaceutical industry in promoting randomised trials (<a href="./references#CD013874-bbs2-0125" title="GreenfieldAL , HauserSL . B cell therapy for multiple sclerosis: entering an era. Annals of Neurology2018;83(1):13-26.">Greenfield 2018</a>). However, rituximab is used in many countries globally (<a href="./references#CD013874-bbs2-0107" title="DelateT , HansenML , GutierrezAC , LeKN . Indications for rituximab use in an integrated health care delivery system. Journal of managed care &amp; speciality pharmacy2020;26(7):832-8.">Delate 2020</a>; <a href="./references#CD013874-bbs2-0168" title="SarsourK , Beckley-KarteyS , MelegaS , OdueyungboA , KirchnerP , KhalifeN , et al. Rituximab utilization for approved and off-label nononcology indications and patients' experiences with the Patient Alert Card. Pharmacology Research &amp; Perspectives2020;8(1):e00555.">Sarsour 2020</a>; <a href="./references#CD013874-bbs2-0184" title="WongseelashoteS , TayalV , BourkePF . Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008–2016. Internal Medicine Journal2018;48(2):165-72.">Wongseelashote 2018</a>), and is considered a feasible option in low‐ and middle‐income countries because it has considerably lower cost and less frequent administration (<a href="./references#CD013874-bbs2-0137" title="Lancet Neurology. Essential medicines for patients with multiple sclerosis. Lancet Neurology2019;18(12):1067.">Lancet Neurology 2019</a>; <a href="./references#CD013874-bbs2-0145" title="MathewT , JohnSK , KamathV , MurgodU , ThomasK , BaptistAA , et al. Efficacy and safety of rituximab in multiple sclerosis: experience from a developing country. Multiple Sclerosis and Related Disorders2020;43:102210.">Mathew 2020</a>). Treatment with rituximab requires specialist care and infusion facilities, but other approved DMTs also have these requirements.  </p> <p>Evidence on harms of treatment with rituximab in people with MS during the COVID‐19 pandemic was not included in this review since it was published after the review search was conducted.  </p> </section> <section id="CD013874-sec-0141"> <h3 class="title" id="CD013874-sec-0141">Quality of the evidence</h3> <p>The majority of the evidence was low or very‐low certainty for the critical and important outcomes included in the review.  </p> <p>Our assessment of the risk of bias in five included RCTs is summarised in <a href="#CD013874-fig-0002">Figure 2</a> and <a href="#CD013874-fig-0003">Figure 3</a>. Four (80%) RCTs were at a high risk of bias due to having two or more domains at high risk of bias. The certainty of the evidence in reported outcomes was further reduced because of the small information size and imprecise estimates.  </p> <p> We included 10 controlled NRSIs and assessed risk of bias with the ROBINS‐I tool (<a href="#CD013874-fig-0004">Figure 4</a>; <a href="#CD013874-fig-0005">Figure 5</a>; <a href="./appendices#CD013874-sec-0151">Appendix 2</a>). We did not include data from one NRSI in data synthesis because of critical risk of bias. We judged four (40%) NRSIs at serious risk of bias. The other included NRSIs were at moderate risk of bias. The evidence we have obtained from NRSIs was limited mainly due to the risk of confounding, selection bias, and retrospective data collection. Moreover, numbers of people and number of events in each comparison group were small, with imprecise estimates, for several outcomes in the included NRSIs. The outcome measures were also heterogeneous with wide variation in reporting across the included studies. </p> </section> <section id="CD013874-sec-0142"> <h3 class="title" id="CD013874-sec-0142">Potential biases in the review process</h3> <p>To avoid a possible risk of publication bias, we searched a range of databases and trials registries to identify ongoing studies and results of unpublished completed studies, and applied no time or language restriction to the search. However, it is possible that we have not identified other sources of unpublished observational eligible studies. </p> <p>Two review authors independently identified eligible studies and assessed risk of bias. We requested additional data through correspondence with four study authors and obtained missing information from two of them. </p> <p>Much of the non‐randomised data in the review came from the Swedish MS Register. We wished to use most of the available information on the comparison of rituximab with other DMTs in the absence of direct randomised evidence. Six retrospective cohort studies based on the Swedish MS Register compared rituximab separately against each other DMT. We did not pool the comparators, and performed separate analyses of each comparison; however, there was likely double counting of the rituximab participants from one comparison to another. </p> <p>We cannot exclude the possible presence of reporting bias.</p> </section> <section id="CD013874-sec-0143"> <h3 class="title" id="CD013874-sec-0143">Agreements and disagreements with other studies or reviews</h3> <p>In one previous Cochrane Review including only RCTs of rituximab for relapsing MS, authors concluded, based on low‐certainty evidence, that there was insufficient evidence to support the use of rituximab for relapsing MS because there was only one small RCT versus placebo (<a href="./references#CD013874-bbs2-0189" title="HeD , GuoR , ZhangF , ZhangC , DongS , ZhouH . Rituximab for relapsing‐remitting multiple sclerosis. Cochrane Database of Systematic Reviews2013, Issue 12. Art. No.: CD009130. Art. No: CD009130. [DOI: 10.1002/14651858.CD009130.pub3]">He 2013</a>). We widened the evidence base adding NRSIs to the review and used of ROBINS‐I in critical evaluation of the validity of NRSIs. By using new criteria for considering studies for our review, we can suggest the following. People with relapsing MS receiving rituximab as 'first choice' treatment likely have significantly lower risks of experiencing new relapses over 24 months compared to interferons or glatiramer acetate, and may have lower risk of relapses compared with dimethyl fumarate and natalizumab. Moreover, rituximab used to escalate participants with relapsing MS from other DMTs or when other DMTs become contraindicated (switching), likely results in a large reduction in recurrence of relapses over 24 months, compared with interferons or glatiramer acetate and fingolimod. We now added progressive forms of MS to the review, which was previously restricted to relapsing MS (<a href="./references#CD013874-bbs2-0189" title="HeD , GuoR , ZhangF , ZhangC , DongS , ZhouH . Rituximab for relapsing‐remitting multiple sclerosis. Cochrane Database of Systematic Reviews2013, Issue 12. Art. No.: CD009130. Art. No: CD009130. [DOI: 10.1002/14651858.CD009130.pub3]">He 2013</a>), and found that there is limited information to determine the effect of rituximab for progressive forms of MS. </p> <p>Comparing other reviews with ours points out some challenges inherent in evidence synthesis in the context of reviews including randomised and non‐randomised studies. Important issues we need to consider are differences in study selection and inclusion, assessment of study quality, methods for data synthesis, and interpretations and inferences made by the review authors. In fact, most of our findings cannot be compared to the results reported by other reviews (<a href="./references#CD013874-bbs2-0103" title="Castillo-TrivinoT , BraithwaiteD , BacchettiP , WaubantE . Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PloS One2013;8(7):e66308.">Castillo‐Trivino 2013</a>; <a href="./references#CD013874-bbs2-0121" title="GhajarzadehM , AzimiA , ValizadehZ , SahraianMA , MohammadifarM . Efficacy and safety of rituximab in treating patients with multiple sclerosis (MS): a systematic review and meta-analysis. Autoimmunity Reviews2020;19(8):102585.">Ghajarzadeh 2020</a>; <a href="./references#CD013874-bbs2-0133" title="HuY , NieH , YuHH , QinC , WuLJ , TangZP , et al. Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. Autoimmunity Reviews2019;18(5):542-8.">Hu 2019</a>; <a href="./references#CD013874-bbs2-0172" title="SiddiquiMK , SinghB , AttriS , VeraartC , HartyG , WongSL . Use of rituximab in adults with relapsing-remitting multiple sclerosis: a systematic literature review. Current Medical Research and Opinion2020;36(5):809-26.">Siddiqui 2020</a>; <a href="./references#CD013874-bbs2-0177" title="TianX , ChenC , MaL , WeiR , LiM , WangX , et al. Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. Journal of Neuroimmunology2020;347:577317.">Tian 2020</a>), since the authors included mostly uncontrolled observational studies, the quality of evidence for the results arising from their reviews was often not assessed and methods for data synthesis differed from ours. For example, one narrative review examined 38 studies, five of which were RCTs and 33 were uncontrolled observational studies, of rituximab for relapsing MS and highly active relapsing MS (<a href="./references#CD013874-bbs2-0172" title="SiddiquiMK , SinghB , AttriS , VeraartC , HartyG , WongSL . Use of rituximab in adults with relapsing-remitting multiple sclerosis: a systematic literature review. Current Medical Research and Opinion2020;36(5):809-26.">Siddiqui 2020</a>). The authors reported that their results needed to be interpreted with caution because the quality of the included studies was poor, but they suggested that rituximab was beneficial for people with relapsing MS compared with placebo as well as with glatiramer acetate, interferons, fingolimod, and natalizumab without indicating the certainty of evidence for each comparison. Moreover, the review was sponsored by EMD Serono Inc., two of the co‐authors were employees of the pharmaceutical company, and this might have influenced authors' conclusions or interpretations of their findings. <a href="./references#CD013874-bbs2-0133" title="HuY , NieH , YuHH , QinC , WuLJ , TangZP , et al. Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. Autoimmunity Reviews2019;18(5):542-8.">Hu 2019</a> reported a significant reduction of disability worsening in 946 participants with relapsing MS treated with rituximab, but the result was based on a meta‐analysis of data from 15 uncontrolled observational studies. <a href="./references#CD013874-bbs2-0121" title="GhajarzadehM , AzimiA , ValizadehZ , SahraianMA , MohammadifarM . Efficacy and safety of rituximab in treating patients with multiple sclerosis (MS): a systematic review and meta-analysis. Autoimmunity Reviews2020;19(8):102585.">Ghajarzadeh 2020</a> reported a meta‐analysis of seven uncontrolled pre–post studies (399 participants with MS) and concluded that rituximab treatment was effective in controlling relapses and disability worsening in all forms of MS, but the authors did not assess the quality of evidence for the outcomes. </p> <p>Our confidence in the effect estimate of rituximab on SAEs was limited since they were relatively rare in people with MS and observed over a short time period. There is extensive experience of long‐term use of rituximab in people with rheumatoid arthritis with a good acceptance profile and adherence to the treatment (<a href="./references#CD013874-bbs2-0181" title="vanVollenhovenRF , FleischmannRM , FurstDE , LaceyS , LehanePB . Long-term safety of rituximab: final report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 years. Journal of Rheumatology2015;42(10):1761-6.">van Vollenhoven 2015</a>); however, indirect comparison with MS is difficult owing to differences in patient populations, dose, administration regimens, and co‐interventions. </p> <p>In our review, we used treatment discontinuation due to adverse events as an indirect outcome to assess acceptability. Results from the included studies suggested that rituximab was superior to all other investigated DMTs in terms of treatment discontinuation over a median follow‐up of two years. Some reviews on adherence to approved DMTs are available in the literature. One systematic review, including 151 studies, reported poor adherence to the traditional 'first choice' treatments for MS (e.g. interferon beta and glatiramer acetate) (<a href="./references#CD013874-bbs2-0122" title="GiovannoniG , SouthamE , WaubantE . Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Multiple sclerosis (Houndmills, Basingstoke, England)2012;18(7):932-46.">Giovannoni 2012</a>). The mean discontinuation rates after two years' treatment ranged from 22% to 43%, and the reasons most frequently mentioned for discontinuation were occurrence of adverse events or perceived lack of efficacy. Another systematic review of studies published between January 2010 and April 2018 showed that approximately one in five people with MS did not adhere to once‐ or twice‐daily oral maintenance DMT regimens, and one in four people discontinued oral treatments before one year (<a href="./references#CD013874-bbs2-0154" title="NicholasJA , EdwardsNC , EdwardsRA , DellaroleA , GrossoM , PhillipsAL . Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis. BMC Neurology2020;20(1):281.">Nicholas 2020</a>). The authors reported a high heterogeneity among the included studies. <a href="./references#CD013874-bbs2-0160" title="PustGE , UntiedtB , RanderathJ , BarabaschA , KöpkeS , RahnAC , et al. Exploring adherence to first-line and second-line immunotherapies in multiple sclerosis: an interview study. International Journal of MS Care2020;22(5):219-25.">Pust 2020</a> conducted semi‐structured interviews with 23 people with MS: 11 receiving first‐line treatment and 12 receiving second‐line treatment. One key reason for non‐adherence reported by people receiving first‐line treatment was undesirable adverse effects, and for adherence was belief in medication effectiveness. In people with MS receiving second‐line treatment, lack of perceived medication effectiveness was a key category related to discontinuation of treatment.  </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013874-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram. Search updated to 31 January 2021. DMT: disease‐modifying treatment." data-id="CD013874-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram. Search updated to 31 January 2021. DMT: disease‐modifying treatment.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included randomised controlled trials." data-id="CD013874-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included randomised controlled trials. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included randomised controlled trial." data-id="CD013874-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included randomised controlled trial. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-FIG-04" target="_blank"><b></b></a></p> </div><img alt="ROBINS‐I summary: review authors' judgements about each risk of bias item for each included non‐randomised study and for outcomes assessed to estimate the &quot;effect of assignment to the intervention&quot; (including disability worsening, relapses, treatment discontinuation due to adverse events, T1 and T2 magnetic resonance imaging lesions).Note: two studies did not report the outcomes and were not included in the figure (Alping 2020; Luna 2020)." data-id="CD013874-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>ROBINS‐I summary: review authors' judgements about each risk of bias item for each included non‐randomised study and for outcomes assessed to estimate the "effect of assignment to the intervention" (including disability worsening, relapses, treatment discontinuation due to adverse events, T1 and T2 magnetic resonance imaging lesions). </p> <p>Note: two studies did not report the outcomes and were not included in the figure (<a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>; <a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-FIG-05" target="_blank"><b></b></a></p> </div><img alt="ROBINS‐I summary: review authors' judgments about each risk of bias item for each included non‐randomised study and for outcomes assessed to estimate the &quot;effect of adherence to the intervention&quot; (including serious adverse events and further adverse events).Note: two studies did not report the outcomes and were not included in the figure (Naegelin 2019; Spelman 2018)." data-id="CD013874-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>ROBINS‐I summary: review authors' judgments about each risk of bias item for each included non‐randomised study and for outcomes assessed to estimate the "effect of adherence to the intervention" (including serious adverse events and further adverse events). </p> <p>Note: two studies did not report the outcomes and were not included in the figure (<a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>; <a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-FIG-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison: rituximab as 'first choice' versus other disease‐modifying treatments (DMT) for relapsing multiple sclerosis – results from non‐randomised studies of interventions (NRSIs), Outcome 1: Time to relapse over 24 months " data-id="CD013874-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Comparison: rituximab as 'first choice' versus other disease‐modifying treatments (DMT) for relapsing multiple sclerosis – results from non‐randomised studies of interventions (NRSIs), Outcome 1: Time to relapse over 24 months  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison: rituximab as 'first choice' versus other disease‐modifying treatments (DMT) for relapsing multiple sclerosis – results from non‐randomised studies of interventions (NRSIs), Outcome 2: Gadolinium magnetic resonance imaging (MRI) lesions " data-id="CD013874-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Comparison: rituximab as 'first choice' versus other disease‐modifying treatments (DMT) for relapsing multiple sclerosis – results from non‐randomised studies of interventions (NRSIs), Outcome 2: Gadolinium magnetic resonance imaging (MRI) lesions  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison: rituximab as 'first choice' versus other disease‐modifying treatments (DMT) for relapsing multiple sclerosis – results from non‐randomised studies of interventions (NRSIs), Outcome 3: Treatment discontinuation due to adverse events" data-id="CD013874-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Comparison: rituximab as 'first choice' versus other disease‐modifying treatments (DMT) for relapsing multiple sclerosis – results from non‐randomised studies of interventions (NRSIs), Outcome 3: Treatment discontinuation due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Comparison: rituximab as 'first choice' versus other disease‐modifying treatments (DMT) for relapsing multiple sclerosis – results from non‐randomised studies of interventions (NRSIs), Outcome 4: Grade 3–4 adverse events over 24 months " data-id="CD013874-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Comparison: rituximab as 'first choice' versus other disease‐modifying treatments (DMT) for relapsing multiple sclerosis – results from non‐randomised studies of interventions (NRSIs), Outcome 4: Grade 3–4 adverse events over 24 months  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 1: Disability worsening over 24 months " data-id="CD013874-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 1: Disability worsening over 24 months  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 2: Relapse over 24 months " data-id="CD013874-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 2: Relapse over 24 months  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 3: Serious adverse events over 24 months " data-id="CD013874-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 3: Serious adverse events over 24 months  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 4: Common infections over 24 months " data-id="CD013874-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 4: Common infections over 24 months  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 5: Cancer over 24 months " data-id="CD013874-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 5: Cancer over 24 months  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 6: Mortality over 24 months " data-id="CD013874-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 6: Mortality over 24 months  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 7: Treatment discontinuation due to adverse events" data-id="CD013874-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 7: Treatment discontinuation due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 8: Grade 3 or 4 adverse events" data-id="CD013874-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 8: Grade 3 or 4 adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 9: First infusion reactions" data-id="CD013874-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 9: First infusion reactions </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 10: Second infusion reactions" data-id="CD013874-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) , Outcome 10: Second infusion reactions </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 1: Relapse over 12 months in relapsing MS" data-id="CD013874-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 1: Relapse over 12 months in relapsing MS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 2: Serious adverse events (SAEs)" data-id="CD013874-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 2: Serious adverse events (SAEs) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 3: Common infections" data-id="CD013874-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 3: Common infections </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 4: Cancer" data-id="CD013874-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 4: Cancer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 5: Mortality" data-id="CD013874-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 5: Mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 6: Annualised relapse rate " data-id="CD013874-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 6: Annualised relapse rate  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 7: Gadolinium MRI lesions over 12 months" data-id="CD013874-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 7: Gadolinium MRI lesions over 12 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 8: Treatment discontinuation due to adverse events" data-id="CD013874-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 8: Treatment discontinuation due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 9: Grade 3–4 adverse events" data-id="CD013874-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 9: Grade 3–4 adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 10: Cardiovascular events" data-id="CD013874-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 10: Cardiovascular events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 11: First infusion reactions" data-id="CD013874-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 11: First infusion reactions </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 12: Second infusion reactions" data-id="CD013874-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs, Outcome 12: Second infusion reactions </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 1: Time to disability worsening over 24 months " data-id="CD013874-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 1: Time to disability worsening over 24 months  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 2: Time to relapse over 24 months " data-id="CD013874-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 2: Time to relapse over 24 months  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 3: Common infections " data-id="CD013874-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 3: Common infections  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 4: Mortality " data-id="CD013874-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 4: Mortality  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 5: Annualised relapse rate (change from baseline) – by type of DMT" data-id="CD013874-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 5: Annualised relapse rate (change from baseline) – by type of DMT </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 6: T2 MRI lesions " data-id="CD013874-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 6: T2 MRI lesions  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 7: Gadolinium MRI lesions " data-id="CD013874-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 7: Gadolinium MRI lesions  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 8: Treatment discontinuation due to adverse events – by type of DMT" data-id="CD013874-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 8: Treatment discontinuation due to adverse events – by type of DMT </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 9: Grade 3–4 adverse events over 24 months " data-id="CD013874-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 9: Grade 3–4 adverse events over 24 months  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-004.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 10: Cardiovascular events – by type of DMT" data-id="CD013874-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-004.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 10: Cardiovascular events – by type of DMT </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-004.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 11: First infusion reactions" data-id="CD013874-fig-0042" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-004.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4: Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI, Outcome 11: First infusion reactions </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-004.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison: rituximab as 'switching' versus placebo for secondary progressive MS – results from RCTs, Outcome 1: Serious adverse events" data-id="CD013874-fig-0043" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Comparison: rituximab as 'switching' versus placebo for secondary progressive MS – results from RCTs, Outcome 1: Serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison: rituximab as 'switching' versus placebo for secondary progressive MS – results from RCTs, Outcome 2: Cancer" data-id="CD013874-fig-0044" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Comparison: rituximab as 'switching' versus placebo for secondary progressive MS – results from RCTs, Outcome 2: Cancer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Comparison: rituximab as 'switching' versus placebo for secondary progressive MS – results from RCTs, Outcome 3: Cardiovascular events" data-id="CD013874-fig-0045" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Comparison: rituximab as 'switching' versus placebo for secondary progressive MS – results from RCTs, Outcome 3: Cardiovascular events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from RCTs , Outcome 1: Serious adverse events " data-id="CD013874-fig-0046" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from RCTs , Outcome 1: Serious adverse events  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from RCTs , Outcome 2: Common infections – by different DMTs" data-id="CD013874-fig-0047" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from RCTs , Outcome 2: Common infections – by different DMTs </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from RCTs , Outcome 3: Annualised relapse rate" data-id="CD013874-fig-0048" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from RCTs , Outcome 3: Annualised relapse rate </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from RCTs , Outcome 4: Gadolinium MRI lesions " data-id="CD013874-fig-0049" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from RCTs , Outcome 4: Gadolinium MRI lesions  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from RCTs , Outcome 5: Treatment discontinuation due to adverse events " data-id="CD013874-fig-0050" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from RCTs , Outcome 5: Treatment discontinuation due to adverse events  </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from RCTs , Outcome 6: Opportunistic infections" data-id="CD013874-fig-0051" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from RCTs , Outcome 6: Opportunistic infections </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from NRSIs, Outcome 1: Time to disability worsening over 36 months in secondary progressive MS" data-id="CD013874-fig-0052" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from NRSIs, Outcome 1: Time to disability worsening over 36 months in secondary progressive MS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Comparison: rituximab as 'switching' versus other DMTs for grouped data as relapsing or progressive MS – results from NRSIs, Outcome 1: Relapse over 24 months – by type of DMT (unadjusted data)" data-id="CD013874-fig-0053" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Comparison: rituximab as 'switching' versus other DMTs for grouped data as relapsing or progressive MS – results from NRSIs, Outcome 1: Relapse over 24 months – by type of DMT (unadjusted data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Comparison: rituximab as 'switching' versus other DMTs for grouped data as relapsing or progressive MS – results from NRSIs, Outcome 2: Common infections – by type of DMT" data-id="CD013874-fig-0054" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Comparison: rituximab as 'switching' versus other DMTs for grouped data as relapsing or progressive MS – results from NRSIs, Outcome 2: Common infections – by type of DMT </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Comparison: rituximab as 'switching' versus other DMTs for grouped data as relapsing or progressive MS – results from NRSIs, Outcome 3: Cancer – by type of DMT" data-id="CD013874-fig-0055" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Comparison: rituximab as 'switching' versus other DMTs for grouped data as relapsing or progressive MS – results from NRSIs, Outcome 3: Cancer – by type of DMT </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-008.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Comparison: rituximab as 'switching' versus other DMTs for grouped data as relapsing or progressive MS – results from NRSIs, Outcome 4: T2 MRI lesions – by DMT (unadjusted data)" data-id="CD013874-fig-0056" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-008.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-008.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8: Comparison: rituximab as 'switching' versus other DMTs for grouped data as relapsing or progressive MS – results from NRSIs, Outcome 4: T2 MRI lesions – by DMT (unadjusted data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-008.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-008.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Comparison: rituximab as 'switching' versus other DMTs for grouped data as relapsing or progressive MS – results from NRSIs, Outcome 5: Gadolinium MRI lesions (unadjusted data)" data-id="CD013874-fig-0057" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-008.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-008.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8: Comparison: rituximab as 'switching' versus other DMTs for grouped data as relapsing or progressive MS – results from NRSIs, Outcome 5: Gadolinium MRI lesions (unadjusted data) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-008.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-008.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Comparison: rituximab as 'switching' versus other DMTs for grouped data as relapsing or progressive MS – results from NRSIs, Outcome 6: Discontinuation due to adverse events – by type of DMT" data-id="CD013874-fig-0058" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-008.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-008.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.6</div> <div class="figure-caption"> <p>Comparison 8: Comparison: rituximab as 'switching' versus other DMTs for grouped data as relapsing or progressive MS – results from NRSIs, Outcome 6: Discontinuation due to adverse events – by type of DMT </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-008.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013874-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/urn:x-wiley:14651858:media:CD013874:CD013874-CMP-008.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Comparison: rituximab as 'switching' versus other DMTs for grouped data as relapsing or progressive MS – results from NRSIs, Outcome 7: Cardiovascular events – by DMT" data-id="CD013874-fig-0059" src="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-008.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_t/tCD013874-CMP-008.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.7</div> <div class="figure-caption"> <p>Comparison 8: Comparison: rituximab as 'switching' versus other DMTs for grouped data as relapsing or progressive MS – results from NRSIs, Outcome 7: Cardiovascular events – by DMT </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/media/CDSR/CD013874/image_n/nCD013874-CMP-008.07.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013874-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Rituximab as 'first choice' versus other disease‐modifying treatments for relapsing multiple sclerosis – results from non‐randomised studies of intervention</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> relapsing multiple sclerosis<br/><b>Settings:</b> inpatient or outpatient<br/><b>Intervention:</b> rituximab as first choice treatment<br/><b>Comparison:</b> other disease‐modifying treatments as first choice treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comparison</b> </p> <p><b>intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b>* </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with rituximab</b> </p> <p><b>(95% CI)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability worsening</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study<sup>a</sup> did not measure the outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Chance of experiencing ≥ 1 relapses:</b> visits over 24 months. Data collected from the Swedish MS registry and medical records. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Interferon beta or glatiramer acetate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>270 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b><br/>(16 to 116) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.14</b> </p> <p>(0.05 to 0.39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>335<br/>(1 retrospective cohort study)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias. Rituximab likely results in a large reduction in relapses when compared with interferon beta or glatiramer acetate. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Dimethyl fumarate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>120 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b><br/>(10 to 120) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.29</b> </p> <p>(0.08 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206<br/>(1 retrospective cohort study)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 1 level for imprecision. Rituximab may reduce relapses when compared with dimethyl fumarate. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200</b> <b>per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>52</b> <b>per 1000</b> </p> <p>(13 to 200)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.24</b> </p> <p>(0.06 to 1.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170<br/>(1 retrospective cohort study)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 1 level for imprecision. Rituximab may reduce relapses when compared with natalizumab. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>180 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50</b> <b>per 1000</b> </p> <p>(8 to 285)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.26 </b> </p> <p>(0.04 to 1.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137<br/>(1 retrospective cohort study)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 2 levels for serious imprecision. The evidence is very uncertain about the effect of rituximab on relapses when compared with fingolimod. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study<sup>a</sup> did not measure the outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study<sup>a</sup> did not measure the outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Common infections</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study<sup>a</sup> did not measure the outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cancer</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study<sup>a</sup> did not measure the outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="7" rowspan="1" valign=""> <p>No reported deaths in any comparison group over 24 months' follow‐up. Death related to adverse events defined as CTCAE grade 5. Data collected from the Swedish MS registry and medical records. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*The <b>assumed risk</b> was calculated in GRADEpro based on the number of participants with the event over the total sample size in the control group, for binary and time‐to‐event outcomes. The <b>risk</b> <b>in the rituximab group </b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> (odds ratio or HR) of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>CTCAE:</b> National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0; <b>HR:</b> hazard ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Explanations:</b> event rates in comparator based on the number of events in the included study. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD013874-bbs2-0008" title="GranqvistM , BoremalmM , PoorghobadA , SvenningssonA , SalzerJ , FrisellT , et al. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurology2018;75(3):320-7. ">Granqvist 2018</a>.<br/><sup>b</sup>Bias due to confounding by indication expected in the retrospective cohort study.<br/><sup>c</sup>The optimal information size criterion was not met (very few events).<br/><sup>d</sup>Results included both no effect and appreciable benefit or harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Rituximab as 'first choice' versus other disease‐modifying treatments for relapsing multiple sclerosis – results from non‐randomised studies of intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013874-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Rituximab as 'first choice' versus placebo for progressive multiple sclerosis – results from randomised controlled trials</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> primary progressive multiple sclerosis </p> <p><b>Settings:</b> inpatient or outpatient </p> <p><b>Intervention:</b> rituximab as first choice treatment </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with rituximab</b> </p> <p><b>(95% CI)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability worsening</b> measured by EDSS over 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>361 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>286 per 1000</b><br/>(202 to 385) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.71 </b> </p> <p>(0.45 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for some imprecision. Rituximab likely resulted in little to no difference in the number of participants who had disability worsening over 24 months when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> measured by clinical assessment over 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34</b> <b>per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21</b> <b>per 1000</b> </p> <p>(6 to 65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.60</b> </p> <p>(0.18 to 1.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels for very serious imprecision. Rituximab may have resulted in little to no difference in recurrence of relapses when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> measured by clinical assessment over 28 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>136 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>164 per 1000</b> </p> <p>(101 to 257)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.25</b> </p> <p>(0.71 to 2.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439<br/>(1 RCTs)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels for very serious imprecision. Rituximab may slightly increase the number of participants who have serious adverse events compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study<sup>a</sup> did not measure the outcome </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Common infections</b> measured by clinical assessment over 28 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>653 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>682 per 1000</b> </p> <p>(585 to 765)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.14 </b> </p> <p>(0.75 to 1.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439<br/>(1 RCTs)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels for very serious imprecision. Rituximab may increase common infections compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cancer</b> measured by clinical assessment over 28 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> <p>(1 to 47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.50 </b> </p> <p>(0.07 to 3.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels for very serious imprecision. Quote: "Rituximab group: 1 patient had breast cancer and 1 had adenocarcinoma. Placebo group: 1 patient had parathyroid tumour, 1 had prostate cancer". </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> measured by clinical assessment over 28 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>14 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>3 per 1000</b> </p> <p>(0 to 37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.25</b> </p> <p>(0.02 to 2.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>439<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels for very serious imprecision. Rituximab may result in little to no difference in mortality compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The <b>assumed risk</b> was calculated based on the number of participants with the event over the total sample size in the placebo group, for binary outcomes. The <b>risk</b> <b>in the rituximab group </b> (and its 95% confidence interval) is based on the assumed risk in the placebo group and the <b>relative effect</b> (OR) of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>EDSS:</b> Expanded Disability Status Scale; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD013874-bbs2-0010" title="HawkerK , O'ConnorP , FreedmanM . Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis (PPMS): results of a randomized double-blind placebo-controlled multicenter trial. Neurology2009;72 (11 Suppl 3):A254. HawkerK , O'ConnorP , FreedmanMS , CalabresiPA , AntelJ , SimonJ , et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology2009;66(4):460-71. NCT00087529. A study to evaluate the safety and efficacy of rituximab in adults with primary progressive multiple sclerosis (OLYMPUS). clinicaltrials.gov/show/NCT00087529 (first received 13 July 2004). ">Hawker 2009</a>.<br/><sup>b</sup>Results included both appreciable benefit and no effect.<br/><sup>c</sup>We did not downgrade for risk of bias, even though the included study has some concerns.<br/><sup>d</sup>Results included both no effect and appreciable benefit or harm.<br/><sup>e</sup>Results included both no harm and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Rituximab as 'first choice' versus placebo for progressive multiple sclerosis – results from randomised controlled trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013874-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Rituximab as 'switching' versus placebo for relapsing multiple sclerosis – results from randomised controlled trials</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> relapsing multiple sclerosis<br/><b>Settings:</b> inpatient or outpatient<br/><b>Intervention:</b> rituximab as 'switching' treatment<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> <p><b> </b> </p> <p><b> </b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants</b> <br/><b>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk with rituximab</b> </p> <p><b>(95% CI)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability worsening</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study<sup>a</sup> did not measure the outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> measured by clinical assessment over 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b><br/>(96 to 383) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.38 </b> </p> <p>(0.16 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 1 level for serious imprecision. Rituximab may result in a large reduction in recurrence of relapse over 12 months' follow‐up when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> measured by clinical assessment over 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b><br/>(45 to 327) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.90</b> </p> <p>(0.28 to 2.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on serious adverse events, when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study<sup>a</sup> did not measure the outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Common infections</b> measured by clinical assessment over 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>695 per 1000</b><br/>(481 to 848) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.91</b> </p> <p>(0.37 to 2.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 </p> <p>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on infections, when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cancer</b> measured by clinical assessment over 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.55</b> </p> <p>(0.06 to 39.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on the number of participants who have cancer, when compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> measured by clinical assessment over 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.55</b> </p> <p>(0.06 to 39.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on mortality compared with placebo. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The <b>assumed risk</b> was calculated based on the number of participants with the event over the total sample size in the placebo group for binary outcomes. The <b>risk</b> <b>in the rituximab group </b> (and its 95% CI) is based on the assumed risk in the placebo group and the <b>relative effect</b> (OR) of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>.<br/><sup>b</sup>High risk of bias for unblinding of personnel and incomplete outcome data. Unclear risk of bias for allocation concealment and blinding of participants.<br/><sup>c</sup>The optimal information size criterion was not met (few events).<br/><sup>d</sup>The optimal information size criterion was not met (very few events). Results included both no harm and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Rituximab as 'switching' versus placebo for relapsing multiple sclerosis – results from randomised controlled trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013874-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Rituximab as 'switching' versus other disease‐modifying treatments for relapsing multiple sclerosis – results from non‐randomised studies of intervention</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> relapsing multiple sclerosis<br/><b>Settings:</b> inpatient or outpatient<br/><b>Intervention:</b> rituximab as 'switching' treatment<br/><b>Comparison:</b> other disease‐modifying treatments as 'switching' </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comparison</b> </p> <p><b>intervention</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b>* </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk with rituximab</b> </p> <p><b>(95% CI)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Disability worsening</b> measured by EDSS over 24 months: data collected from the Swedish MS registry and medical records </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Interferons or glatiramer acetate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>90 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b><br/>(48 to 125) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.86</b> </p> <p>(0.52 to 1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>853<br/>(1 retrospective cohort study)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels for very serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on disability worsening when compared with interferon beta or glatiramer acetate  </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Relapse</b> measured by clinical assessment over 24 months: data collected from the Swedish MS registry and medical records </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Interferons or glatiramer acetate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>270 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b><br/>(22 to 143) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.18 </b> </p> <p>(0.07 to 0.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1383<br/>(1 retrospective cohort study)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level due to serious risk of bias. Rituximab likely results in a large reduction in recurrence of relapses when compared with interferons or glatiramer. The NNTB is 11 (95% CI 10 to 18). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b><br/>(4 to 60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.08 </b> </p> <p>(0.02 to 0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>256<br/>(1 retrospective cohort study)<sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level due to serious risk of bias. Rituximab likely results in a large reduction in recurrence of relapses when compared with fingolimod. The NNTB is 6 (95% CI 6 to 9). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b><br/>(12 to 266) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.00 </b> </p> <p>(0.20 to 5.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153<br/>(1 retrospective cohort study)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on recurrence of relapses when compared with natalizumab. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the studies measured the outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies measured the outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Long‐term adverse events: common infections</b> over 24 months: data collected from MS registries and medical records. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Interferon beta or glatiramer acetate</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b><br/>(40 to 89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.71</b> </p> <p>(1.11 to 2.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5477<br/>(1 retrospective cohort study‐ the national Swedish MS Register linked to national healthcare and census registries)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias in measurement of the outcome. Rituximab likely increases infections when compared with interferons or glatiramer acetate. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b><br/>(51 to 95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.26</b> </p> <p>(0.90 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5187</p> <p>(3 retrospective multicentre cohort studies)<sup>e,f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>i,j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias and 1 level for imprecision. Heterogeneity: P = 0.24, I² = 30%. Rituximab may increase slightly common infections when compared with fingolimod. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b><br/>(51 to 95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.58</b> </p> <p>(1.08 to 2.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5001</p> <p>(2 retrospective multicentre cohort studies)<sup>f,g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias. Heterogeneity: P = 0.39, I² = 0%. Rituximab likely increases the number of participants who have common infections when compared with natalizumab. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Ocrelizumab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/>(0 to 26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.02</b> </p> <p>(0.00 to 0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>472</p> <p>(1 retrospective multicentre cohort study). The Swedish MS register and medical records at the Rocky Mountain MS Clinic, Utah, US<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>j,l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels for very serious risk of bias and 1 level for imprecision. The evidence is very uncertain about the effect of rituximab on the number of participants who have common infections when compared with ocrelizumab. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Cancer</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies measured the outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Mortality over 24 months:</b> defined as CTCAE grade 5. Data collected from the Swedish MS registry and medical records. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 5.59</b> </p> <p>(0.22 to 139.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136<br/>(1 retrospective multicentre cohort study)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>d,i,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias, 1 level for indirectness, and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on mortality compared with fingolimod. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 6.66</b> </p> <p>(0.27 to 166.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153<br/>(1 retrospective multicentre cohort study)<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>d,i,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level for serious risk of bias, 1 level for indirectness, and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on mortality compared with natalizumab. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*The <b>assumed risk</b> was calculated in GRADEpro based on the number of participants with the event over the total sample size in the control group, for binary and time‐to‐event outcomes. The <b>risk</b> <b>in the rituximab group </b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> (OR or HR) of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>CTCAE:</b> National Cancer Institute. Common Terminology Criteria for Adverse Events version 4.0; <b>HR:</b> hazard ratio; <b>NNTB: </b> number needed to treat for an additional beneficial effect; <b>OR:</b> odds ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Explanations</b> </p> <p>Event rates in comparator based on the number of events in the included studies.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>.<br/><sup>b</sup>Bias due to missing data since time to disability worsening was limited to participants with a minimum of three EDSS scores reported, i.e. 321/461 (70%) participants in the rituximab group and 532/922 (58%) participants in the interferon or glatiramer acetate group.<br/><sup>c</sup>The optimal information size criterion was not met (few events). Results included both no effect and appreciable benefit or harm.<br/><sup>d</sup>Bias due to residual confounding is expected in a retrospective cohort study.<br/><sup>e</sup><a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>.<br/><sup>f</sup><a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>.<br/><sup>g</sup><a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>.<br/><sup>h</sup>Quote: "Data are not available on the validity of the registries to measure infections and on different reporting of infections between interventions" (<a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>).<br/><sup>i</sup>The optimal information size criterion was not met (very few events). Results included both no harm and appreciable harm.<br/><sup>j</sup>All retrospective cohort studies at serious risk of bias.<br/><sup>k</sup><a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>.<br/><sup>l</sup>The optimal information size criterion was not met (few events).<br/><sup>m</sup>Indirectness of outcome, one suicide in the rituximab group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Rituximab as 'switching' versus other disease‐modifying treatments for relapsing multiple sclerosis – results from non‐randomised studies of intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013874-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Treatment guidelines for multiple sclerosis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>European ECTRIMS/EAN Guideline</b> </p> <p><b>(</b><a href="./references#CD013874-bbs2-0151" title="MontalbanX , GoldR , ThompsonAJ , Otero-RomeroS , AmatoMP , ChandraratnaD , et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal2018;24(2):96-120."><b>Montalban 2018</b> </a><b>)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>American Academy of Neurology practice guideline</b> (<a href="./references#CD013874-bbs2-0161" title="Rae-GrantA , DayGS , MarrieRA , RabinsteinA , CreeBA , GronsethGS , et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology2018;90(17):777-88.">Rae‐Grant 2018</a>) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Brazilian Consensus</b> (<a href="./references#CD013874-bbs2-0144" title="MarquesVD , PassosGR , MendesMF , CallegaroD , Lana-PeixotoMA , Comini-FrotaER , et al. Brazilian consensus for the treatment of multiple sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis. Arquivos de Neuro-psiquiatria2018;76(8):539-54.">Marques 2018</a>) </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>The Middle East and North Africa Committee Consensus</b> (<a href="./references#CD013874-bbs2-0185" title="YamoutB , SahraianM , BohlegaS , Al-JumahM , GoueiderR , DahdalehM , et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Multiple Sclerosis and Related Disorders2020;37:101459.">Yamout 2020</a>) </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Question 1</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with CIS, what is the benefit of starting treatment with a DMT compared to no treatment? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with CIS, are DMTs superior to placebo in decreasing the risk of conversion to MS? </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with CIS, are DMTs efficacious in preventing conversion to MS?</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Should people with CIS be treated with DMTs?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recommendation</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Offer interferon or glatiramer acetate to people with CIS and an abnormal MRI with lesions suggestive of MS who do not fulfil criteria for MS. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Clinicians may recommend at least annual MRI for the first 5 years and follow‐up rather than initiating DMT in people with CIS who have not had relapses in the preceding 2 years, and do not have active new MRI lesions on recent imaging. </p> <p>2. After discussing the risks and benefits, clinicians should prescribe DMT to people with CIS and ≥ 2 brain lesions characteristic of MS who decide they want this therapy. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It seems reasonable to start DMTs only in people with high‐risk CIS<sup>a</sup> as well as to choose safer drugs. Efficacy in CIS has been demonstrated with the interferon betas, cladribine, glatiramer </p> <p>acetate, and teriflunomide. Since no direct comparison between these is available, any of these drugs are deemed appropriate for the treatment of high‐risk CIS<sup>a</sup>. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>If the overall clinical and radiological picture is suggestive of MS, people with CIS and high MRI lesion load (&gt; 9 T2 lesions), or with severe relapses with incomplete recovery, or both, should be treated. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Strong</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Level C: "may"</p> <p>2. Level B: "should"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Question 2</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with RRMS, what is the benefit of treating with a DMT compared to no treatment or another DMT? </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with RRMS, are DMTs superior to placebo or other DMTs in preventing relapse at 2 years, reducing MRI new disease activity, and preventing disease progression? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with relapsing MS, are DMTs efficacious in reducing relapses, MRI disease activity, and disability? </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Should people with RRMS be treated with DMTs?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recommendation</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Offer early treatment with DMTs to people with active RRMS<sup>b</sup>. </p> <p>2. For active RRMS, choosing between the wide range of available DMTs, from the modestly effective to the highly efficacious, depends on individual characteristics and comorbidities, disease severity or activity, drug safety profile, and accessibility of the drug, in discussion with the person with active RRMS. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinicians should:</p> <p>1. offer DMTs to people with RRMS with recent clinical relapses or MRI activity;</p> <p>2. prescribe alemtuzumab, fingolimod, or natalizumab for people with highly active MS<sup>b</sup>. </p> <p>Clinicians may:</p> <p>3. recommend azathioprine or cladribine for people with RRMS who do not have access to approved DMTs. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. It would seem reasonable to start</p> <p>treatment with interferons, glatiramer acetate, pegylated interferon beta, dimethyl fumarate, or teriflunomide, (good safety profile and more easily available, including in the Brazilian public health system). </p> <p>2. Consider alemtuzumab, cladribine, fingolimod, natalizumab, and ocrelizumab for people with highly active relapsing MS<sup>c</sup>. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. In treatment‐naive people, interferons, glatiramer acetate, teriflunomide, and dimethyl fumarate can be initiated. </p> <p>2. In people with highly active disease<sup>d</sup> fingolimod, siponimod, natalizumab, ocrelizumab, or cladribine may be initiated. </p> <p>3. In people with rapidly evolving aggressive disease<sup>e</sup> natalizumab, ocrelizumab, or alemtuzumab are recommended after careful risk stratification. </p> <p>4. Rituximab can be used off‐label for highly active disease and rapidly evolving aggressive disease in special populations such as refugees, or in countries where other appropriate </p> <p>options are not available.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of evidence</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Strong</p> <p>2. Consensus statement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. and 2. Level B: "should"</p> <p>3. Level C: "may"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Question 3</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with active SPMS, what is the benefit of treating with a DMT compared to no treatment or another DMT? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with SPMS, are DMTs efficacious?</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with non‐active SPMS, are DMTs efficacious?</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Should people with SPMS be treated with DMTs?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recommendation</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consider treatment with interferons, mitoxantrone, ocrelizumab, or cladribine for people with active SPMS. </p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Clinicians should prescribe alemtuzumab, fingolimod, or natalizumab for people with highly active MS<sup>b</sup>. </p> <p>2. Clinicians may advise discontinuation of DMT in people with SPMS who do not have ongoing relapses or MRI activity and have not been ambulatory (EDSS ≥ 7) for ≥ 2 years. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Not prescribing a DMT is an acceptable choice in people with SPMS who no longer present relapses. </p> <p>2. In cases of rapidly progressive disease, cyclophosphamide, mitoxantrone, and autologous haematopoietic stem cell transplantation may be used as off‐label treatments. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Consider treatment with ocrelizumab or siponimod in people with active SPMS, aged ≤ 60 years and EDSS ≤ 6.5 (i.e. not needing a wheelchair). </p> <p>2. In people with rapidly progressive SPMS not responding to ocrelizumab or siponimod or who have no access to these medications, cyclophosphamide, methotrexate, or mycophenolate may be warranted. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weak</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Level B: "should"</p> <p>2. Level C: "may"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Question 4</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with PPMS, what is the benefit of treating with a DMT compared to no treatment?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with PPMS, are DMTs superior to placebo or other DMTs as measured by relapse rate or disease progression? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with PPMS, are DMTs efficacious in delaying the progression of disability?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Should people with PPMS be treated with DMTs?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recommendation</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consider treatment with ocrelizumab for people with PPMS.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinicians should offer ocrelizumab to people with PPMS.</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ocrelizumab should be the treatment of choice for people with PPMS, after consideration</p> <p>of the expected benefits and potential risks on a case‐by‐case basis.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Consider treatment with ocrelizumab for people with PPMS, aged ≤ 55 years, EDSS ≤ 6.5 (i.e. not needing a wheelchair), and disease duration ≤ 10–15 years. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weak</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Level B: "should"</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Question 5</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. In people with RRMS treated with interferon or glatiramer acetate and evidence of disease activity at 6 or 12 months, what is the benefit of switching to more efficacious drugs? </p> <p>2. In people with relapsing MS who stop taking a highly efficacious drug, what is the benefit of further treatment? </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with RRMS who experience disease activity while on a DMT, is changing to a different DMT superior to continuing the present DMT in terms of relapse and MRI disease activity? </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>When to consider DMT switching in people with RRMS?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>When to consider DMT switching in people with RRMS?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recommendation</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Offer a more efficacious drug to people treated with interferon or glatiramer acetate who show evidence of disease activity. </p> <p>2. Consider starting another highly efficacious drug, taking into account disease activity, half‐life and biological activity of the previous drug, and the potential for rebound (particularly with natalizumab). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Clinicians should discuss switching from 1 DMT to another in people with MS treated long enough for the treatment to take full effect when they experience ≥ 1 relapse, ≥ 2 new MRI lesions, or increased disability, over a 1‐year period of using a DMT. </p> <p>2. Clinicians should evaluate the degree of disease activity, adherence, AE profiles, and mechanism of action of DMTs when switching DMTs in people with MS with breakthrough disease activity during DMT use. </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. If the management of highly active MS<sup>c</sup> with potent DMTs has achieved a satisfactory response and stability for several years, it would be </p> <p>acceptable (though not mandatory) to consider switching to a lower potency DMT.</p> <p>2. If a person with relapsing MS fails to achieve satisfactory responses, presents intolerance or safety concerns with interferons, dimethyl fumarate, glatiramer acetate, pegylated interferon, teriflunomide, a switch to alemtuzumab, cladribine, fingolimod, natalizumab, ocrelizumab should be considered. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. In people with moderately active disease and suboptimal response<sup>f</sup> to interferons, dimethyl fumarate, glatiramer acetate, teriflunomide, treatment escalation to fingolimod, siponimod, natalizumab, ocrelizumab, or cladribine should be considered. </p> <p>2. Rituximab can be used off‐label as an escalation therapy for all levels of MS activity, in special populations such as refugees, or in countries </p> <p>where other appropriate options are not available.</p> <p>3. In people with evidence of suboptimal response to any of the second‐line medications, off‐label cyclophosphamide, autologous haematopoietic stem cell transplantation, or mitoxantrone should be considered. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Strong</p> <p>2. Consensus statement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. and 2. Level B: "should"</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Question 6</b> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>In people with RRMS who experience AEs while on a DMT, is switching necessary?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Recommendation</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinicians should:</p> <p>1. discuss a change to non‐injectable or less frequently injectable DMTs in people with MS who report intolerable discomfort with the injections or in those who report injection fatigue on injectable DMTs; </p> <p>2. discuss a medication switch with people with MS for whom AEs negatively influence adherence; </p> <p>3. discuss switching DMT or reducing dosage or frequency when there are serious infections or persistent laboratory abnormalities; </p> <p>4. discuss switching to a DMT with a lower risk of progressive multifocal leucoencephalopathy with people with MS taking natalizumab who are or become antibody–positive to John Cunningham (JCV) virus, while on therapy; </p> <p>5. discuss switching to an alternate DMT for people with MS who develop a malignancy while using azathioprine, methotrexate, mycophenolate, cyclophosphamide, fingolimod, teriflunomide, alemtuzumab, or dimethyl fumarate; </p> <p>6. switch DMTs in people with MS who have persistent natalizumab antibodies.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of evidence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1., 2., 3., 4., 5., and 6. Level B: "should"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>High‐risk CIS defined by one or more typical MRI T2 lesion(s), provided both the clinical presentation and MRI lesion(s) are suggestive of central nervous system demyelination and not attributable to other diseases.<br/><sup>b</sup>Active RRMS or highly active MS defined by clinical relapses or MRI activity (active lesions – contrast‐enhancing lesions; new or unequivocally enlarging T2 lesions assessed at least annually), or both.<br/><sup>c</sup>Highly active MS defined as: 1. at least two disabling relapses with incomplete resolution and at least one contrast‐enhancing lesion or significant increase in T2 lesion load in the previous year in treatment‐naive people; or 2. breakthrough disease activity in the previous year, under an adequate course of at least one DMT (in the absence of intolerance or non‐adherence), presenting with at least one relapse in the previous year while on therapy and at least nine MRI T2 lesions or at least one contrast‐enhancing lesion.<br/><sup>d</sup>Highly active disease defined as: 1. at least two relapses in the previous year; 2. relapse severity; 3. incomplete recovery; 4. at least 10 MRI T2 lesions; 5. multiple contrast enhancing lesions.<br/><sup>e</sup>Rapidly evolving aggressive disease defined as the presence of at least two disabling relapses with incomplete recovery in the previous year and at least 10 MRI T2 lesions.<br/><sup>f</sup>Suboptimal response to chronic DMTs should be considered after one year of treatment in people with at least one relapse or disability progression or both, or at least two active MRI lesions (gadolinium or new T2‐weighted, or both) after one year of adequate treatment and using as baseline an MRI performed six months after treatment initiation. </p> <p>AE: adverse events; CIS: clinically isolated syndrome; DMT: disease‐modifying treatment; ECTRIMS/EAN: European Committee of Treatment of Research in Multiple Sclerosis and European Academy of Neurology; EDSS: Expanded Disability Status Scale; MRI: magnetic resonance imaging; MS: multiple sclerosis; PPMS: primary progressive multiple sclerosis; RRMS: relapsing‐remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Treatment guidelines for multiple sclerosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013874-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Rituximab as 'switching' for multiple sclerosis – results from RCTs and non‐randomised studies of intervention</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> relapsing or progressive forms of multiple sclerosis<br/><b>Settings:</b> inpatient or outpatient<br/><b>Intervention:</b> rituximab as 'switching' from another DMT<br/><b>Comparison:</b> placebo or other DMTs as 'switching' treatment </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comparison</b> </p> <p><b>intervention</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects</b>* </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence</b> </p> <p><b>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk with comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk with rituximab</b> </p> <p><b>(95% CI)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chance of sustained disability worsening</b> over 24–36 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Interferons or glatiramer acetate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>90 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>78 per 1000</b><br/>(48 to 125) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.86</b> </p> <p>(0.52 to 1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>853<br/>(1 retrospective cohort study)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on disability worsening at 24 months' follow‐up, when compared with interferon beta or glatiramer acetate. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Other DMTs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>SPMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>360 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>196 per 1000</b><br/>(110 to 340) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.49</b> </p> <p>(0.26 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88<br/>(1 retrospective cohort study)<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>e,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on disability worsening at 36 months' follow‐up, when compared with other DMTs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Chance of experiencing ≥ 1 relapses</b> over 12–24 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>202 per 1000</b><br/>(96 to 383) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.38 </b> </p> <p>(0.16 to 0.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>f,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is low, downgraded 1 level for serious risk of bias and 1 level for serious imprecision. Rituximab may result in a large reduction in recurrence of relapse over 12 months' follow‐up when compared with placebo </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Interferons or glatiramer acetate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b><i>RRMS</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>270 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b><br/>(22 to 143) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.18 </b> </p> <p>(0.07 to 0.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1383<br/>(1 retrospective cohort study)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is moderate, downgraded 1 level due to serious risk of bias. Rituximab likely results in a very large reduction in recurrence of relapses over 24 months' follow‐up, when compared with interferons or glatiramer. The NNTB is 11 (95% CI 10 to 18). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b><i>RRMS</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>176 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b><br/>(4 to 60) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 0.08 </b> </p> <p>(0.02 to 0.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>256<br/>(1 retrospective cohort study)<sup>i</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is moderate, downgraded 1 level due to serious risk of bias. Rituximab likely results in a large reduction in recurrence of relapses over 24 months' follow‐up, when compared with fingolimod. The NNTB is 6 (95% CI 6 to 9). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b><i>RRMS</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b><br/>(12 to 266) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR 1.0 </b> </p> <p>(0.2 to 5.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153<br/>(1 retrospective cohort study)<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on recurrence of relapses over 24 months' follow‐up, when compared with natalizumab.  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b><i>MS of all types</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/>(13 to 79) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.35</b> </p> <p>(0.14 to 0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453<br/>(1 retrospective cohort study)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>f,l,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias, 1 level for indirectness, and 1 level for serious imprecision. The evidence is very uncertain about the effect of rituximab on recurrence of relapses over 24 months' follow‐up, when compared with fingolimod. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dimethyl fumarate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b><i>MS of all types</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>129 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/>(15 to 75) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.23</b> </p> <p>(0.10 to 0.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>524<br/>(1 retrospective cohort study)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>f,l,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias, 1 level for indirectness, and 1 level for serious imprecision. The evidence is very uncertain about the effect of rituximab on recurrence of relapses over 24 months' follow‐up, when compared with dimethyl fumarate. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b><i>MS of all types</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/>(14 to 78) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.54</b> </p> <p>(0.22 to 1.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>633<br/>(1 retrospective cohort study)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>f,l,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias, 1 level for indirectness, and 1 level for serious imprecision. The evidence is very uncertain about the effect of rituximab on recurrence of relapses over 24 months' follow‐up, when compared with natalizumab. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>SAEs</b> over 12–24 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>143 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>130 per 1000</b><br/>(45 to 327) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.90</b> </p> <p>(0.28 to 2.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>h,n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on SAEs, when compared with placebo. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b><i>SPMS</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>444 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>224 per 1000</b><br/>(46 to 615) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.36</b> </p> <p>(0.06 to 2.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/>(1 RCT)<sup>o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>n,p</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on SAEs, when compared with placebo. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Other DMTs</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS </i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b> </b>No data were available </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Glatiramer acetate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>SPMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84<br/>(1 RCT)<sup>q</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cheshmavar 2021 reported 0 SAEs over 12 months' follow‐up.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Chance of impaired quality of life:</b> none of the studies reported the outcome. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Common infections</b> over 12–24 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>714 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>695 per 1000</b><br/>(481 to 848) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.91</b> </p> <p>(0.37 to 2.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 </p> <p>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>h,n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on infections, when compared with placebo. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>SPMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>444 per 1000</b><br/>(138 to 809) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.40</b> </p> <p>(0.08 to 2.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/>(1 RCT)<sup>o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>n,p</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on infections, when compared with placebo. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Interferon beta or glatiramer acetate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>60 per 1000</b><br/>(40 to 89) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.71</b> </p> <p>(1.11 to 2.62)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5477<br/>(The national Swedish MS Register linked to national healthcare and census registries)<sup>r</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>s</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is moderate, downgraded 1 level for serious risk of bias in measurement of the outcome. Rituximab likely increases infections when compared with interferons or glatiramer acetate. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b><br/>(51 to 95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.26</b> </p> <p>(0.90 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5187</p> <p>(3 retrospective cohort studies)<sup>i,j,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>n,t</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is low, downgraded 1 level for serious risk of bias and 1 level for imprecision. Heterogeneity: P = 0.24, I² = 30%. Rituximab may increase slightly infections when compared with fingolimod. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b><br/>(51 to 95) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.58</b> </p> <p>(1.08 to 2.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5001</p> <p>(2 non‐randomised studies: the national Swedish MS Register linked to national healthcare and census registries, and 2 retrospective cohort studies)<sup>j,r</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>Moderate</b><sup>t</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is moderate, downgraded 1 level for serious risk of bias. Heterogeneity: P = 0.39, I² = 0%. Rituximab likely increases the number of participants who have common infections when compared with natalizumab. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Ocrelizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1 per 1000</b><br/>(0 to 26) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.02</b> </p> <p>(0.00 to 0.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>472</p> <p>(1 retrospective cohort study)<sup>u</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>f,l</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias and 1 level for imprecision. The evidence is very uncertain about the effect of rituximab on the number of participants who have infections when compared with ocrelizumab. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Glatiramer acetate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>SPMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b><br/>(7 to 429) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 3.00</b> </p> <p>(0.30 to 30.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> <p>(1 RCT)<sup>q</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>c,v</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on common infections, when compared with glatiramer acetate. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Cyclophosphamide</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>SPMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>433 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>230 per 1000</b><br/>(97 to 459) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.39</b> </p> <p>(0.14 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> <p>(1 RCT)<sup>w</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>c,x</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias and 1 level for some imprecision. The evidence is very uncertain about the effect of rituximab on the number of participants who have infections, when compared with cyclophosphamide. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>MS of all types</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b><br/>(9 to 80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.06</b> </p> <p>(0.34 to 3.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453<br/>(1 retrospective cohort study)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>l,m,n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias, 1 level for indirectness, and 1 level for serious imprecision. The evidence is very uncertain about the effect of rituximab on infections when compared with fingolimod. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Dimethyl fumarate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>MS of all types</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b><br/>(7 to 96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 2.39</b> </p> <p>(0.63 to 9.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453<br/>(1 retrospective cohort study)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>l.m.n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias, 1 level for indirectness, and 1 level for some imprecision. The evidence is very uncertain about the effect of rituximab on infections when compared with dimethyl fumarate. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>MS of all types</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b><br/>(7 to 107) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 4.22</b> </p> <p>(1.00 to 17.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>453<br/>(1 retrospective cohort study)<sup>k</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>f,l,m</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Our confidence in this result is very low, downgraded 2 levels for very serious risk of bias, 1 level for indirectness, and 1 level for some imprecision. The evidence is very uncertain about the effect of rituximab on infections when compared with natalizumab </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Cancer</b> over 24–36 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.55</b> </p> <p>(0.06 to 39.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>h,n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on the number of participants who have cancer, when compared with placebo. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>SPMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>111 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b><br/>(4 to 516) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.47</b> </p> <p>(0.03 to 8.52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/>(1 RCT)<sup>o</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>n,p</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on the number of participants who have cancer, when compared with placebo. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>MS of all types</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b><br/>(6 to 18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.60</b> </p> <p>(0.35 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5807<br/> (The Swedish MS Register linked to the Swedish Cancer Register and the national patient Register)<sup>y</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>f,z</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is low downgraded 1 level for serious risk of bias and 1 level for some imprecision. Rituximab may reduce the number of participants who have cancer over 36 months, when compared with fingolimod. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>MS of all types</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b><br/>(4 to 13) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.74</b> </p> <p>(0.42 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5857<br/> (The Swedish MS Register linked to the Swedish Cancer Register and the national patient Register)<sup>y</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>f,z</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is low, downgraded 1 level for serious risk of bias and 1 level for some imprecision. Rituximab may reduce the number of participants who have cancer over 36 months, when compared with natalizumab. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Mortality</b> over 24 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 1.55</b> </p> <p>(0.06 to 39.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104<br/>(1 RCT)<sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>h,n</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on mortality compared with placebo. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Fingolimod</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 5.59</b> </p> <p>(0.22 to 139.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136<br/>(1 retrospective cohort study)<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>e,n,aa</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias, 1 level for indirectness, and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on mortality compared with fingolimod. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rituximab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Natalizumab</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b><i>RRMS</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 6.66</b> </p> <p>(0.27 to 166.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153<br/>(1 retrospective cohort study)<sup>j</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very</b> <b>low</b><sup>e,n,aa</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Our confidence in this result is very low, downgraded 1 level for serious risk of bias, 1 level for indirectness, and 2 levels for very serious imprecision. The evidence is very uncertain about the effect of rituximab on mortality compared with natalizumab. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median risk of comparator across studies) is provided in footnotes. The <b>risk</b> <b>in the rituximab group </b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>DMT:</b> disease‐modifying treatment; <b>HR:</b> hazard ratio; <b>MS:</b> multiple sclerosis; <b>NNTB: </b> number needed to treat for an additional beneficial effect; <b>OR:</b> odds ratio;<b> RCT:</b> randomised controlled trial; <b>RRMS:</b> relapsing‐remitting multiple sclerosis; <b>SAE:</b> serious adverse event; <b>SPMS:</b> secondary progressive multiple sclerosis. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Explanations</b> </p> <p>Event rates in comparator based on the number of events in the included studies.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD013874-bbs2-0014" title="SpelmanT , FrisellT , PiehlF , HillertJ . Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Multiple Sclerosis2018;24(8):1087-95. ">Spelman 2018</a>.<br/><sup>b</sup>Bias due to missing data since time to disability worsening was limited to people with a minimum of three Expanded Disability Status Scale scores reported, i.e. 321/461 (70%) participants in the rituximab group and 532/922 (58%) participants in the interferon or glatiramer acetate group.<br/><sup>c</sup>The optimal information size criterion was not met (few events). Results included both no effect and appreciable benefit or harm.<br/><sup>d</sup><a href="./references#CD013874-bbs2-0013" title="NaegelinY , NaegelinP , vonFeltenS , LorscheiderJ , SonderJ , UitdehaagBM , et al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology2019;76(3):274-81. ">Naegelin 2019</a>.<br/><sup>e</sup>Bias due to residual confounding is expected in a retrospective cohort study.<br/><sup>f</sup>The optimal information size criterion was not met (few events).<br/><sup>g</sup><a href="./references#CD013874-bbs2-0009" title="HauserSL , WaubantE , ArnoldDL , VollmerT , AntelJ , FoxRJ , et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New England Journal of Medicine2008;358(7):676-88. NCT00097188. A study to evaluate rituximab in adults with relapsing remitting multiple sclerosis. clinicaltrials.gov/show/NCT00097188 (first received 19 November 2004). ">Hauser 2008</a>.<br/><sup>h</sup>High risk of bias for unblinding of personnel and incomplete outcome data. Unclear risk of bias for allocation concealment and blinding of participants.<br/><sup>i</sup><a href="./references#CD013874-bbs2-0002" title="AlpingP , FrisellT , NovakovaL , Islam-JakobssonP , SalzerJ , BjörckA , et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Annals of Neurology2016;79(6):950-8. ">Alping 2016</a>.<br/><sup>j</sup><a href="./references#CD013874-bbs2-0004" title="BoremalmM , JutoA , AxelssonM , NovakovaL , FrisellT , SvenningssonA , et al. Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis. European Journal of Neurology2019;26(8):1060-7. SalzerJ , BoremalmM , JutoA , NovakovaL , AxelssonM , FrisellT , et al. Comparison of rituximab and highly effective second line disease modifying therapies after breakthrough disease activity in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal2017;23(3):323. ">Boremalm 2019</a>.<br/><sup>k</sup><a href="./references#CD013874-bbs2-0015" title="VollmerB , NairK , SillauS , CorboyJ , VollmerT , AlvarezE . Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Neurology2018;90:15. VollmerBL , NairK , SillauS , CorboyJR , VollmerT , AlvarezE . Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology2020;7(9):1466-76. ">Vollmer 2020a</a>.<br/><sup>l</sup>Very serious risk of bias. All known important confounding domains not appropriately measured and controlled for.<br/><sup>m</sup>Indirectness of population.<br/><sup>n</sup>The optimal information size criterion was not met (very few events). Results included both no harm and appreciable harm.<br/><sup>o</sup><a href="./references#CD013874-bbs2-0011" title="KomoriM , LinYC , CorteseI , BlakeA , OhayonJ , CherupJ , et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis. Annals of Clinical and Translational Neurology2016;3(3):166-79. NCT01212094. Double blind combination of rituximab by intravenous and intrathecal injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis (RIVITaLISe). clinicaltrials.gov/show/NCT01212094 (first received 30 September 2010). ">Komori 2016</a>.<br/><sup>p</sup>High risk of bias for inadequate allocation concealment, incomplete outcome data, and other bias. Unclear risk of bias for blinding of participants and outcome assessment.<br/><sup>q</sup><a href="./references#CD013874-bbs2-0005" title="CheshmavarM , MirmosayyebO , BadihianN , BadihianS , ShaygannejadV . Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: a randomized clinical trial. Acta Neurologica Scandinavica2021;143(2):178-87. NCT03315923. Comparison of clinical effects of rituximab and glatiramer acetate in secondary progressive multiple sclerosis patients. clinicaltrials.gov/show/NCT03315923 (first received 20 October 2017). ">Cheshmavar 2021</a>.<br/><sup>r</sup><a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>.<br/><sup>s</sup>Quote: "Data are not available on the validity of the registries to measure infections and on different reporting of infections between interventions"(<a href="./references#CD013874-bbs2-0012" title="LunaG , AlpingP , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurology2020;77(2):184-91. LunaG , PiehlF , FrisellT . Infection risks among Swedish multiple sclerosis patients treated with rituximab compared to natalizumab, fingolimod, and injectable therapies: a nationwide cohort study. Multiple Sclerosis Journal2018;24(2):502-3. ">Luna 2020</a>).<br/><sup>t</sup>All the retrospective cohort studies were at serious risk of bias.<br/><sup>u</sup><a href="./references#CD013874-bbs2-0007" title="EvertssonB , HoytT , ChristensenA , NimerFA , FoleyJ , PiehlF . A comparative study of tolerability and effects on immunoglobulin levels and CD19 cell counts with ocrelizumab vs low dose of rituximab in multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical2020;6(4):2055217320964505. ">Evertsson 2020</a>.<br/><sup>v</sup>High risk of bias for inadequate allocation concealment and lack of blinding of participants and personnel.<br/><sup>w</sup><a href="./references#CD013874-bbs2-0006" title="EtemadifarM , GhourchianS , MahinparvarN , SalariM , EtemadifarF , NikanpourY , et al. Cyclophosphamide versus rituximab in progressive forms of multiple sclerosis. Acta Medica Iranica2019;57(8):484‐91. ">Etemadifar 2019</a>.<br/><sup>x</sup>High risk of bias for inadequate allocation concealment, lack of blinding of participants, personnel and outcome assessment, and incomplete outcome data.<br/><sup>y</sup><a href="./references#CD013874-bbs2-0003" title="AlpingP , AsklingJ , BurmanJ , FinkK , Fogdell-HahnA , GunnarssonM , et al. Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Annals of Neurology2020;87(5):688-99. AlpingP , PiehlF , FrisellT . Cancer risk among Swedish multiple sclerosis patients: a nationwide cohort study comparing rituximab, fingolimod and natalizumab. Multiple Sclerosis Journal2018;24(2):36. ">Alping 2020</a>.<br/><sup>z</sup>The register linkage allowed adjustment for many important confounders; however, residual confounding might still be an issue.<br/><sup>aa</sup>Indirectness of outcome, one suicide in the rituximab group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Rituximab as 'switching' for multiple sclerosis – results from RCTs and non‐randomised studies of intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013874-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">PICOS table to summarise the current evidence identified in the review</span></div> <tbody> <tr> <th align="" class="headercell" colspan="4" rowspan="1" scope="col" valign="top"> <p><b>Intervention: rituximab as first‐choice </b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Population</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study design (number of included studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes (☑ evidence identified) </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Relapsing MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 0</p> <p>NRSI 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening</p> <p>Recurrence of relapse</p> <p>SAEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections</p> <p>Cancer</p> <p>Mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR</p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions</p> <p>New T1 (gadolinium) MRI lesions</p> <p>Discontinuation due to AEs</p> <p>Grade 3–4 AEs</p> <p>Long‐term AEs</p> <p>Short‐term AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Other DMTs</p> <p> </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Relapsing MS</p> <p><i>Also see: </i><a href="./full#CD013874-tbl-0001">summary of findings Table 1</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 0</p> <p>NRSI 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening</p> <p>Recurrence of relapse <b>☑</b> </p> <p>SAEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections</p> <p>Cancer</p> <p>Mortality <b>☑</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR</p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions</p> <p>New T1 (gadolinium) MRI lesions <b>☑</b> </p> <p>Discontinuation due to AEs <b>☑ </b> </p> <p>Grade 3–4 AEs <b>☑ </b> </p> <p>Long‐term AEs</p> <p>Short‐term AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Progressive MS (primary)</p> <p><i>Also see: </i><a href="./full#CD013874-tbl-0002">summary of findings Table 2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 1</p> <p>NRSI 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening <b>☑</b> </p> <p>Recurrence of relapse <b>☑</b> </p> <p>SAEs <b>☑</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections <b>☑</b> </p> <p>Cancer <b>☑</b> </p> <p>Mortality <b>☑</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR</p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions</p> <p>New T1 (gadolinium) MRI lesions</p> <p>Discontinuation due to AEs <b>☑</b> </p> <p>Grade 3–4 AEs <b>☑</b> </p> <p>Long‐term AEs</p> <p>Short‐term AEs <b>☑ (infusion‐related)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Other DMTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Progressive MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 0</p> <p>NRSI 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening</p> <p>Recurrence of relapse</p> <p>SAEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections</p> <p>Cancer</p> <p>Mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR</p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions</p> <p>New T1 MRI lesions</p> <p>Discontinuation due to AEs</p> <p>Grade 3–4 AEs</p> <p>Long‐term AEs</p> <p>Short‐term AEs</p> </td> </tr> <tr> <th align="" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>Intervention: rituximab as 'switching' </b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparator</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Population</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study design (number of included studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Relapsing MS</p> <p><i>Also see: </i><a href="./full#CD013874-tbl-0003">summary of findings Table 3</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 1</p> <p>NRSI 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening</p> <p>Recurrence of relapse <b>☑</b> </p> <p>SAEs <b>☑</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections <b>☑</b> </p> <p>Cancer <b>☑</b> </p> <p>Mortality <b>☑</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR <b>☑</b> </p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions</p> <p>New T1 (gadolinium) MRI lesions <b>☑</b> </p> <p>Discontinuation due to AEs <b>☑</b> </p> <p>Grade 3–4 AEs <b>☑</b> </p> <p>Long‐term AEs <b>☑ </b>(CV events; opportunistic infections) </p> <p>Short‐term AEs <b>☑ </b>(infusion‐related) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Other DMTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Relapsing MS</p> <p><i>Also see: </i><a href="./full#CD013874-tbl-0004">summary of findings Table 4</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 0</p> <p>NRSI 5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening <b>☑ </b>(1 NRSI) </p> <p>Recurrence of relapse <b>☑ </b>(3 NRSI) </p> <p>SAEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections <b>☑ </b>(4 NRSI) </p> <p>Cancer</p> <p>Mortality <b>☑ </b>(1 NRSI) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR <b>☑ </b>(1 study) </p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions <b>☑ </b>(1 NRSI) </p> <p>New T1 (gadolinium) MRI lesions <b>☑ </b>(2 NRSI) </p> <p>Discontinuation due to AEs <b>☑ </b>(2 NRSI) </p> <p>Grade 3–4 AEs <b>☑ </b>(2 NRSI) </p> <p>Long‐term AEs <b>☑</b> (CV events (2 NRSI)) </p> <p>Short‐term AEs <b>☑ </b>(infusion‐related) (2 NRSI) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Progressive MS (secondary)</p> <p><i>Also see: </i><a href="#CD013874-tbl-0006">Table 2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 1</p> <p>NRSI 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening</p> <p>Recurrence of relapse</p> <p>SAEs <b>☑</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections</p> <p>Cancer <b>☑</b> </p> <p>Mortality </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR</p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions</p> <p>New T1 (gadolinium) MRI lesions</p> <p>Discontinuation due to AEs</p> <p>Grade 3–4 AEs</p> <p>Long‐term AEs <b>☑ </b>(CV events) </p> <p>Short‐term AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Other DMTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Progressing MS (secondary)</p> <p><i>Also see: </i><a href="#CD013874-tbl-0006">Table 2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 2</p> <p>NRSI 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening <b>☑</b> (1 NRSI) </p> <p>Recurrence of relapse</p> <p>SAEs <b>☑ </b>(1 RCT) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections <b>☑ </b>(2 RCTs) </p> <p>Cancer</p> <p>Mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR <b>☑ </b>(1 RCT) </p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions</p> <p>New T1 (gadolinium) MRI lesions <b>☑ </b>(1 RCT) </p> <p>Discontinuation due to AEs <b>☑ </b>(1 RCT) </p> <p>Grades 3–4 AEs</p> <p>Long‐term AEs <b>☑ </b>(opportunistic infections, 1 RCT) </p> <p>Short‐term AEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Other DMTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Relapsing + progressing MS</p> <p><i>Also see: </i><a href="#CD013874-tbl-0006">Table 2</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>RCT 0</p> <p>NRSI 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical </p> <p>Disability worsening</p> <p>Recurrence of relapse <b>☑ </b>(1 NRSI) </p> <p>SAEs</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important prioritised </p> <p>QoL</p> <p>Common infections <b>☑ </b>(1 NRSI) </p> <p>Cancer <b>☑ </b>(1 NRSI) </p> <p>Mortality</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Important </p> <p>ARR </p> <p>Cognitive decline</p> <p>New or enlarging T2 MRI lesions <b>☑ </b>(1 NRSI) </p> <p>New T1 (gadolinium) MRI lesions <b>☑ </b>(1 NRSI) </p> <p>Discontinuation due to AEs <b>☑ </b>(1 NRSI) </p> <p>Grades 3–4 AEs</p> <p>Long‐term AEs <b>☑ </b>(CV events, 1 NRSI) </p> <p>Short‐term AEs</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>AE: adverse event; ARR: annualised relapse rate; CV: cardiovascular events; MRI: magnetic resonance imaging; MS: multiple sclerosis; NRSI: non‐randomised study of intervention; QoL: quality of life; RCT: randomised controlled trial; SAE: serious adverse event. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">PICOS table to summarise the current evidence identified in the review</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/full#CD013874-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013874-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison: rituximab as 'first choice' versus other disease‐modifying treatments (DMT) for relapsing multiple sclerosis – results from non‐randomised studies of interventions (NRSIs)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Time to relapse over 24 months  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Rituximab vs interferons beta or glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.05, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Rituximab vs dimethyl fumarate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.08, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.06, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.04, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Gadolinium magnetic resonance imaging (MRI) lesions  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Rituximab vs interferons beta or glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [0.02, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Rituximab vs dimethyl fumarate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.02, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.01, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.4 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 10.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Treatment discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Rituximab vs interferon beta or glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [0.00, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Rituximab vs dimethyl fumarate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.01, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.02, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.4 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.00, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Grade 3–4 adverse events over 24 months  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Rituximab vs interferon beta or glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.26, 3.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Rituximab vs dimethyl fumarate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.93 [0.32, 26.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.07, 26.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.10, 1.65]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison: rituximab as 'first choice' versus other disease‐modifying treatments (DMT) for relapsing multiple sclerosis – results from non‐randomised studies of interventions (NRSIs)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013874-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) </span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Disability worsening over 24 months  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Relapse over 24 months  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Serious adverse events over 24 months  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Common infections over 24 months  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Cancer over 24 months  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Mortality over 24 months  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Treatment discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Grade 3 or 4 adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 First infusion reactions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Second infusion reactions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Comparison: rituximab as 'first choice' versus placebo for primary progressive multiple sclerosis – results from randomised controlled trials (RCTs) </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013874-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Relapse over 12 months in relapsing MS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Serious adverse events (SAEs) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 SAEs over 12 months in relapsing MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.28, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Common infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 Common infections over 12 months in relapsing MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.37, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 Common infections over 24 months in secondary progressive MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.08, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 Relapsing MS over 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.06, 39.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Annualised relapse rate  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Gadolinium MRI lesions over 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Treatment discontinuation due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 Rituximab when switching from another DMT in relapsing MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.12, 4.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.2 Rituximab when switching from another DMT in secondary progressive MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.06, 44.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Grade 3–4 adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.1 Rituximab when switching from another DMT in relapsing MS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.06, 39.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 First infusion reactions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Second infusion reactions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Comparison: rituximab as 'switching' versus placebo for relapsing multiple sclerosis (MS) – results from RCTs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013874-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Time to disability worsening over 24 months  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Rituximab vs interferons or glatiramer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.52, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Time to relapse over 24 months  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Rituximab vs interferons beta or glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.07, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.02, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.3 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.20, 5.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Common infections  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Rituximab vs interferons beta or glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.11, 2.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.90, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [1.08, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.4 Rituximab vs ocrelizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [0.00, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Mortality  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.59 [0.22, 139.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.66 [0.27, 166.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Annualised relapse rate (change from baseline) – by type of DMT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Rituximab vs interferons beta or glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.03, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 T2 MRI lesions  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [0.00, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Gadolinium MRI lesions  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.03, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.20, 5.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Treatment discontinuation due to adverse events – by type of DMT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.01, 2.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.2 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.02, 5.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.3 Rituximab vs ocrelizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.11, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Grade 3–4 adverse events over 24 months  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.1 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.06, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.2 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.01, 4.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.10 Cardiovascular events – by type of DMT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.1 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.05, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.2 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.11 First infusion reactions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.1 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.71 [2.19, 10.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.2 Rituximab vs ocrelizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.07, 3.69]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Comparison: rituximab as 'switching' versus other DMTs for relapsing MS  – results from NRSI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013874-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Comparison: rituximab as 'switching' versus placebo for secondary progressive MS – results from RCTs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Cardiovascular events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Comparison: rituximab as 'switching' versus placebo for secondary progressive MS – results from RCTs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013874-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from RCTs </span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Serious adverse events  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 Rituximab vs glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Common infections – by different DMTs <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Rituximab vs glatiramer acetate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.30, 30.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 Rituximab vs cyclophosphamide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.14, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Annualised relapse rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 Rituximab vs glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.09, 0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Gadolinium MRI lesions  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Treatment discontinuation due to adverse events  <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.1 Rituximab vs glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.13, 7.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Opportunistic infections <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.1 Rituximab vs glatiramer acetate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from RCTs </span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013874-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from NRSIs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Time to disability worsening over 36 months in secondary progressive MS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Rituximab vs other DMTs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.26, 0.93]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Comparison: rituximab as 'switching' versus other DMTs for secondary progressive MS – results from NRSIs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013874-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Comparison: rituximab as 'switching' versus other DMTs for grouped data as relapsing or progressive MS – results from NRSIs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Relapse over 24 months – by type of DMT (unadjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.1 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.14, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.2 Rituximab vs dimethyl fumarate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.10, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1.3 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.22, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Common infections – by type of DMT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.34, 3.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 Rituximab vs dimethyl fumarate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [0.63, 9.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.3 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.22 [1.00, 17.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Cancer – by type of DMT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.1 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.35, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3.2 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5857</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.42, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.4 T2 MRI lesions – by DMT (unadjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.1 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.25, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.2 Rituximab vs dimethyl fumarate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.30, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4.3 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.41, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.5 Gadolinium MRI lesions (unadjusted data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.1 Rituximab vs dimethyl fumarate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [0.01, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.2 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.00, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5.3 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.01, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.6 Discontinuation due to adverse events – by type of DMT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6.1 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>453</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.13, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6.2 Rituximab vs dimethyl fumarate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.15, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6.3 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.48, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.7 Cardiovascular events – by DMT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7.1 Rituximab vs fingolimod</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.01, 3.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7.2 Rituximab vs dimethyl fumarate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>523</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7.3 Rituximab vs natalizumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>633</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.03, 20.29]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Comparison: rituximab as 'switching' versus other DMTs for grouped data as relapsing or progressive MS – results from NRSIs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013874.pub2/references#CD013874-tbl-0015">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013874.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013874-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013874-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013874-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD013874-note-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD013874-note-0014">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013874-note-0012">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013874-note-0013">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013874\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013874\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013874\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013874\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013874\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013874\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013874\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013874\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013874\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013874\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013874\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013874\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013874\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013874\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013874\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013874\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013874\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013874\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013874.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013874.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013874.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013874.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013874.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714952792"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013874.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714952796"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013874.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7b404c809368',t:'MTc0MDcxNDk1My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 